Unnamed: 0
stringlengths 3
8
| Date
stringlengths 23
23
| Article_title
stringlengths 1
250
| Stock_symbol
stringlengths 1
5
| Url
stringlengths 44
135
| Publisher
stringclasses 1
value | Author
stringclasses 1
value | Article
stringlengths 1
343k
| Lsa_summary
stringlengths 3
53.9k
| Luhn_summary
stringlengths 1
53.9k
| Textrank_summary
stringlengths 1
53.9k
| Lexrank_summary
stringlengths 1
53.9k
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
715300.0
|
2023-12-01 00:00:00 UTC
|
Axis Capital (AXS) is a Top-Ranked Growth Stock: Should You Buy?
|
DCOMP
|
https://www.nasdaq.com/articles/axis-capital-axs-is-a-top-ranked-growth-stock%3A-should-you-buy-1
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Axis Capital (AXS)
Incorporated on Dec 9, 2002, AXIS Capital Holdings Limited is the Bermuda-based holding company for the AXIS group of companies. AXIS Specialty Bermuda commenced operations on Nov 20, 2001. AXIS Specialty Bermuda and its subsidiaries became wholly owned subsidiaries of AXIS Capital pursuant to an exchange offer consummated on Dec 31, 2002.
AXS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. AXS has a Growth Style Score of B, forecasting year-over-year earnings growth of 47.3% for the current fiscal year.
For fiscal 2023, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.15 to $8.56 per share. AXS boasts an average earnings surprise of 22.5%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, AXS should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Axis Capital Holdings Limited (AXS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Click to get this free report Axis Capital Holdings Limited (AXS) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio. You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B.
|
What are the Zacks Style Scores? That's where the Style Scores come in. AXS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors.
|
f56ee0db-5d12-43b2-81d0-b9eb6ac1d727
|
715301.0
|
2023-12-01 00:00:00 UTC
|
Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now
|
DCOMP
|
https://www.nasdaq.com/articles/bears-are-losing-control-over-maia-biotechnology-inc.-maia-heres-why-its-a-buy-now
|
nan
|
nan
|
Shares of MAIA Biotechnology, Inc. (MAIA) have been struggling lately and have lost 14.5% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.
The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.
Understanding Hammer Chart and the Technique to Trade It
This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Makes the Trend Reversal More Likely for MAIA
An upward trend in earnings estimate revisions that MAIA has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
The consensus EPS estimate for the current year has increased 4.6% over the last 30 days. This means that the Wall Street analysts covering MAIA are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
If this is not enough, you should note that MAIA currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Moreover, the Zacks Rank has proven to be an excellent timing indicator, helping investors identify precisely when a company's prospects are beginning to improve. So, for the shares of MAIA Biotechnology, Inc. a Zacks Rank of 2 is a more conclusive fundamental indication of a potential turnaround.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MAIA Biotechnology, Inc. (MAIA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price. This means that the Wall Street analysts covering MAIA are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
|
On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). Click to get this free report MAIA Biotechnology, Inc. (MAIA) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Here's What Makes the Trend Reversal More Likely for MAIA An upward trend in earnings estimate revisions that MAIA has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. If this is not enough, you should note that MAIA currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Moreover, the Zacks Rank has proven to be an excellent timing indicator, helping investors identify precisely when a company's prospects are beginning to improve.
|
On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. Here's What Makes the Trend Reversal More Likely for MAIA An upward trend in earnings estimate revisions that MAIA has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. If this is not enough, you should note that MAIA currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises.
|
4dcc2114-7763-48ab-9cd6-0e1f88d8b523
|
715302.0
|
2023-12-01 00:00:00 UTC
|
CVS Health's (CVS) Digital Focus Aids Growth, Macro Issues Ail
|
DCOMP
|
https://www.nasdaq.com/articles/cvs-healths-cvs-digital-focus-aids-growth-macro-issues-ail
|
nan
|
nan
|
CVS Health CVS gains from digital health adoption. Strategic buyouts should drive future growth. However, reimbursement pressure and macroeconomic headwinds provide stiff challenges to CVS Health. The stock carries a Zacks Rank #3 (Hold).
CVS Health is continuously focusing and investing in fast-growing spaces like enterprise data platforms, cloud capabilities and digital products to offer innovative solutions through mobile and web channels. The company is investing in emerging technology capabilities, such as voice, artificial intelligence and robotics, to automate, reduce the cost and improve the experience for its constituents.
In terms of the latest update, the company exceeded 55 million unique digital customers till the third quarter, an increase of nearly 20% versus last year. This strong growth has been powered by its focus on innovating and delivering experiences that matter most to customers.
Further, following the colossal acquisition of the health insurance giant Aetna, CVS Health has introduced its Health Care Benefits business arm. This segment consistently demonstrates value to consumers and clients by successfully managing drug cost trends and bringing innovative clinical solutions to the market.
CVS Health Corporation Price
CVS Health Corporation price | CVS Health Corporation Quote
Medical membership in the third quarter of 2023 grew to 25.7 million, an increase of 1.4 million members versus the prior year, reflecting growth across multiple product lines, including individual exchange, Medicare and commercial. CVS Health demonstrated strong growth, led by significant progress made in restoring its Medicare Advantage Star ratings. Medicare Advantage is a key strategic growth area for the company’s business.
Within Health Service, both Signify Health and Oak Street Health continue to deliver strong business performance consistent with expectations. These assets bring core capabilities to the multi-payor value-based care platform that drives optimal patient engagement with health services across multiple channels.
Meanwhile, a significant portion of CVS Health’s net revenues are derived directly from Medicare, Medicaid and other government-sponsored healthcare programs. Therefore, the company is subject to federal and state reimbursement laws and regulatory requirements, anti-remuneration laws, the Stark Law and/or federal and state false claims laws.
In the third quarter, the reimbursement pressure within the pharmacy business continued despite experiencing certain stabilization. The company is making continued efforts to combat this reimbursement pressure by increasing volume and reducing costs.
Added to this, adverse economic conditions in the United States and abroad are adversely impacting CVS Health’s businesses, operating results and financial condition. The businesses are currently affected by the U.S. economy and consumer confidence in general and in the geographies it serves, including various economic factors, like inflation and changes in consumer purchasing power, preferences or spending patterns.
Key Picks
Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an earnings surprise of 77.4%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it came up with an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an earnings surprise of 47.1%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
CVS Health Corporation (CVS) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CVS Health is continuously focusing and investing in fast-growing spaces like enterprise data platforms, cloud capabilities and digital products to offer innovative solutions through mobile and web channels. The company is investing in emerging technology capabilities, such as voice, artificial intelligence and robotics, to automate, reduce the cost and improve the experience for its constituents. These assets bring core capabilities to the multi-payor value-based care platform that drives optimal patient engagement with health services across multiple channels.
|
CVS Health Corporation Price CVS Health Corporation price | CVS Health Corporation Quote Medical membership in the third quarter of 2023 grew to 25.7 million, an increase of 1.4 million members versus the prior year, reflecting growth across multiple product lines, including individual exchange, Medicare and commercial. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
CVS Health Corporation Price CVS Health Corporation price | CVS Health Corporation Quote Medical membership in the third quarter of 2023 grew to 25.7 million, an increase of 1.4 million members versus the prior year, reflecting growth across multiple product lines, including individual exchange, Medicare and commercial. Within Health Service, both Signify Health and Oak Street Health continue to deliver strong business performance consistent with expectations. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
CVS Health CVS gains from digital health adoption. Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
|
fbcbac38-00b6-4f93-8c50-e436548d1088
|
715303.0
|
2023-12-01 00:00:00 UTC
|
Costco Stock: Buy, Sell, or Hold?
|
DCOMP
|
https://www.nasdaq.com/articles/costco-stock%3A-buy-sell-or-hold-4
|
nan
|
nan
|
Costco Wholesale's (NASDAQ: COST) business has exploded in recent years, helping it become one of the world's most successful retailers. In the last five years alone, shares of the warehouse retailer have soared 166%. The company's unique business model of offering an annual membership in exchange for access to wholesale items at industry-low prices has won over shoppers worldwide.
Yet, Costco is only at the start of its global expansion. The company is on a path to continue seeing significant financial gains year over year as it grows its international footprint. Here's why Costco is a screaming long-term buy right now.
Its stock is outperforming the competition
The retail industry is highly competitive, with Costco up against major corporations such as Amazon, Walmart, and Target. However, Costco has differentiated itself from the competition with its wholesale model and allowed space for its customers to shop at competing stores while also visiting its locations on a regular basis. As a result, Costco has significantly outperformed its peers in recent years.
The chart below shows that since 2018, shares in Costco have delivered close to double the growth of its biggest U.S. competitors. The company's performance over the last five years also illustrates its reliability. While Amazon and Target have experienced dramatic peaks and valleys in their stock prices, Costco shares have more consistently trended upward.
Data by YCharts
In addition to impressive stock gains, Costco's financials are growing at a faster pace than any of the companies above. The chart below shows that Costco's quarterly revenue has risen 125% in the last five years, more than Amazon, Walmart, or Target in the same period.
Data by YCharts
The supermarket and grocery industry hit a value of $11 trillion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 3% through 2030. While its growth might not be as significant as some tech industries, it's a good sector to invest in and hold over several decades. Meanwhile, Costco's history of reliable gains and ability to regularly outperform its competitors makes it an attractive option.
Massive growth potential lies abroad
Costco has an impressive past. However, its future is even more exciting. The company operates 870 stores across 14 countries and is rapidly expanding. Its popular business model has traversed cultures and continents, with customers embracing the company far and wide.
For instance, Costco opened its first store in France in 2017, a country famously difficult for foreign companies to enter (Walt Disney faced protests when opening Disneyland Paris in 1992). Yet Costco's first store was a massive success in the European country, with the company announcing plans to open 15 additional units in France by 2025.
Additionally, in 2023 the company ventured into China for the first time and has already expanded to five stores in the country. Despite operating in 14 countries, Costco continues to have significant growth potential abroad. In six of those countries, the company has five or fewer locations, indicating almost endless expansion possibilities within those regions and new ones.
In the fourth quarter of Costco's fiscal 2023, revenue rose 9.5% year over year, beating Wall Street expectations by more than $1 billion. The company's international segment reported revenue growth of 4%, surpassing the 3% revenue growth of the U.S. The company opens an average of 25 new locations annually and will likely see its international stores eventually surpass its domestic business. Costco's focus on expanding abroad is promising for its long-term future and will likely provide consistent growth for years.
Like most retail businesses, Costco is vulnerable to economic fluctuations. However, its history of reliability and solid revenue growth is a compelling reason to make a long-term investment in its stock.
10 stocks we like better than Costco Wholesale
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Costco Wholesale wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 27, 2023
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Dani Cook has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Costco Wholesale, Target, and Walmart. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The company's unique business model of offering an annual membership in exchange for access to wholesale items at industry-low prices has won over shoppers worldwide. However, Costco has differentiated itself from the competition with its wholesale model and allowed space for its customers to shop at competing stores while also visiting its locations on a regular basis. Data by YCharts The supermarket and grocery industry hit a value of $11 trillion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 3% through 2030.
|
The company is on a path to continue seeing significant financial gains year over year as it grows its international footprint. Data by YCharts In addition to impressive stock gains, Costco's financials are growing at a faster pace than any of the companies above. Despite operating in 14 countries, Costco continues to have significant growth potential abroad.
|
Its stock is outperforming the competition The retail industry is highly competitive, with Costco up against major corporations such as Amazon, Walmart, and Target. Data by YCharts In addition to impressive stock gains, Costco's financials are growing at a faster pace than any of the companies above. Costco's focus on expanding abroad is promising for its long-term future and will likely provide consistent growth for years.
|
The company opens an average of 25 new locations annually and will likely see its international stores eventually surpass its domestic business. Costco's focus on expanding abroad is promising for its long-term future and will likely provide consistent growth for years. The Motley Fool has positions in and recommends Amazon, Costco Wholesale, Target, and Walmart.
|
0ddd46c7-e043-429b-9056-dab0db248462
|
715304.0
|
2023-12-01 00:00:00 UTC
|
Why Strategic Education (STRA) is a Top Momentum Stock for the Long-Term
|
DCOMP
|
https://www.nasdaq.com/articles/why-strategic-education-stra-is-a-top-momentum-stock-for-the-long-term
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Strategic Education (STRA)
Strategic Education, Inc. or SEI, through its subsidiaries Strayer University and New York Code and Design Academy (NYCDA), provides a range of post-secondary education and other academic programs in the United States. NYCDA is a New York City-based provider of web and application software development courses.
STRA is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Consumer Discretionary stock. STRA has a Momentum Style Score of B, and shares are up 3.3% over the past four weeks.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.20 to $3.41 per share. STRA boasts an average earnings surprise of 7.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, STRA should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Strategic Education Inc. (STRA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance.
|
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. Click to get this free report Strategic Education Inc. (STRA) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B.
|
What are the Zacks Style Scores? That's where the Style Scores come in. STRA is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
|
89d33089-392a-493c-9acc-cf067c309d60
|
715305.0
|
2023-12-01 00:00:00 UTC
|
Here's Why Meta Platforms (META) is a Strong Momentum Stock
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-meta-platforms-meta-is-a-strong-momentum-stock
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Meta Platforms (META)
Meta Platforms is the world’s largest social media platform. The company’s portfolio offering evolved from a single Facebook app to multiple apps like photo and video sharing app Instagram and WhatsApp messaging app owing to acquisitions. Along with in-house developed Messenger, these apps now form Meta’s family of products used by almost 3.96 billion people on a monthly basis as of Sep 30, 2023.
META is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Computer and Technology stock. META has a Momentum Style Score of B, and shares are up 5.2% over the past four weeks.
15 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.71 to $14.26 per share. META boasts an average earnings surprise of 27.5%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, META should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Meta Platforms, Inc. (META) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Click to get this free report Meta Platforms, Inc. (META) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
|
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. That's where the Style Scores come in. META is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
|
45edb1ff-9bd7-4002-abe4-c18b4689fab1
|
715306.0
|
2023-12-01 00:00:00 UTC
|
Sunoco LP (SUN) is a Top-Ranked Momentum Stock: Should You Buy?
|
DCOMP
|
https://www.nasdaq.com/articles/sunoco-lp-sun-is-a-top-ranked-momentum-stock%3A-should-you-buy
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Sunoco LP (SUN)
Headquartered in Dallas, TX, Sunoco LP is a master limited partnership (MLP). The partnership’s prime business comprises the distribution of motor fuel to roughly 10,000 customers that include independent dealers, commercial customers, convenience stores as well as distributors. The customers are based in more than 30 states. Sunoco GP LLC, a general partner of the partnership, is owned by Energy Transfer Operating LP — an affiliate of Energy Transfer LP.
SUN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Oils-Energy stock. SUN has a Momentum Style Score of A, and shares are up 3.5% over the past four weeks.
For fiscal 2023, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.96 to $5.19 per share. SUN boasts an average earnings surprise of 28.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, SUN should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sunoco LP (SUN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Click to get this free report Sunoco LP (SUN) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
|
What are the Zacks Style Scores? That's where the Style Scores come in. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
|
87c7e135-1680-4bf2-8dd1-5c8a60ee56d8
|
715307.0
|
2023-12-01 00:00:00 UTC
|
McDonald's (MCD) is a Top-Ranked Momentum Stock: Should You Buy?
|
DCOMP
|
https://www.nasdaq.com/articles/mcdonalds-mcd-is-a-top-ranked-momentum-stock%3A-should-you-buy
|
nan
|
nan
|
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: McDonald's (MCD)
Founded in 1948, Oak Brook, IL-based McDonald’s is a leading fast-food chain that currently operates more than 39,000 restaurants in more than 100 countries. The company mainly operates and franchises quick-service restaurants (QSRs) under the McDonald’s brand. Nearly 93% of the company’s restaurants worldwide are owned and operated by independent local businessmen as well as women. The company’s revenues include sales by company-operated restaurants and fees from restaurants, which franchisees manage.
MCD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Retail-Wholesale stock. MCD has a Momentum Style Score of A, and shares are up 5.6% over the past four weeks.
13 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.23 to $11.75 per share. MCD boasts an average earnings surprise of 10%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MCD should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McDonald's Corporation (MCD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. #1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio. With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MCD should be on investors' short list.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
|
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
|
df61d028-befc-460b-a86e-4af5d9a592ad
|
715308.0
|
2023-12-01 00:00:00 UTC
|
Here's Why You Should Hold on to Envestnet (ENV) Stock for Now
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-you-should-hold-on-to-envestnet-env-stock-for-now-0
|
nan
|
nan
|
Envestnet, Inc. ENV is gaining from strategic partnerships, collaborations and platform improvements. The company has been working on strong recurring revenue growth backed by asset-based and subscription-based models. Customer concentration is a cause of concern.
Factors in Favor
Envestnet, a key player in financial solutions, expands through strategic partnerships. In collaboration with Morningstar Retirement, it plans a managed IRA service powered by IRALOGIX. Envestnet's advanced ecosystem is now available to First Command Financial Services' advisors. An investment of $28.36 million in partnerships and the acquisition of 401kplans.com LLC in 2022 reinforce its commitment to the retirement plan sector, thus enhancing advisor productivity in the Envestnet Wealth Solutions segment.
Envestnet has partnered with iconik, a voting technology provider, to improve proxy voting for Sustainable Quantitative Portfolios, allowing investors to express views effectively. This collaboration meets the demand for choice, aiding advisors in retention and promoting long-term capital stewardship, thus enhancing the company's competitive edge.
Envestnet, Inc Revenue (TTM)
Envestnet, Inc revenue-ttm | Envestnet, Inc Quote
Envestnet has exhibited strong recurring revenue growth, primarily fueled by asset-based and subscription-based models. Adopting a business-to-business-to-consumer approach, the company enables financial service clients to offer its platform solutions. With a 4.5% YoY increase in 2022, following gains of 20.2% in 2021 and 10.2% in 2020, Envestnet's recurring revenues have shown consistent growth.
Envestnet's current ratio at the end of third-quarter 2023 was pegged at 0.75, higher than the previous quarter's current ratio of 0.73 and the year-ago quarter's current ratio of 0.77. Increasing the current ratio indicates the company is not likely to face any problems meeting its short-term obligations.
Risks
Envestnet’s revenues are concentrated on a few customers, which implies the termination of one contract with such clients will have a major impact on the company’s revenues. For the fiscal years ending Dec 31, 2022, 2021 and 2020, Envestnet's revenues linked to the association with Fidelity, specifically FMR LLC, accounted for approximately 16%, 17% and 15%, respectively, of its total revenues. The top ten clients constituted around 34%, 33% and 29% of the total revenues during these periods.
The company has a negative times interest earned of 3.4. Times interest earned ratio (TIE) is a solvency ratio indicating the company’s ability to pay all interest on business debt obligations. TIE is calculated as EBIT (earnings before interest and taxes) divided by total interest expense. This implies the company has lower EBIT than its interest charges, which poses a risk of default.
ENV is currently having Zacks Rank #3 (Hold).
Stocks to Consider
Here are a few better-ranked stocks from the Business Services sector that may be considered:
Gartner IT: The Zacks Consensus Estimate of Gartner’s 2023 revenues indicates 7.9% growth from the year-ago figure, while earnings are expected to decline 1.9%. The company has beaten the consensus estimate in all four quarters, with an average surprise of 34.4%.
IT sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
FTI Consulting FCN: The Zacks Consensus Estimate of FCN’s 2023 revenues indicates 12.1% growth from the year-ago figure, while earnings are expected to grow 3.4%. The company has beaten the consensus estimate in three of the four quarters and missed on one instance, the average surprise being 8.5%.
FCN holds a Zacks Rank #2 (Buy).
Broadridge Financial Solutions BR: The Zacks Consensus Estimate of Broadridge’s 2023 revenues indicates 7.7% growth from the year-ago figure, while earnings are expected to grow 10.1%. The company has beaten the consensus estimate in three of the past four quarters and matched on one instance, the average surprise being 5.4%.
BR holds a Zacks Rank of 2.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report
FTI Consulting, Inc. (FCN) : Free Stock Analysis Report
Gartner, Inc. (IT) : Free Stock Analysis Report
Envestnet, Inc (ENV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
An investment of $28.36 million in partnerships and the acquisition of 401kplans.com LLC in 2022 reinforce its commitment to the retirement plan sector, thus enhancing advisor productivity in the Envestnet Wealth Solutions segment. This collaboration meets the demand for choice, aiding advisors in retention and promoting long-term capital stewardship, thus enhancing the company's competitive edge. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
FTI Consulting FCN: The Zacks Consensus Estimate of FCN’s 2023 revenues indicates 12.1% growth from the year-ago figure, while earnings are expected to grow 3.4%. Broadridge Financial Solutions BR: The Zacks Consensus Estimate of Broadridge’s 2023 revenues indicates 7.7% growth from the year-ago figure, while earnings are expected to grow 10.1%. Click to get this free report Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report FTI Consulting, Inc. (FCN) : Free Stock Analysis Report Gartner, Inc. (IT) : Free Stock Analysis Report Envestnet, Inc (ENV) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Envestnet, Inc Revenue (TTM) Envestnet, Inc revenue-ttm | Envestnet, Inc Quote Envestnet has exhibited strong recurring revenue growth, primarily fueled by asset-based and subscription-based models. Stocks to Consider Here are a few better-ranked stocks from the Business Services sector that may be considered: Gartner IT: The Zacks Consensus Estimate of Gartner’s 2023 revenues indicates 7.9% growth from the year-ago figure, while earnings are expected to decline 1.9%. Click to get this free report Broadridge Financial Solutions, Inc. (BR) : Free Stock Analysis Report FTI Consulting, Inc. (FCN) : Free Stock Analysis Report Gartner, Inc. (IT) : Free Stock Analysis Report Envestnet, Inc (ENV) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
An investment of $28.36 million in partnerships and the acquisition of 401kplans.com LLC in 2022 reinforce its commitment to the retirement plan sector, thus enhancing advisor productivity in the Envestnet Wealth Solutions segment. Risks Envestnet’s revenues are concentrated on a few customers, which implies the termination of one contract with such clients will have a major impact on the company’s revenues. You can see the complete list of today’s Zacks #1 Rank stocks here.
|
3c6faac8-b95b-4188-a293-5498c001e192
|
715309.0
|
2023-12-01 00:00:00 UTC
|
5 Stocks to Buy as Inflation Continues to Cool and Q3 GDP Grows
|
DCOMP
|
https://www.nasdaq.com/articles/5-stocks-to-buy-as-inflation-continues-to-cool-and-q3-gdp-grows
|
nan
|
nan
|
November turned out to be the best month of the year for Wall Street as stocks rallied on investor optimism that the Federal Reserve may be done with its interest rate hikes. The Dow and the S&P 500 rose 8.9% each for November while the Nasdaq gained 10.7% for the month.
Experts believe that the rally will continue through the year-end given the high chances that the Fed may not go for another rate hike in its December policy meeting.
The renewed vigor comes as the U.S. economy grew 5.2% in the third quarter at a seasonally adjusted annual rate, up from the earlier reported 4.9% and well above the consensus estimate of 5%.
Also, inflation continued to ease in October. The Commerce Department reported on Nov 30 that personal consumption expenditure (PCE) was unchanged in October, while the core PCE index rose a meager 0.2%.
Year over year, core PCE, which excludes the volatile food and energy prices, rose 3.5% in October compared to a rise of 3.7% in September.
Easing inflation has raised hopes that the Fed may be done with its monetary tightening campaign after having raised interest rates by 525 basis points since March 2022.
Dovish comments from several Fed officials that the economy may have a softer landing as inflation may steadily ease to 2% over time also led to optimism among investors.
Market participants are now expecting a 76% chance that the central bank will go for a 25-basis point rate cut in May 2023, according to the CME FedWatch tool.
The fresh optimism is also boosting consumer confidence, which rose to 102 in November, beating estimates of 101 and coming in well above October’s downwardly revised reading of 99.1. This was the first jump in consumer confidence in the past three months.
Our Choices
Given this scenario, investors should invest in consumer discretionary stocks like DoubleDown Interactive Co., Ltd. DDI, Grand Canyon Education, Inc. LOPE, Royal Caribbean Cruises Ltd. RCL, Live Nation Entertainment, Inc. LYV and Comcast Corporation CMCSA.
DoubleDown Interactive Co., Ltd. is a developer and publisher of digital social casino games. DDI is based in Seattle.
DoubleDown Interactive’s expected earnings growth rate for the current year is 334.8%. The Zacks Consensus Estimate for current-year earnings has improved 9.3% over the past 60 days. DDI currently sports a Zacks Rank #1 (Strong Buy).
Grand Canyon Education, Inc. is a regionally accredited provider of online postsecondary education services focused on offering graduate and undergraduate degree programs in its core disciplines of education, business and healthcare. In addition to its online programs, LOPE offers programs at its traditional campus in Phoenix, AZ and onsite at the facilities of employers.
Grand Canyon Education’sexpected earnings growth rate for the current year is 17.1%. The Zacks Consensus Estimate for current-year earnings has improved 4.5% over the past 60 days. LOPE presently carries a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here.
Royal Caribbean Cruises Ltd. owns and operates three global brands — Royal Caribbean International, Celebrity Cruises and Azamara Club Cruises. Additionally, RCL has a 50% investment in a joint venture with TUI AG, which operates the brand TUI Cruises. Royal Caribbean Cruises' brands primarily serve the contemporary, premium and deluxe segments of the cruise vacation industry, which also includes the budget and luxury segments.
Royal Caribbean Cruises' expected earnings growth rate for the current year is 187.9%. The Zacks Consensus Estimate for current-year earnings has improved 7.3% over the past 90 days. RCL currently has a Zacks Rank #2.
Live Nation Entertainment, Inc. operates as a live entertainment company. LYV operates through the Concerts, Ticketing, and Sponsorship and Advertising segments. Live Nation Entertainment has more than 580 million fans across all of its concerts and ticketing platforms in 46 countries.
Live Nation Entertainment’s expected earnings growth rate for the current year is 132.8%. The Zacks Consensus Estimate for current-year earnings has improved 47.5% over the past 60 days. LYV presently has a Zacks Rank #2.
Comcast Corporationi s a global media and technology company with three primary businesses: Comcast Cable, NBCUniversal and Sky. Beginning first-quarter 2023, CMCSA changed its presentation of segment operating results around its two primary businesses, Connectivity & Platforms, and Content & Experiences.
Comcast Corporation’s expected earnings growth rate for the current year is 8%. The Zacks Consensus Estimate for current-year earnings has improved 3.1% over the past 60 days. CMCSA presently carries a Zacks Rank #2.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Comcast Corporation (CMCSA) : Free Stock Analysis Report
Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report
Live Nation Entertainment, Inc. (LYV) : Free Stock Analysis Report
Grand Canyon Education, Inc. (LOPE) : Free Stock Analysis Report
DoubleDown Interactive Co., Ltd. Sponsored ADR (DDI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
November turned out to be the best month of the year for Wall Street as stocks rallied on investor optimism that the Federal Reserve may be done with its interest rate hikes. Dovish comments from several Fed officials that the economy may have a softer landing as inflation may steadily ease to 2% over time also led to optimism among investors. Our Choices Given this scenario, investors should invest in consumer discretionary stocks like DoubleDown Interactive Co., Ltd. DDI, Grand Canyon Education, Inc. LOPE, Royal Caribbean Cruises Ltd. RCL, Live Nation Entertainment, Inc. LYV and Comcast Corporation CMCSA.
|
Our Choices Given this scenario, investors should invest in consumer discretionary stocks like DoubleDown Interactive Co., Ltd. DDI, Grand Canyon Education, Inc. LOPE, Royal Caribbean Cruises Ltd. RCL, Live Nation Entertainment, Inc. LYV and Comcast Corporation CMCSA. Royal Caribbean Cruises' expected earnings growth rate for the current year is 187.9%. Click to get this free report Comcast Corporation (CMCSA) : Free Stock Analysis Report Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report Live Nation Entertainment, Inc. (LYV) : Free Stock Analysis Report Grand Canyon Education, Inc. (LOPE) : Free Stock Analysis Report DoubleDown Interactive Co., Ltd.
|
Our Choices Given this scenario, investors should invest in consumer discretionary stocks like DoubleDown Interactive Co., Ltd. DDI, Grand Canyon Education, Inc. LOPE, Royal Caribbean Cruises Ltd. RCL, Live Nation Entertainment, Inc. LYV and Comcast Corporation CMCSA. The Zacks Consensus Estimate for current-year earnings has improved 9.3% over the past 60 days. Click to get this free report Comcast Corporation (CMCSA) : Free Stock Analysis Report Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report Live Nation Entertainment, Inc. (LYV) : Free Stock Analysis Report Grand Canyon Education, Inc. (LOPE) : Free Stock Analysis Report DoubleDown Interactive Co., Ltd.
|
Dovish comments from several Fed officials that the economy may have a softer landing as inflation may steadily ease to 2% over time also led to optimism among investors. This was the first jump in consumer confidence in the past three months. Our Choices Given this scenario, investors should invest in consumer discretionary stocks like DoubleDown Interactive Co., Ltd. DDI, Grand Canyon Education, Inc. LOPE, Royal Caribbean Cruises Ltd. RCL, Live Nation Entertainment, Inc. LYV and Comcast Corporation CMCSA.
|
4aaea065-1a87-45ba-9590-35ba7dfeaba7
|
715310.0
|
2023-12-01 00:00:00 UTC
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
DCOMP
|
https://www.nasdaq.com/articles/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick-344
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Dave & Buster's (PLAY)
Founded in 1982 and headquartered in Dallas, TX, Dave & Buster's Entertainment, is a leading owner and operator of high-volume venues in North America that combine dining and entertainment for both adults and families. As of Apr 30, 2023, the company owned and operated 208 stores in 42 states, Puerto Rico and one Canadian province. The core concept of this restaurant chain is “Eat Drink Play and Watch”, all in one location. Under the Eat concept, the company offers a wide variety of starters, burgers, choice-grade steaks and health-conscious food.
PLAY is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. PLAY has a Growth Style Score of A, forecasting year-over-year earnings growth of 2.2% for the current fiscal year.
For fiscal 2024, one analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0 to $2.85 per share. PLAY boasts an average earnings surprise of 16.7%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, PLAY should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dave & Buster's Entertainment, Inc. (PLAY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Click to get this free report Dave & Buster's Entertainment, Inc. (PLAY) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio. You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B.
|
What are the Zacks Style Scores? That's where the Style Scores come in. PLAY has a Growth Style Score of A, forecasting year-over-year earnings growth of 2.2% for the current fiscal year.
|
488722f9-9e68-4cc7-b327-613a2399df6c
|
715311.0
|
2023-12-01 00:00:00 UTC
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
DCOMP
|
https://www.nasdaq.com/articles/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick-345
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: ResMed (RMD)
ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep.
RMD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. RMD has a Growth Style Score of B, forecasting year-over-year earnings growth of 13.2% for the current fiscal year.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.25 to $7.29 per share. RMD boasts an average earnings surprise of 1.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, RMD should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ResMed Inc. (RMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Momentum Score Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
|
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. That's where the Style Scores come in.
|
c47d36ad-3701-4ef4-b4ea-08ab415cc537
|
715312.0
|
2023-12-01 00:00:00 UTC
|
Alibaba dips on MS downgrade as PDD grabs spot of most valuable Chinese e-commerce firm
|
DCOMP
|
https://www.nasdaq.com/articles/alibaba-dips-on-ms-downgrade-as-pdd-grabs-spot-of-most-valuable-chinese-e-commerce-firm-0
|
nan
|
nan
|
Updates prices throughout, adds details on P/E ratio in the penultimate graph
Dec 1 (Reuters) - U.S.-listed shares of Alibaba Group Holding declined on Friday following a Morgan Stanley downgrade on concerns over slower turnaround in its key businesses, hours after PDD raced past its rival to become the most valuable Chinese e-commerce firm.
Alibaba's stock BABA.N slipped 3.2% to $72.5, touching a fresh one-year low. The shares are down nearly 17% since the company last month posted in line second-quarter revenue and scrapped plans to spin off its cloud business.
Meanwhile, shares of PDD Holdings PDD.O have surged this week following stellar quarterly results from the Temu parent. The company closed with a market capitalization of nearly $196 billion on Thursday, surpassing Alibaba's market value of $190.45 billion.
Morgan Stanley analysts downgraded Alibaba to "equal-weight" from "overweight", flagging concerns over softness in its customer management revenue and cloud business due to sagging economic recovery in China.
They also noted uncertainties from Alibaba's decision to scrap the spin-off of its cloud business.
Morgan Stanley cut its price target on the stock to $90 from $110, the second lowest among analysts, as per LSEG data. The downgrade is the third in as many weeks by Wall Street brokerages.
Alibaba's U.S. shares, down about 18% so far this year, are set for their third consecutive year of losses.
On the other hand, Morgan Stanley named PDD as its top pick in the sector, saying the company is best placed to navigate the current economic environment with its heavy discounting steps.
"We expect PDD to continue to gain share in the domestic market thanks to its favorable business model amid consumers' behavior shift," Morgan Stanley's Eddy Wang noted, adding that its cross-border e-commerce business, Temu, is not fully valued by the market.
PDD shares were down 2.1% at $144.4 but have surged almost 80% in 2023, handily outperforming its peers.
At 21.4, PDD has the highest forward price-to-earnings ratio among rivals including JD.com JD.O and Vipshop Holdings VIPS.N. Alibaba's forward PE was 7.62, according to LSEG estimates.
Share performance of Alibaba, PDD Holdings so far this year https://tmsnrt.rs/3uGNk9m
(Reporting by Sruthi Shankar in Bengaluru; Editing by Sriraj Kalluvila)
((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Updates prices throughout, adds details on P/E ratio in the penultimate graph Dec 1 (Reuters) - U.S.-listed shares of Alibaba Group Holding declined on Friday following a Morgan Stanley downgrade on concerns over slower turnaround in its key businesses, hours after PDD raced past its rival to become the most valuable Chinese e-commerce firm. Morgan Stanley analysts downgraded Alibaba to "equal-weight" from "overweight", flagging concerns over softness in its customer management revenue and cloud business due to sagging economic recovery in China. On the other hand, Morgan Stanley named PDD as its top pick in the sector, saying the company is best placed to navigate the current economic environment with its heavy discounting steps.
|
Updates prices throughout, adds details on P/E ratio in the penultimate graph Dec 1 (Reuters) - U.S.-listed shares of Alibaba Group Holding declined on Friday following a Morgan Stanley downgrade on concerns over slower turnaround in its key businesses, hours after PDD raced past its rival to become the most valuable Chinese e-commerce firm. Meanwhile, shares of PDD Holdings PDD.O have surged this week following stellar quarterly results from the Temu parent. Morgan Stanley analysts downgraded Alibaba to "equal-weight" from "overweight", flagging concerns over softness in its customer management revenue and cloud business due to sagging economic recovery in China.
|
Updates prices throughout, adds details on P/E ratio in the penultimate graph Dec 1 (Reuters) - U.S.-listed shares of Alibaba Group Holding declined on Friday following a Morgan Stanley downgrade on concerns over slower turnaround in its key businesses, hours after PDD raced past its rival to become the most valuable Chinese e-commerce firm. "We expect PDD to continue to gain share in the domestic market thanks to its favorable business model amid consumers' behavior shift," Morgan Stanley's Eddy Wang noted, adding that its cross-border e-commerce business, Temu, is not fully valued by the market. Share performance of Alibaba, PDD Holdings so far this year https://tmsnrt.rs/3uGNk9m (Reporting by Sruthi Shankar in Bengaluru; Editing by Sriraj Kalluvila) ((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Meanwhile, shares of PDD Holdings PDD.O have surged this week following stellar quarterly results from the Temu parent. Morgan Stanley cut its price target on the stock to $90 from $110, the second lowest among analysts, as per LSEG data. "We expect PDD to continue to gain share in the domestic market thanks to its favorable business model amid consumers' behavior shift," Morgan Stanley's Eddy Wang noted, adding that its cross-border e-commerce business, Temu, is not fully valued by the market.
|
fcd0076e-8ced-4299-b16a-0e2d6d9a4d21
|
715313.0
|
2023-12-01 00:00:00 UTC
|
Why W.R. Berkley (WRB) is a Top Value Stock for the Long-Term
|
DCOMP
|
https://www.nasdaq.com/articles/why-w.r.-berkley-wrb-is-a-top-value-stock-for-the-long-term-0
|
nan
|
nan
|
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: W.R. Berkley (WRB)
Founded in 1967 and based in Greenwich, CT., W.R. Berkley Corp. is a Fortune 500 company. It is one of the nation’s largest commercial lines property casualty insurance providers. The company offers a variety of insurance services from reinsurance, to workers comp third party administrators (TPAs).
WRB is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.1; value investors should take notice.
For fiscal 2023, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.28 to $4.80 per share. WRB boasts an average earnings surprise of 4.4%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, WRB should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
W.R. Berkley Corporation (WRB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. #1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame.
|
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
|
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio. The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
|
What are the Zacks Style Scores? That's where the Style Scores come in. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B.
|
86b1feb5-d144-4e01-a9f5-370c18d5f0d0
|
715314.0
|
2023-12-01 00:00:00 UTC
|
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
|
DCOMP
|
https://www.nasdaq.com/articles/does-arvinas-inc.-arvn-have-the-potential-to-rally-145.52-as-wall-street-analysts-expect
|
nan
|
nan
|
Shares of Arvinas, Inc. (ARVN) have gained 35.5% over the past four weeks to close the last trading session at $21.97, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $53.94 indicates a potential upside of 145.5%.
The mean estimate comprises 16 short-term price targets with a standard deviation of $24.88. While the lowest estimate of $20 indicates a 9% decline from the current price level, the most optimistic analyst expects the stock to surge 332.4% to reach $95. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for ARVN, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You May Not Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in ARVN
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 13% over the past month, as 10 estimates have gone higher compared to no negative revision.
Moreover, ARVN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much ARVN could gain, the direction of price movement it implies does appear to be a good guide.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arvinas, Inc. (ARVN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Arvinas, Inc. (ARVN) have gained 35.5% over the past four weeks to close the last trading session at $21.97, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
|
Shares of Arvinas, Inc. (ARVN) have gained 35.5% over the past four weeks to close the last trading session at $21.97, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
|
Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ARVN could gain, the direction of price movement it implies does appear to be a good guide.
|
Going by the price targets, the mean estimate of $53.94 indicates a potential upside of 145.5%. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ARVN could gain, the direction of price movement it implies does appear to be a good guide.
|
3092230d-aa9e-490f-81fd-3177cf072616
|
715315.0
|
2023-12-01 00:00:00 UTC
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
DCOMP
|
https://www.nasdaq.com/articles/why-this-1-growth-stock-could-be-a-great-addition-to-your-portfolio-286
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Shake Shack (SHAK)
Founded in 2001, Shake Shack, Inc. is a New York-based fast food hamburger restaurant chain. Shake Shack restaurants operate in the United States and internationally. The company operates and grants licenses for Shake Shack restaurants, commonly known as "Shacks". Here they present a menu featuring burgers, chicken, hot dogs, crinkle-cut fries, shakes, frozen custard, beer, wine and additional offerings.
SHAK is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. SHAK has a Growth Style Score of A, forecasting year-over-year earnings growth of 209.7% for the current fiscal year.
For fiscal 2023, 11 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.08 to $0.34 per share. SHAK boasts an average earnings surprise of 80.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, SHAK should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Shake Shack, Inc. (SHAK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy. Here they present a menu featuring burgers, chicken, hot dogs, crinkle-cut fries, shakes, frozen custard, beer, wine and additional offerings.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Momentum Score Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." Click to get this free report Shake Shack, Inc. (SHAK) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
|
What are the Zacks Style Scores? That's where the Style Scores come in. SHAK has a Growth Style Score of A, forecasting year-over-year earnings growth of 209.7% for the current fiscal year.
|
a433e110-1c6a-4140-8bbe-140b5b0b0e57
|
715316.0
|
2023-12-01 00:00:00 UTC
|
Here's Why Fortinet (FTNT) is a Strong Growth Stock
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-fortinet-ftnt-is-a-strong-growth-stock-2
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Fortinet (FTNT)
Headquartered in Sunnyvale, CA, Fortinet, Inc. is a provider of network security appliances and Unified Threat Management (UTM) network security solutions to enterprises, service providers and government entities worldwide.
FTNT is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. FTNT has a Growth Style Score of A, forecasting year-over-year earnings growth of 31.1% for the current fiscal year.
For fiscal 2023, 16 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.05 to $1.56 per share. FTNT boasts an average earnings surprise of 14.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, FTNT should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fortinet, Inc. (FTNT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. Click to get this free report Fortinet, Inc. (FTNT) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
|
What are the Zacks Style Scores? That's where the Style Scores come in. FTNT has a Growth Style Score of A, forecasting year-over-year earnings growth of 31.1% for the current fiscal year.
|
6b6beeee-5c34-42c0-ba80-8e65dadc9c12
|
715317.0
|
2023-12-01 00:00:00 UTC
|
Is Ardmore Shipping (ASC) a Great Value Stock Right Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-ardmore-shipping-asc-a-great-value-stock-right-now
|
nan
|
nan
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One stock to keep an eye on is Ardmore Shipping (ASC). ASC is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A.
Investors should also recognize that ASC has a P/B ratio of 1.12. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. ASC's current P/B looks attractive when compared to its industry's average P/B of 1.17. Within the past 52 weeks, ASC's P/B has been as high as 1.64 and as low as 0.96, with a median of 1.13.
Finally, investors will want to recognize that ASC has a P/CF ratio of 3.22. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. ASC's current P/CF looks attractive when compared to its industry's average P/CF of 4.59. Over the past year, ASC's P/CF has been as high as 5.67 and as low as 2.19, with a median of 2.98.
Scorpio Tankers (STNG) may be another strong Transportation - Shipping stock to add to your shortlist. STNG is a # 2 (Buy) stock with a Value grade of A.
Shares of Scorpio Tankers are currently trading at a forward earnings multiple of 5.41 and a PEG ratio of 0.16 compared to its industry's P/E and PEG ratios of 5.78 and 0.33, respectively.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ardmore Shipping Corporation (ASC) : Free Stock Analysis Report
Scorpio Tankers Inc. (STNG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. ASC's current P/B looks attractive when compared to its industry's average P/B of 1.17. Click to get this free report Ardmore Shipping Corporation (ASC) : Free Stock Analysis Report Scorpio Tankers Inc. (STNG) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Click to get this free report Ardmore Shipping Corporation (ASC) : Free Stock Analysis Report Scorpio Tankers Inc. (STNG) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today. Investors should also recognize that ASC has a P/B ratio of 1.12. Shares of Scorpio Tankers are currently trading at a forward earnings multiple of 5.41 and a PEG ratio of 0.16 compared to its industry's P/E and PEG ratios of 5.78 and 0.33, respectively.
|
03105db0-1f19-4a33-8e60-1a52aeb373fc
|
715318.0
|
2023-12-01 00:00:00 UTC
|
RTX Secures a $225M Navy Contract to Aid Radar Production
|
DCOMP
|
https://www.nasdaq.com/articles/rtx-secures-a-%24225m-navy-contract-to-aid-radar-production
|
nan
|
nan
|
RTX Corp.’s RTX Missiles & Defense unit recently clinched a modification contract involving radars. The award has been offered by the Naval Sea Systems Command, Washington, D.C.
Details of the Deal
Valued at $225.3 million, the contract is expected to be completed by November 2024. Per the terms of the deal, RTX will provide integration and production support for Air and Missile Defense Radar and Enterprise Air Surveillance Radar.
A major portion of the work related to this deal will be carried out in Marlborough, MA.
Radars & RTX
With the rapid escalation of geopolitical tensions globally in recent times, developed as well as developing nations have been boosting their defense arsenal significantly. Radars constitute a vital part of their defense equipment. While radars have been in use since World War II for locating threats and targets, they are being used today for multiple purposes like ground surveillance, missile control, fire control, air traffic control, moving target indication, weapons location and vehicle search.
Demand for military radar systems has expanded manifold in recent times, driven by factors like a rise in defense spending of emerging economies, an increase in regional tensions and inter-country conflicts that have increased threats from missiles and aircraft. These, in turn, have been benefiting radar manufacturing companies like RTX in the form of contract wins like the latest one.
Notably, RTX’s product portfolio consists of varied radars like integrated air and missile defense radars, ballistic missile radars, surveillance radars and air dominance radars. Radars like AN-SPY 6, AN-TPY-2, APG-79 and APG-82 are some of the company’s combat-proven products that enjoy solid demand in the global military radar market.
Growth Prospects
Amid the invasion of Russia in Ukraine in the recent past, as well as the ongoing hostile conflict in the Middle East, nations across the globe can be expected to have strengthened their surveillance system to avoid any unprecedented attack. Consequently, it is reasonable to expect that the demand for an effective radar system, which boasts the features of next-generation technology-based warfare capabilities, will gain further momentum in the coming days due to the growing importance of radars in military surveillance.
To this end, the Fortune Business Insights firm projects the global military radar market to reach $22.1 billion by 2028 at a CAGR of 6.3% from 2021. Such growth projections should benefit RTX and other prominent radar manufacturers like Northrop Grumman NOC, Lockheed Martin LMT and L3Harris Technologies LHX.
Northrop’s radar solutions provide total surveillance for air and missile defense as well as air traffic control. Its diverse product portfolio includes a handful of radars like the F-35 fire control radar and Distributed Aperture System, the LONGBOW Fire Control Radar, the Scalable Agile Beam Radar, the APR-39 DV(2), the EV(2) Radar Warning Receiver programs and a few more.
NOC boasts a long-term earnings growth rate of 2.4%. The Zacks Consensus Estimate for its 2023 sales indicates an improvement of 6.6% from the 2022 reported figure.
Lockheed Martin’s radars are designed with the highest degree of commonality and fully integrated systems. These radars can operate in all environments, are available in highly mobile configurations and can be deployed worldwide. Its portfolio of radars includes the AN/APY-9 radar, the IRST21 Sensos system, AN/TPQ-53 radar systems, SPY-7, the long-range discrimination radar and a few more.
LMT boasts a long-term earnings growth rate of 8.6%. The stock has a four-quarter average earnings surprise of 4.35%.
L3Harris manufactures a handful of combat-proven radars like the SPS-48, land-based surveillance radars, the AN/APY-11 Multimode radar, the Tactical Air Surveillance radar, the AN/SPS-48G Long-range 3D surveillance radar and many more.
L3 Harris boasts a long-term earnings growth rate of 3.6%. The Zacks Consensus Estimate for its 2023 sales indicates an improvement of 12.6% from the 2022 reported figure.
Price Performance
In the past year, RTX’s shares have lost 19.3% compared with the industry’s 14.2% decline.
Image Source: Zacks Investment Research
Zacks Rank
RTX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lockheed Martin Corporation (LMT) : Free Stock Analysis Report
Northrop Grumman Corporation (NOC) : Free Stock Analysis Report
L3Harris Technologies Inc (LHX) : Free Stock Analysis Report
RTX Corporation (RTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Growth Prospects Amid the invasion of Russia in Ukraine in the recent past, as well as the ongoing hostile conflict in the Middle East, nations across the globe can be expected to have strengthened their surveillance system to avoid any unprecedented attack. To this end, the Fortune Business Insights firm projects the global military radar market to reach $22.1 billion by 2028 at a CAGR of 6.3% from 2021. Such growth projections should benefit RTX and other prominent radar manufacturers like Northrop Grumman NOC, Lockheed Martin LMT and L3Harris Technologies LHX.
|
Notably, RTX’s product portfolio consists of varied radars like integrated air and missile defense radars, ballistic missile radars, surveillance radars and air dominance radars. Such growth projections should benefit RTX and other prominent radar manufacturers like Northrop Grumman NOC, Lockheed Martin LMT and L3Harris Technologies LHX. Click to get this free report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report Northrop Grumman Corporation (NOC) : Free Stock Analysis Report L3Harris Technologies Inc (LHX) : Free Stock Analysis Report RTX Corporation (RTX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Notably, RTX’s product portfolio consists of varied radars like integrated air and missile defense radars, ballistic missile radars, surveillance radars and air dominance radars. L3Harris manufactures a handful of combat-proven radars like the SPS-48, land-based surveillance radars, the AN/APY-11 Multimode radar, the Tactical Air Surveillance radar, the AN/SPS-48G Long-range 3D surveillance radar and many more. Click to get this free report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report Northrop Grumman Corporation (NOC) : Free Stock Analysis Report L3Harris Technologies Inc (LHX) : Free Stock Analysis Report RTX Corporation (RTX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Notably, RTX’s product portfolio consists of varied radars like integrated air and missile defense radars, ballistic missile radars, surveillance radars and air dominance radars. L3Harris manufactures a handful of combat-proven radars like the SPS-48, land-based surveillance radars, the AN/APY-11 Multimode radar, the Tactical Air Surveillance radar, the AN/SPS-48G Long-range 3D surveillance radar and many more. Image Source: Zacks Investment Research Zacks Rank RTX currently carries a Zacks Rank #3 (Hold).
|
a055c0f4-9045-446b-8755-89c74b44d972
|
715319.0
|
2023-12-01 00:00:00 UTC
|
Crypto stocks set to start December on high note as bitcoin hits near 19-month high
|
DCOMP
|
https://www.nasdaq.com/articles/crypto-stocks-set-to-start-december-on-high-note-as-bitcoin-hits-near-19-month-high
|
nan
|
nan
|
Updates prices to market open
Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies rose on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite.
Bitcoin BTC=BTSP, up 1.6% at $38,337, has been gaining since October on optimism that a potential approval of a spot exchange-traded fund is likely to unleash more capital investments in the digital asset sector.
"Tailwinds have been gathering strength all year, especially in recent months, as spot ETF expectations build, the Binance uncertainty is resolved, and 2024's accelerated money printing becomes more inevitable," crypto-focused economist Noelle Acheson said, referring to the bitcoin rally.
Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O and TeraWulf WULF.O rose between 1.7% and 4%.
J.P.Morgan raised its price targets on Cipher Mining CIFR.O, CleanSpark CLSK.O, Iris Energy IREN.O, Marathon Digital and Riot Platforms to reflect the rally in bitcoin.
The mining companies are also increasing production before bitcoin's "halving" event next year, when rewards for producing the tokens are cut in half.
Coinbase's shares COIN.O rose about 2.5% following the 62% jump in November that outperformed bitcoin's 11% climb even as the U.S. crypto exchange reported a decline in trading volume earlier in the month.
"Higher crypto prices should lead to a boost in transaction volume and transaction revenues for Coinbase as we enter 2024," said CFRA Research analyst Michael Elliott.
However, Elliott cautioned the crypto exchange faces both legal challenges and new regulations that are likely to take time to play out and will continue to result in volatility for the stock.
The ETF approval bets have helped counter latest concerns after Changpeng Zhao, the founder of the world's largest crypto exchange, stepped down and pleaded guilty to breaking U.S. anti-money laundering laws.
Among other gainers were U.S. software developer and bitcoin investor Microstrategy MSTR.O, up nearly 3.5%, and ProShares Bitcoin Strategy ETF BITO.P, which added 2.1%.
(Reporting by Medha Singh in Bengaluru; Editing by Sriraj Kalluvila and Krishna Chandra Eluri)
((Medha.Singh@thomsonreuters.com; +91 80 6210 0592; X, formerly Twitter: @medhasinghs;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Updates prices to market open Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies rose on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite. "Tailwinds have been gathering strength all year, especially in recent months, as spot ETF expectations build, the Binance uncertainty is resolved, and 2024's accelerated money printing becomes more inevitable," crypto-focused economist Noelle Acheson said, referring to the bitcoin rally. The ETF approval bets have helped counter latest concerns after Changpeng Zhao, the founder of the world's largest crypto exchange, stepped down and pleaded guilty to breaking U.S. anti-money laundering laws.
|
Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O and TeraWulf WULF.O rose between 1.7% and 4%. J.P.Morgan raised its price targets on Cipher Mining CIFR.O, CleanSpark CLSK.O, Iris Energy IREN.O, Marathon Digital and Riot Platforms to reflect the rally in bitcoin. The ETF approval bets have helped counter latest concerns after Changpeng Zhao, the founder of the world's largest crypto exchange, stepped down and pleaded guilty to breaking U.S. anti-money laundering laws.
|
Updates prices to market open Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies rose on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite. Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O and TeraWulf WULF.O rose between 1.7% and 4%. Coinbase's shares COIN.O rose about 2.5% following the 62% jump in November that outperformed bitcoin's 11% climb even as the U.S. crypto exchange reported a decline in trading volume earlier in the month.
|
Bitcoin BTC=BTSP, up 1.6% at $38,337, has been gaining since October on optimism that a potential approval of a spot exchange-traded fund is likely to unleash more capital investments in the digital asset sector. Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O and TeraWulf WULF.O rose between 1.7% and 4%. Coinbase's shares COIN.O rose about 2.5% following the 62% jump in November that outperformed bitcoin's 11% climb even as the U.S. crypto exchange reported a decline in trading volume earlier in the month.
|
394081bb-118b-4531-a776-71bc7af0ea8b
|
715320.0
|
2023-12-01 00:00:00 UTC
|
Should Value Investors Buy Air Canada (ACDVF) Stock?
|
DCOMP
|
https://www.nasdaq.com/articles/should-value-investors-buy-air-canada-acdvf-stock-0
|
nan
|
nan
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Air Canada (ACDVF) is a stock many investors are watching right now. ACDVF is currently sporting a Zacks Rank of #1 (Strong Buy) and an A for Value. The stock has a Forward P/E ratio of 4.68. This compares to its industry's average Forward P/E of 9.78. ACDVF's Forward P/E has been as high as 20.37 and as low as -5.39, with a median of 12.40, all within the past year.
Investors should also note that ACDVF holds a PEG ratio of 0.20. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ACDVF's industry currently sports an average PEG of 0.35. Over the past 52 weeks, ACDVF's PEG has been as high as 0.21 and as low as 0.20, with a median of 0.20.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. ACDVF has a P/S ratio of 0.29. This compares to its industry's average P/S of 0.36.
Finally, we should also recognize that ACDVF has a P/CF ratio of 1.63. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. ACDVF's current P/CF looks attractive when compared to its industry's average P/CF of 5.40. Within the past 12 months, ACDVF's P/CF has been as high as 9.27 and as low as -133.81, with a median of 1.78.
If you're looking for another solid Transportation - Airline value stock, take a look at SkyWest (SKYW). SKYW is a # 2 (Buy) stock with a Value score of A.
Shares of SkyWest currently holds a Forward P/E ratio of 9.96, and its PEG ratio is 0.89. In comparison, its industry sports average P/E and PEG ratios of 9.78 and 0.35.
SKYW's price-to-earnings ratio has been as high as 11,210.77 and as low as -3,534.23, with a median of 14.90, while its PEG ratio has been as high as 1.84 and as low as 0.79, with a median of 0.98, all within the past year.
SkyWest also has a P/B ratio of 0.88 compared to its industry's price-to-book ratio of 2.65. Over the past year, its P/B ratio has been as high as 0.91, as low as 0.31, with a median of 0.60.
These are only a few of the key metrics included in Air Canada and SkyWest strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, ACDVF and SKYW look like an impressive value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Air Canada (ACDVF) : Free Stock Analysis Report
SkyWest, Inc. (SKYW) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
ACDVF's industry currently sports an average PEG of 0.35. Shares of SkyWest currently holds a Forward P/E ratio of 9.96, and its PEG ratio is 0.89. Click to get this free report Air Canada (ACDVF) : Free Stock Analysis Report SkyWest, Inc. (SKYW) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SKYW's price-to-earnings ratio has been as high as 11,210.77 and as low as -3,534.23, with a median of 14.90, while its PEG ratio has been as high as 1.84 and as low as 0.79, with a median of 0.98, all within the past year. Click to get this free report Air Canada (ACDVF) : Free Stock Analysis Report SkyWest, Inc. (SKYW) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. ACDVF has a P/S ratio of 0.29. Shares of SkyWest currently holds a Forward P/E ratio of 9.96, and its PEG ratio is 0.89.
|
c99c5c49-3615-4090-bd91-ca06b34a98b9
|
715321.0
|
2023-12-01 00:00:00 UTC
|
Should Value Investors Buy Modine Manufacturing (MOD) Stock?
|
DCOMP
|
https://www.nasdaq.com/articles/should-value-investors-buy-modine-manufacturing-mod-stock-5
|
nan
|
nan
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Modine Manufacturing (MOD) is a stock many investors are watching right now. MOD is currently sporting a Zacks Rank of #1 (Strong Buy) and an A for Value. The stock has a Forward P/E ratio of 15.46. This compares to its industry's average Forward P/E of 20.20. MOD's Forward P/E has been as high as 18.55 and as low as 7.35, with a median of 11.60, all within the past year.
Investors should also note that MOD holds a PEG ratio of 0.62. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MOD's industry currently sports an average PEG of 0.90. Over the past 52 weeks, MOD's PEG has been as high as 0.74 and as low as 0.29, with a median of 0.46.
Finally, investors should note that MOD has a P/CF ratio of 10.30. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. MOD's P/CF compares to its industry's average P/CF of 28.54. Within the past 12 months, MOD's P/CF has been as high as 11.08 and as low as 4.99, with a median of 8.64.
These are only a few of the key metrics included in Modine Manufacturing's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, MOD looks like an impressive value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Modine Manufacturing Company (MOD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
MOD's industry currently sports an average PEG of 0.90. Click to get this free report Modine Manufacturing Company (MOD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Click to get this free report Modine Manufacturing Company (MOD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
90b809ee-335b-4716-ac9c-4569041f0be1
|
715322.0
|
2023-12-01 00:00:00 UTC
|
Is Chubb Limited (CB) a Great Value Stock Right Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-chubb-limited-cb-a-great-value-stock-right-now-0
|
nan
|
nan
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One company to watch right now is Chubb Limited (CB). CB is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with a P/E ratio of 11, which compares to its industry's average of 25.81. Over the last 12 months, CB's Forward P/E has been as high as 14.59 and as low as 9.96, with a median of 10.92.
We also note that CB holds a PEG ratio of 1.10. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. CB's industry has an average PEG of 2.43 right now. CB's PEG has been as high as 1.46 and as low as 1, with a median of 1.09, all within the past year.
Value investors will likely look at more than just these metrics, but the above data helps show that Chubb Limited is likely undervalued currently. And when considering the strength of its earnings outlook, CB sticks out at as one of the market's strongest value stocks.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chubb Limited (CB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. Click to get this free report Chubb Limited (CB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. CB's PEG has been as high as 1.46 and as low as 1, with a median of 1.09, all within the past year.
|
56b0565a-8fab-4844-b7dd-e479d201d1f8
|
715323.0
|
2023-12-01 00:00:00 UTC
|
Is Spectris (SEPJY) Stock Undervalued Right Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-spectris-sepjy-stock-undervalued-right-now
|
nan
|
nan
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Spectris (SEPJY) is a stock many investors are watching right now. SEPJY is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock holds a P/E ratio of 14.04, while its industry has an average P/E of 16.79. Over the last 12 months, SEPJY's Forward P/E has been as high as 20.13 and as low as 13.58, with a median of 16.66.
Another notable valuation metric for SEPJY is its P/B ratio of 2.13. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 3.79. Over the past year, SEPJY's P/B has been as high as 2.87 and as low as 2.04, with a median of 2.35.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Spectris is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, SEPJY feels like a great value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Spectris (SEPJY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. Click to get this free report Spectris (SEPJY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. These figures are just a handful of the metrics value investors tend to look at, but they help show that Spectris is likely being undervalued right now. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
e39e4498-83a1-4fc3-b453-c131274d70ce
|
715324.0
|
2023-12-01 00:00:00 UTC
|
Is Accel Entertainment (ACEL) Stock Undervalued Right Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-accel-entertainment-acel-stock-undervalued-right-now
|
nan
|
nan
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
Accel Entertainment (ACEL) is a stock many investors are watching right now. ACEL is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock holds a P/E ratio of 13.51, while its industry has an average P/E of 32.29. ACEL's Forward P/E has been as high as 16.73 and as low as 8.55, with a median of 13.27, all within the past year.
We should also highlight that ACEL has a P/B ratio of 4.38. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 9.61. ACEL's P/B has been as high as 5.45 and as low as 3.60, with a median of 4.45, over the past year.
Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. ACEL has a P/S ratio of 0.75. This compares to its industry's average P/S of 1.02.
Finally, investors will want to recognize that ACEL has a P/CF ratio of 8.66. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. ACEL's current P/CF looks attractive when compared to its industry's average P/CF of 27.02. Within the past 12 months, ACEL's P/CF has been as high as 9.41 and as low as 5.60, with a median of 6.95.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Accel Entertainment is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, ACEL feels like a great value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Accel Entertainment, Inc. (ACEL) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. Click to get this free report Accel Entertainment, Inc. (ACEL) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. Accel Entertainment (ACEL) is a stock many investors are watching right now.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Value investors also use the P/S ratio. ACEL has a P/S ratio of 0.75.
|
3e08d993-5d20-468f-9bc8-07f5da2273db
|
715325.0
|
2023-12-01 00:00:00 UTC
|
Is 3M (MMM) Stock Undervalued Right Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-3m-mmm-stock-undervalued-right-now
|
nan
|
nan
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
3M (MMM) is a stock many investors are watching right now. MMM is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock holds a P/E ratio of 10.06, while its industry has an average P/E of 19.40. MMM's Forward P/E has been as high as 13.84 and as low as 8.97, with a median of 11.31, all within the past year.
Investors will also notice that MMM has a PEG ratio of 1.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MMM's PEG compares to its industry's average PEG of 1.75. Within the past year, MMM's PEG has been as high as 1.65 and as low as 1.09, with a median of 1.27.
These figures are just a handful of the metrics value investors tend to look at, but they help show that 3M is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, MMM feels like a great value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
3M Company (MMM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Click to get this free report 3M Company (MMM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
451d3f06-83c2-4275-b19b-7edc9cad4b84
|
715326.0
|
2023-12-01 00:00:00 UTC
|
Is ArcBest (ARCB) Stock Undervalued Right Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-arcbest-arcb-stock-undervalued-right-now-0
|
nan
|
nan
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One stock to keep an eye on is ArcBest (ARCB). ARCB is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 11.63, which compares to its industry's average of 22.98. Over the last 12 months, ARCB's Forward P/E has been as high as 14.40 and as low as 4.96, with a median of 9.19.
We should also highlight that ARCB has a P/B ratio of 2.31. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 4.03. Over the past 12 months, ARCB's P/B has been as high as 2.41 and as low as 1.46, with a median of 1.91.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. ARCB has a P/S ratio of 0.62. This compares to its industry's average P/S of 1.01.
Finally, our model also underscores that ARCB has a P/CF ratio of 8.80. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 15.86. Within the past 12 months, ARCB's P/CF has been as high as 9.15 and as low as 3.79, with a median of 5.56.
These are just a handful of the figures considered in ArcBest's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that ARCB is an impressive value stock right now.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ArcBest Corporation (ARCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Click to get this free report ArcBest Corporation (ARCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today. ARCB has a P/S ratio of 0.62. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook.
|
1dc34c80-2362-48af-a920-bc856ac6912f
|
715327.0
|
2023-12-01 00:00:00 UTC
|
1 Underrated Reason to Buy Eli Lilly Stock
|
DCOMP
|
https://www.nasdaq.com/articles/1-underrated-reason-to-buy-eli-lilly-stock
|
nan
|
nan
|
Eli Lilly (NYSE: LLY) is a top growth stock to own. The business is worth $560 billion, and that valuation is likely to get bigger in the years ahead. You might be tempted to buy the stock for the company's well-diversified product portfolio or perhaps for Zepbound, a weight-loss treatment that regulators recently approved, which could generate tens of billions in revenue.
Those are all solid reasons to invest in the company, but there's also one you may not have considered: its dividend. Although Eli Lilly's payout doesn't look like anything to get excited about (it currently yields less than 1%), that's deceptively low. The yield is another great reason to consider holding the stock in your portfolio.
Here's why you shouldn't discount Eli Lilly as a top dividend stock.
Lilly has aggressively raised its dividend for years
Eli Lilly has been paying dividends for well over a century. In fact, its first dividend dates back to 1885. Over the years the pharmaceutical giant has also increased its dividend payments. But what's encouraging is that the company isn't going to raise them by a few cents just so it can keep a streak going and say it's a Dividend King.
In the mid-2000s, Eli Lilly's dividend growth streak hit 40 straight years. Ultimately, due to the financial crisis of 2008-2009, the company ended its streak. It could have borrowed from the playbook of other dividend growth stocks and gone to more decimal places for the sake of saying it was increasing the dividend, without really making any significant change to the payout. Instead, it wasn't afraid to break its impressive streak by leaving its dividend unchanged.
In 2015, Lilly went back to raising its dividend payments. And as its financial results have gotten stronger, its dividend has increased by larger amounts as well. This year, the quarterly dividend of $1.13 is 15% higher than the $0.98 shareholders received last year. The chart below helps illustrate just how Eli Lilly's dividend increases started out small years ago and have gotten larger over time (note the big jump this past year):
LLY Dividend data by YCharts.
As a dividend investor, I'd prefer to see large increases rather than $0.01 bump-ups just for the sake of continuing a streak. Eli Lilly's practical approach to dividend increases is just one of the reasons why this is an underrated dividend stock to own.
More dividend hikes could be coming
If you're bullish on Zepbound and the game-changing effect it may have on Eli Lilly's business, you should also be excited for the dividend hikes which could follow. In the chart above, it's evident that Lilly has been willing to make significant increases to the dividend. And with the company's top and bottom lines potentially soaring in the future because Zepbound could generate tens of billions of dollars in revenue at its peak, there's likely to be a significant corresponding increase in the bottom line.
Today, the stock's payout ratio sits at around 80%; that suggests the dividend is manageable. But without factoring in the huge growth potential from Zepbound, I'd expect the rate of increases to slow down. However, given the significant profit and revenue growth Zepbound may generate for Eli Lilly in the long run, there could soon be a lot more room for the company to raise its payouts further.
A modest yield because of a soaring stock
Eli Lilly's current dividend yield of 0.8% doesn't look impressive when compared to the S&P 500, which is averaging a yield of 1.6%. But Lilly's yield is a victim of the stock's own success: Over the past three years, shares have quadrupled in value.
Suppose, for instance, that the stock was still trading at around $150, as it was back in November 2020. At that price, the current dividend would yield more than 3%. Lilly's stock would arguably be more attractive to dividend investors, and it would get picked up by more of the screeners that investors use to look for high-yielding stocks.
It's not that Eli Lilly pays a low dividend -- it's that the stock's impressive growth over the past few years has outpaced the increases to the payout, which haven't been modest.
A great buy for both growth and dividend investors
Eli Lilly is one of the best healthcare stocks for investors to buy today; there's a compelling argument for growth investors just as there is for dividend investors.
While the dividend yield may turn off some investors, a closer look at the business illustrates how this can be a fantastic investment in the long run. Your dividend income may be modest to start with, but over time, as the business gets bigger and as earnings rise, the company is likely to hike payments generously as it has in the past, leading to greater dividend income in the years ahead.
Between the underrated dividend and the promising growth prospects of the business, Eli Lilly is a no-brainer buy. It looks like an excellent investment that's suitable for any portfolio.
10 stocks we like better than Eli Lilly
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Eli Lilly wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 27, 2023
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
You might be tempted to buy the stock for the company's well-diversified product portfolio or perhaps for Zepbound, a weight-loss treatment that regulators recently approved, which could generate tens of billions in revenue. However, given the significant profit and revenue growth Zepbound may generate for Eli Lilly in the long run, there could soon be a lot more room for the company to raise its payouts further. It's not that Eli Lilly pays a low dividend -- it's that the stock's impressive growth over the past few years has outpaced the increases to the payout, which haven't been modest.
|
However, given the significant profit and revenue growth Zepbound may generate for Eli Lilly in the long run, there could soon be a lot more room for the company to raise its payouts further. A modest yield because of a soaring stock Eli Lilly's current dividend yield of 0.8% doesn't look impressive when compared to the S&P 500, which is averaging a yield of 1.6%. It's not that Eli Lilly pays a low dividend -- it's that the stock's impressive growth over the past few years has outpaced the increases to the payout, which haven't been modest.
|
Lilly has aggressively raised its dividend for years Eli Lilly has been paying dividends for well over a century. Eli Lilly's practical approach to dividend increases is just one of the reasons why this is an underrated dividend stock to own. A great buy for both growth and dividend investors Eli Lilly is one of the best healthcare stocks for investors to buy today; there's a compelling argument for growth investors just as there is for dividend investors.
|
The chart below helps illustrate just how Eli Lilly's dividend increases started out small years ago and have gotten larger over time (note the big jump this past year): LLY Dividend data by YCharts. It's not that Eli Lilly pays a low dividend -- it's that the stock's impressive growth over the past few years has outpaced the increases to the payout, which haven't been modest. A great buy for both growth and dividend investors Eli Lilly is one of the best healthcare stocks for investors to buy today; there's a compelling argument for growth investors just as there is for dividend investors.
|
dfc6c031-dfd4-42ba-bc90-5a3306e93dfd
|
715328.0
|
2023-12-01 00:00:00 UTC
|
Are Finance Stocks Lagging BTCS Inc. (BTCS) This Year?
|
DCOMP
|
https://www.nasdaq.com/articles/are-finance-stocks-lagging-btcs-inc.-btcs-this-year
|
nan
|
nan
|
Investors interested in Finance stocks should always be looking to find the best-performing companies in the group. BTCS Inc. (BTCS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
BTCS Inc. is one of 845 companies in the Finance group. The Finance group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BTCS Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BTCS' full-year earnings has moved 18.2% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, BTCS has moved about 56.3% on a year-to-date basis. In comparison, Finance companies have returned an average of 10.9%. This means that BTCS Inc. is outperforming the sector as a whole this year.
Another stock in the Finance sector, Mr Cooper (COOP), has outperformed the sector so far this year. The stock's year-to-date return is 50.8%.
For Mr Cooper, the consensus EPS estimate for the current year has increased 16.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, BTCS Inc. belongs to the Financial - Miscellaneous Services industry, which includes 63 individual stocks and currently sits at #172 in the Zacks Industry Rank. This group has gained an average of 9.2% so far this year, so BTCS is performing better in this area.
On the other hand, Mr Cooper belongs to the Financial - Consumer Loans industry. This 16-stock industry is currently ranked #224. The industry has moved +15.1% year to date.
Investors interested in the Finance sector may want to keep a close eye on BTCS Inc. and Mr Cooper as they attempt to continue their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BTCS Inc. (BTCS) : Free Stock Analysis Report
MR. COOPER GROUP INC (COOP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. Investors interested in the Finance sector may want to keep a close eye on BTCS Inc. and Mr Cooper as they attempt to continue their solid performance. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Another stock in the Finance sector, Mr Cooper (COOP), has outperformed the sector so far this year. Click to get this free report BTCS Inc. (BTCS) : Free Stock Analysis Report MR. COOPER GROUP INC (COOP) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Another stock in the Finance sector, Mr Cooper (COOP), has outperformed the sector so far this year. Looking more specifically, BTCS Inc. belongs to the Financial - Miscellaneous Services industry, which includes 63 individual stocks and currently sits at #172 in the Zacks Industry Rank. Click to get this free report BTCS Inc. (BTCS) : Free Stock Analysis Report MR. COOPER GROUP INC (COOP) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
BTCS Inc. is one of 845 companies in the Finance group. The Finance group currently sits at #8 within the Zacks Sector Rank. Another stock in the Finance sector, Mr Cooper (COOP), has outperformed the sector so far this year.
|
22a892ea-79f5-40e9-ac9b-dbcd9e78db70
|
715329.0
|
2023-12-01 00:00:00 UTC
|
Here's Why Encompass Health (EHC) is a Strong Value Stock
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-encompass-health-ehc-is-a-strong-value-stock-1
|
nan
|
nan
|
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Encompass Health (EHC)
Encompass Health Corporation is a provider of integrated healthcare services. It offers facility-based patient care through its network of inpatient rehabilitation hospitals. With a national footprint that includes 158 hospitals across 36 states and Puerto Rico, the company delivers high-quality, cost-effective, integrated care in the healthcare space. It provides a continuum of facility-based for its patients and their families, which will gain more prevalence as coordinated care and integrated delivery payment models, such as accountable care organizations and bundled payment arrangements.
EHC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 18.53; value investors should take notice.
Eight analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.07 to $3.52 per share. EHC boasts an average earnings surprise of 17.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, EHC should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Encompass Health Corporation (EHC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy. With a national footprint that includes 158 hospitals across 36 states and Puerto Rico, the company delivers high-quality, cost-effective, integrated care in the healthcare space.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio. Click to get this free report Encompass Health Corporation (EHC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
|
What are the Zacks Style Scores? How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio. That's where the Style Scores come in.
|
a211e3f2-f2a1-4931-88a0-f309b424969f
|
715330.0
|
2023-12-01 00:00:00 UTC
|
Is fuboTV (FUBO) Stock Outpacing Its Consumer Discretionary Peers This Year?
|
DCOMP
|
https://www.nasdaq.com/articles/is-fubotv-fubo-stock-outpacing-its-consumer-discretionary-peers-this-year-1
|
nan
|
nan
|
Investors interested in Consumer Discretionary stocks should always be looking to find the best-performing companies in the group. fuboTV Inc. (FUBO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
fuboTV Inc. is one of 281 companies in the Consumer Discretionary group. The Consumer Discretionary group currently sits at #11 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. fuboTV Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for FUBO's full-year earnings has moved 4.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, FUBO has moved about 83.3% on a year-to-date basis. In comparison, Consumer Discretionary companies have returned an average of 11.3%. This means that fuboTV Inc. is outperforming the sector as a whole this year.
Another stock in the Consumer Discretionary sector, Skechers (SKX), has outperformed the sector so far this year. The stock's year-to-date return is 40.4%.
For Skechers, the consensus EPS estimate for the current year has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, fuboTV Inc. belongs to the Broadcast Radio and Television industry, which includes 22 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has gained an average of 31% so far this year, so FUBO is performing better in this area.
On the other hand, Skechers belongs to the Shoes and Retail Apparel industry. This 10-stock industry is currently ranked #21. The industry has moved -7.4% year to date.
Investors interested in the Consumer Discretionary sector may want to keep a close eye on fuboTV Inc. and Skechers as they attempt to continue their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
fuboTV Inc. (FUBO) : Free Stock Analysis Report
Skechers U.S.A., Inc. (SKX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
fuboTV Inc. (FUBO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Investors interested in the Consumer Discretionary sector may want to keep a close eye on fuboTV Inc. and Skechers as they attempt to continue their solid performance. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Another stock in the Consumer Discretionary sector, Skechers (SKX), has outperformed the sector so far this year. Click to get this free report fuboTV Inc. (FUBO) : Free Stock Analysis Report Skechers U.S.A., Inc. (SKX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Another stock in the Consumer Discretionary sector, Skechers (SKX), has outperformed the sector so far this year. Looking more specifically, fuboTV Inc. belongs to the Broadcast Radio and Television industry, which includes 22 individual stocks and currently sits at #86 in the Zacks Industry Rank. Click to get this free report fuboTV Inc. (FUBO) : Free Stock Analysis Report Skechers U.S.A., Inc. (SKX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
fuboTV Inc. is one of 281 companies in the Consumer Discretionary group. The Consumer Discretionary group currently sits at #11 within the Zacks Sector Rank. Another stock in the Consumer Discretionary sector, Skechers (SKX), has outperformed the sector so far this year.
|
6af8f99e-86e5-42b3-8503-328048e204aa
|
715331.0
|
2023-12-01 00:00:00 UTC
|
Are Retail-Wholesale Stocks Lagging Beacon Roofing Supply (BECN) This Year?
|
DCOMP
|
https://www.nasdaq.com/articles/are-retail-wholesale-stocks-lagging-beacon-roofing-supply-becn-this-year
|
nan
|
nan
|
For those looking to find strong Retail-Wholesale stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Beacon Roofing Supply (BECN) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Retail-Wholesale sector should help us answer this question.
Beacon Roofing Supply is a member of our Retail-Wholesale group, which includes 221 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Beacon Roofing Supply is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BECN's full-year earnings has moved 9.3% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, BECN has moved about 52.2% on a year-to-date basis. At the same time, Retail-Wholesale stocks have gained an average of 20.9%. This means that Beacon Roofing Supply is performing better than its sector in terms of year-to-date returns.
Deckers (DECK) is another Retail-Wholesale stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 66.3%.
For Deckers, the consensus EPS estimate for the current year has increased 4.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Beacon Roofing Supply is a member of the Building Products - Retail industry, which includes 8 individual companies and currently sits at #185 in the Zacks Industry Rank. This group has gained an average of 6.5% so far this year, so BECN is performing better in this area.
On the other hand, Deckers belongs to the Retail - Apparel and Shoes industry. This 43-stock industry is currently ranked #91. The industry has moved +14.4% year to date.
Investors with an interest in Retail-Wholesale stocks should continue to track Beacon Roofing Supply and Deckers. These stocks will be looking to continue their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Beacon Roofing Supply, Inc. (BECN) : Free Stock Analysis Report
Deckers Outdoor Corporation (DECK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A quick glance at the company's year-to-date performance in comparison to the rest of the Retail-Wholesale sector should help us answer this question. Beacon Roofing Supply is a member of our Retail-Wholesale group, which includes 221 different companies and currently sits at #7 in the Zacks Sector Rank. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Beacon Roofing Supply is a member of our Retail-Wholesale group, which includes 221 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. Click to get this free report Beacon Roofing Supply, Inc. (BECN) : Free Stock Analysis Report Deckers Outdoor Corporation (DECK) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Beacon Roofing Supply is a member of our Retail-Wholesale group, which includes 221 different companies and currently sits at #7 in the Zacks Sector Rank. Breaking things down more, Beacon Roofing Supply is a member of the Building Products - Retail industry, which includes 8 individual companies and currently sits at #185 in the Zacks Industry Rank. Click to get this free report Beacon Roofing Supply, Inc. (BECN) : Free Stock Analysis Report Deckers Outdoor Corporation (DECK) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
This means that Beacon Roofing Supply is performing better than its sector in terms of year-to-date returns. Deckers (DECK) is another Retail-Wholesale stock that has outperformed the sector so far this year. Investors with an interest in Retail-Wholesale stocks should continue to track Beacon Roofing Supply and Deckers.
|
2c2f57c7-ea3d-4b02-94df-42cf9b176108
|
715332.0
|
2023-12-01 00:00:00 UTC
|
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
|
DCOMP
|
https://www.nasdaq.com/articles/is-corbus-pharmaceuticals-crbp-stock-outpacing-its-medical-peers-this-year
|
nan
|
nan
|
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Corbus Pharmaceuticals (CRBP) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Corbus Pharmaceuticals is one of 1089 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Corbus Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CRBP's full-year earnings has moved 4.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that CRBP has returned about 101.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7.1%. This means that Corbus Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is CVRx (CVRX). The stock is up 11.6% year-to-date.
In CVRx's case, the consensus EPS estimate for the current year increased 6.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Corbus Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 194 individual stocks and currently sits at #64 in the Zacks Industry Rank. On average, this group has lost an average of 10.6% so far this year, meaning that CRBP is performing better in terms of year-to-date returns.
In contrast, CVRx falls under the Medical - Instruments industry. Currently, this industry has 94 stocks and is ranked #72. Since the beginning of the year, the industry has moved -4.5%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Corbus Pharmaceuticals and CVRx as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Corbus Pharmaceuticals Holdings, Inc. (CRBP) : Free Stock Analysis Report
CVRx, Inc. (CVRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. Going forward, investors interested in Medical stocks should continue to pay close attention to Corbus Pharmaceuticals and CVRx as they could maintain their solid performance. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. Looking more specifically, Corbus Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 194 individual stocks and currently sits at #64 in the Zacks Industry Rank. Click to get this free report Corbus Pharmaceuticals Holdings, Inc. (CRBP) : Free Stock Analysis Report CVRx, Inc. (CVRX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. Looking more specifically, Corbus Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 194 individual stocks and currently sits at #64 in the Zacks Industry Rank. Click to get this free report Corbus Pharmaceuticals Holdings, Inc. (CRBP) : Free Stock Analysis Report CVRx, Inc. (CVRX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Has Corbus Pharmaceuticals (CRBP) been one of those stocks this year? This means that Corbus Pharmaceuticals is performing better than its sector in terms of year-to-date returns. One other Medical stock that has outperformed the sector so far this year is CVRx (CVRX).
|
d534fa41-6c2d-413f-8b3f-0c79de93532b
|
715333.0
|
2023-12-01 00:00:00 UTC
|
Is Denison Mine Corp (DNN) Stock Outpacing Its Basic Materials Peers This Year?
|
DCOMP
|
https://www.nasdaq.com/articles/is-denison-mine-corp-dnn-stock-outpacing-its-basic-materials-peers-this-year-0
|
nan
|
nan
|
For those looking to find strong Basic Materials stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Denison Mine (DNN) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Basic Materials peers, we might be able to answer that question.
Denison Mine is one of 230 companies in the Basic Materials group. The Basic Materials group currently sits at #16 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Denison Mine is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for DNN's full-year earnings has moved 300% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that DNN has returned about 59.1% since the start of the calendar year. At the same time, Basic Materials stocks have gained an average of 6.7%. This means that Denison Mine is outperforming the sector as a whole this year.
One other Basic Materials stock that has outperformed the sector so far this year is Energy Fuels (UUUU). The stock is up 28% year-to-date.
Over the past three months, Energy Fuels' consensus EPS estimate for the current year has increased 10.5%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Denison Mine belongs to the Mining - Miscellaneous industry, a group that includes 54 individual companies and currently sits at #141 in the Zacks Industry Rank. On average, this group has gained an average of 8.6% so far this year, meaning that DNN is performing better in terms of year-to-date returns.
On the other hand, Energy Fuels belongs to the Mining - Non Ferrous industry. This 12-stock industry is currently ranked #229. The industry has moved +5.5% year to date.
Going forward, investors interested in Basic Materials stocks should continue to pay close attention to Denison Mine and Energy Fuels as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Denison Mine Corp (DNN) : Free Stock Analysis Report
Energy Fuels Inc (UUUU) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
For those looking to find strong Basic Materials stocks, it is prudent to search for companies in the group that are outperforming their peers. Going forward, investors interested in Basic Materials stocks should continue to pay close attention to Denison Mine and Energy Fuels as they could maintain their solid performance. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Over the past 90 days, the Zacks Consensus Estimate for DNN's full-year earnings has moved 300% higher. To break things down more, Denison Mine belongs to the Mining - Miscellaneous industry, a group that includes 54 individual companies and currently sits at #141 in the Zacks Industry Rank. Click to get this free report Denison Mine Corp (DNN) : Free Stock Analysis Report Energy Fuels Inc (UUUU) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. To break things down more, Denison Mine belongs to the Mining - Miscellaneous industry, a group that includes 54 individual companies and currently sits at #141 in the Zacks Industry Rank. Click to get this free report Denison Mine Corp (DNN) : Free Stock Analysis Report Energy Fuels Inc (UUUU) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Is Denison Mine (DNN) one of those stocks right now? Denison Mine is one of 230 companies in the Basic Materials group. Over the past 90 days, the Zacks Consensus Estimate for DNN's full-year earnings has moved 300% higher.
|
9011c7b4-23dc-4739-8877-620f24dc30ba
|
715334.0
|
2023-12-01 00:00:00 UTC
|
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-ligand-pharmaceuticals-lgnd-is-a-strong-value-stock
|
nan
|
nan
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Ligand Pharmaceuticals (LGND)
San Diego, CA-based Ligand is a biotechnology company whose business model is based on developing or acquiring royalty revenue-generating assets. The company is focused on the development and licensing of biopharmaceutical assets.
LGND is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 10.85; value investors should take notice.
For fiscal 2023, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.29 to $5.38 per share. LGND boasts an average earnings surprise of 67.2%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LGND should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
|
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. What are the Zacks Style Scores? That's where the Style Scores come in.
|
8f00574d-950a-4b32-bafd-1293bdf0342b
|
715335.0
|
2023-12-01 00:00:00 UTC
|
Is Nu (NU) Stock Outpacing Its Business Services Peers This Year?
|
DCOMP
|
https://www.nasdaq.com/articles/is-nu-nu-stock-outpacing-its-business-services-peers-this-year
|
nan
|
nan
|
For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Nu Holdings Ltd. (NU) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Nu Holdings Ltd. is a member of the Business Services sector. This group includes 318 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Nu Holdings Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for NU's full-year earnings has moved 27.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, NU has moved about 100% on a year-to-date basis. In comparison, Business Services companies have returned an average of 15.7%. This means that Nu Holdings Ltd. is outperforming the sector as a whole this year.
Another Business Services stock, which has outperformed the sector so far this year, is FirstCash Holdings (FCFS). The stock has returned 28.9% year-to-date.
For FirstCash Holdings, the consensus EPS estimate for the current year has increased 5.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Nu Holdings Ltd. belongs to the Technology Services industry, which includes 176 individual stocks and currently sits at #79 in the Zacks Industry Rank. This group has gained an average of 37.6% so far this year, so NU is performing better in this area.
In contrast, FirstCash Holdings falls under the Financial Transaction Services industry. Currently, this industry has 39 stocks and is ranked #164. Since the beginning of the year, the industry has moved +17.9%.
Going forward, investors interested in Business Services stocks should continue to pay close attention to Nu Holdings Ltd. and FirstCash Holdings as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Nu Holdings Ltd. (NU) : Free Stock Analysis Report
FirstCash Holdings, Inc. (FCFS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
This group includes 318 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. Click to get this free report Nu Holdings Ltd. (NU) : Free Stock Analysis Report FirstCash Holdings, Inc. (FCFS) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Has Nu Holdings Ltd. (NU) been one of those stocks this year? Looking more specifically, Nu Holdings Ltd. belongs to the Technology Services industry, which includes 176 individual stocks and currently sits at #79 in the Zacks Industry Rank. Click to get this free report Nu Holdings Ltd. (NU) : Free Stock Analysis Report FirstCash Holdings, Inc. (FCFS) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Has Nu Holdings Ltd. (NU) been one of those stocks this year? The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. Over the past 90 days, the Zacks Consensus Estimate for NU's full-year earnings has moved 27.9% higher.
|
35676749-bc5e-4e97-bd13-fbe1a9118470
|
715336.0
|
2023-12-01 00:00:00 UTC
|
Here's Why HP (HPQ) is a Strong Value Stock
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-hp-hpq-is-a-strong-value-stock
|
nan
|
nan
|
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: HP (HPQ)
HP Inc. is the surviving entity following the November 2015 split of Hewlett-Packard Company into publicly traded entities - Hewlett Packard Enterprise Company and HP Inc.
HPQ is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 8.54; value investors should take notice.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.02 to $3.43 per share. HPQ also boasts an average earnings surprise of 1.7%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, HPQ should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HP Inc. (HPQ) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Click to get this free report HP Inc. (HPQ) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
|
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. That's where the Style Scores come in.
|
72323fcd-9fc2-494c-abc0-0770a6e1cb20
|
715337.0
|
2023-12-01 00:00:00 UTC
|
Here's Why CACI International (CACI) is a Strong Value Stock
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-caci-international-caci-is-a-strong-value-stock-0
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: CACI International (CACI)
Based in Reston, VA, CACI International delivers IT applications and infrastructure to improve communications and secure the integrity of information systems and networks, enhance data collection and analysis, and increase efficiency and mission effectiveness. The company’s solutions enrich defense and intelligence capabilities, assure homeland security, improve decision-making, and help customers operate smartly and proficiently.
CACI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.01; value investors should take notice.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.08 to $20.05 per share. CACI also boasts an average earnings surprise of 2.5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, CACI should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CACI International, Inc. (CACI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. The company’s solutions enrich defense and intelligence capabilities, assure homeland security, improve decision-making, and help customers operate smartly and proficiently.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. Click to get this free report CACI International, Inc. (CACI) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio. The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
|
What are the Zacks Style Scores? The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. That's where the Style Scores come in.
|
b272697f-d88a-4745-a52f-6215b4a73f38
|
715338.0
|
2023-12-01 00:00:00 UTC
|
Woodward (WWD) is a Top-Ranked Value Stock: Should You Buy?
|
DCOMP
|
https://www.nasdaq.com/articles/woodward-wwd-is-a-top-ranked-value-stock%3A-should-you-buy
|
nan
|
nan
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Woodward (WWD)
Headquartered in Fort Collins, CO, Woodward, Inc. is an independent designer, manufacturer and service provider of energy control and optimization solutions. The company provides a wide array of products for fuel, combustion, fluid, actuation and electronic applications, which serve the commercial aerospace, business jet, military and energy markets. Apart from serving original equipment manufacturers (OEMs), it also engages in aftermarket repairs, replacements and other service support operations.
WWD is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 28.43; value investors should take notice.
Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.15 to $4.75 per share. WWD also boasts an average earnings surprise of 14.7%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, WWD should be on investors' short list.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Woodward, Inc. (WWD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. The company provides a wide array of products for fuel, combustion, fluid, actuation and electronic applications, which serve the commercial aerospace, business jet, military and energy markets.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks. Click to get this free report Woodward, Inc. (WWD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio. The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
|
What are the Zacks Style Scores? The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum. That's where the Style Scores come in.
|
07d7a6bf-d8ac-48c8-ab2a-302358d835d0
|
715339.0
|
2023-12-01 00:00:00 UTC
|
Should Value Investors Buy TTM Technologies (TTMI) Stock?
|
DCOMP
|
https://www.nasdaq.com/articles/should-value-investors-buy-ttm-technologies-ttmi-stock-2
|
nan
|
nan
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One stock to keep an eye on is TTM Technologies (TTMI). TTMI is currently sporting a Zacks Rank of #1 (Strong Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 9.69, which compares to its industry's average of 20. Over the past year, TTMI's Forward P/E has been as high as 13.14 and as low as 8.27, with a median of 10.28.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. TTMI has a P/S ratio of 0.67. This compares to its industry's average P/S of 1.33.
Finally, our model also underscores that TTMI has a P/CF ratio of 8.74. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. TTMI's P/CF compares to its industry's average P/CF of 25.02. Within the past 12 months, TTMI's P/CF has been as high as 8.74 and as low as 5.09, with a median of 6.82.
These are only a few of the key metrics included in TTM Technologies's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, TTMI looks like an impressive value stock at the moment.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TTM Technologies, Inc. (TTMI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits.
|
Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. Click to get this free report TTM Technologies, Inc. (TTMI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. TTMI has a P/S ratio of 0.67. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
5d03e0cb-3606-4c25-84b8-9fe477f1c41d
|
715340.0
|
2023-12-01 00:00:00 UTC
|
Company News for Dec 1, 2023
|
DCOMP
|
https://www.nasdaq.com/articles/company-news-for-dec-1-2023
|
nan
|
nan
|
Shares of The Kroger Co. (KR) rose 1.4% after the company reported third-quarter fiscal 2023 earnings of $0.95 per share, surpassing the Zacks Consensus Estimate of $0.90 per share.
Frontline plc’s (FRO) shares plummeted 6.1% after the company reported third-quarter 2023 earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.46 per share.
Shares of Five Below, Inc. (FIVE) rose 0.4% after the company reported third-quarter fiscal 2023 earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.23 per share.
Nutanix, Inc.’s (NTNX) shares jumped 3.7% after the company reported first-quarter fiscal 2024 earnings of $0.29 per share, outpacing the Zacks Consensus Estimate of $0.17 per share.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Kroger Co. (KR) : Free Stock Analysis Report
Frontline PLC (FRO) : Free Stock Analysis Report
Five Below, Inc. (FIVE) : Free Stock Analysis Report
Nutanix (NTNX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
Shares of The Kroger Co. (KR) rose 1.4% after the company reported third-quarter fiscal 2023 earnings of $0.95 per share, surpassing the Zacks Consensus Estimate of $0.90 per share. Frontline plc’s (FRO) shares plummeted 6.1% after the company reported third-quarter 2023 earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.46 per share. Click to get this free report The Kroger Co. (KR) : Free Stock Analysis Report Frontline PLC (FRO) : Free Stock Analysis Report Five Below, Inc. (FIVE) : Free Stock Analysis Report Nutanix (NTNX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Shares of The Kroger Co. (KR) rose 1.4% after the company reported third-quarter fiscal 2023 earnings of $0.95 per share, surpassing the Zacks Consensus Estimate of $0.90 per share. Shares of Five Below, Inc. (FIVE) rose 0.4% after the company reported third-quarter fiscal 2023 earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.23 per share. Click to get this free report The Kroger Co. (KR) : Free Stock Analysis Report Frontline PLC (FRO) : Free Stock Analysis Report Five Below, Inc. (FIVE) : Free Stock Analysis Report Nutanix (NTNX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Shares of The Kroger Co. (KR) rose 1.4% after the company reported third-quarter fiscal 2023 earnings of $0.95 per share, surpassing the Zacks Consensus Estimate of $0.90 per share. Frontline plc’s (FRO) shares plummeted 6.1% after the company reported third-quarter 2023 earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.46 per share. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
458f05ff-1da5-4098-a89c-fd6020a7b976
|
715341.0
|
2023-12-01 00:00:00 UTC
|
Better Buy: McDonald's vs. Starbucks
|
DCOMP
|
https://www.nasdaq.com/articles/better-buy%3A-mcdonalds-vs.-starbucks-0
|
nan
|
nan
|
Although both McDonald's (NYSE: MCD) and Starbucks (NASDAQ: SBUX) have seen their share prices rise about 50% in the past five years, neither business has produced a better return than the S&P 500, which is up some 65% during the same time. This might be discouraging for investors.
However, not all hope is lost. These two companies possess favorable traits that might make them worthy investments over the long term. So, is McDonald's or Starbucks a better restaurant stock to buy? Let's look at each in greater detail before coming to a decision.
The case for McDonald's
It's hardly a surprise that McDonald's would be thriving during a time of heightened economic uncertainty, high interest rates, and inflationary pressures. The fast-food burger chain crushed expectations by posting revenue of $6.7 billion and net income of $2.3 billion in the three-month period that ended Sept. 30.
Global same-store sales jumped 8.8%, a clear sign that consumers are finding value by choosing to eat at McDonald's locations. This attractive value proposition should benefit the business if a severe recession happens.
The great Warren Buffett once said, "The best business is a royalty on the growth of others." As a franchise operator, McDonald's fits the description here, as third parties provide the capital to fund store growth. Almost 90% of its restaurants in the U.S. aren't company-owned. And this has helped result in incredibly high gross and operating margins.
Mcdonald's shares currently sell at a forward price-to-earnings (P/E) multiple of 23.9. This represents a slight discount to the average valuation over the past couple of years. Investors might find this P/E ratio too high to pay for such a mature and established company.
But it's worth considering that in the past three years, revenue and diluted earnings per share have increased at compound annual rates of 7.3% and 10.5%, respectively, which are healthy clips. Between 2022 and 2025, Wall Street consensus estimates call for sales to rise at an annualized rate of 7.3%, with diluted EPS increasing at an 18.1% clip.
These figures would point to strong growth still ahead for McDonald's, which can justify its current valuation.
The case for Starbucks
Starbucks also was able to beat Wall Street estimates in its most recent fiscal quarter (Q4 2023, ended Oct. 1). Revenue was up 11.4%, with net income soaring 38.8%. What's very encouraging is that both traffic and the size of average tickets rose in the quarter.
Without a doubt, the coffeehouse giant's most important trait is its powerful brand recognition. The business has done a wonderful job at turning a commoditized product like coffee into something that people are willing to pay premium prices for now. Starbucks resonates with consumers, a standing that all companies want.
As of this writing, Starbucks shares trade at a forward P/E ratio of 24.4, about the same multiple as McDonald's. This represents a sizable discount to the trailing-two-year average of 31.2.
Additionally, Starbucks has registered impressive growth since the pandemic rattled its business. Between fiscal 2020 and 2023, revenue and diluted EPS rose at compound annual rates of 15.2% and 65.5%, respectively. Over the next five fiscal years, sales are expected to rise 10% per year, with diluted EPS increasing at an 18.3% clip.
It's hard not to get excited about these forecasts. Also bolstering Starbucks is an expanding store base. Management sees the potential for 55,000 locations worldwide by 2030, up from about 38,000 today.
Plus, the company's ability to lean heavily on its fantastic tech foundation and thriving rewards program, now with more than 75 million members globally, is a key competitive asset that helps drive engagement and informs strategic decisions around product and marketing initiatives.
And the winner is...
Both McDonald's and Starbucks are resilient restaurant concepts that possess strong brands, impressive growth metrics, and durable competitive positions. This means that they should be on the radar of all long-term investors.
But because I have to choose just one as the winner, I'm going to go with Starbucks. By paying a valuation similar to McDonald's, investors gain exposure to a business that has proven pricing power and greater growth potential.
10 stocks we like better than McDonald's
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and McDonald's wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 28, 2023
Neil Patel and his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Starbucks. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Although both McDonald's (NYSE: MCD) and Starbucks (NASDAQ: SBUX) have seen their share prices rise about 50% in the past five years, neither business has produced a better return than the S&P 500, which is up some 65% during the same time. Plus, the company's ability to lean heavily on its fantastic tech foundation and thriving rewards program, now with more than 75 million members globally, is a key competitive asset that helps drive engagement and informs strategic decisions around product and marketing initiatives. By paying a valuation similar to McDonald's, investors gain exposure to a business that has proven pricing power and greater growth potential.
|
Between 2022 and 2025, Wall Street consensus estimates call for sales to rise at an annualized rate of 7.3%, with diluted EPS increasing at an 18.1% clip. Between fiscal 2020 and 2023, revenue and diluted EPS rose at compound annual rates of 15.2% and 65.5%, respectively. Over the next five fiscal years, sales are expected to rise 10% per year, with diluted EPS increasing at an 18.3% clip.
|
Although both McDonald's (NYSE: MCD) and Starbucks (NASDAQ: SBUX) have seen their share prices rise about 50% in the past five years, neither business has produced a better return than the S&P 500, which is up some 65% during the same time. So, is McDonald's or Starbucks a better restaurant stock to buy? By paying a valuation similar to McDonald's, investors gain exposure to a business that has proven pricing power and greater growth potential.
|
Although both McDonald's (NYSE: MCD) and Starbucks (NASDAQ: SBUX) have seen their share prices rise about 50% in the past five years, neither business has produced a better return than the S&P 500, which is up some 65% during the same time. So, is McDonald's or Starbucks a better restaurant stock to buy? By paying a valuation similar to McDonald's, investors gain exposure to a business that has proven pricing power and greater growth potential.
|
7808ed99-1635-487a-9b6c-b6af058a8c88
|
715342.0
|
2023-12-01 00:00:00 UTC
|
General Dynamics' (GD) Arm Secures $655M Deal for M1128
|
DCOMP
|
https://www.nasdaq.com/articles/general-dynamics-gd-arm-secures-%24655m-deal-for-m1128
|
nan
|
nan
|
General Dynamics Corporation’s GD business unit, Ordnance and Tactical Systems, recently clinched a $654.5 million contract for the metal parts program for M1128. The contract has been awarded by the Army Contracting Command, Newark, NJ.
Work locations will be determined with each order. The contract is expected to be completed by Apr 12, 2028.
What’s Favoring General Dynamics?
Rising geopolitical tensions, perceived threats and the need to guard national interests are resulting in nations consistently reinforcing their defense capabilities. This has led to augmented spending on military arms and ammunition that play an integral role in military missions.
Such increased defense spending on military arms and ammunition often translates to a boost for companies like General Dynamics, renowned for their extensive expertise in the designing, engineering and production of munitions, energetics, weapons, armaments and missile subsystems worldwide.
Consequently, the company witnesses a consistent order inflow for its manufactured arms and ammunition, like the latest one. The latest order win for M1128, which is an eight-wheeled assault mobile gun system for the Stryker family, reflects the significant demand that this product enjoys, thereby boosting the revenue generation prospects of General Dynamics.
Growth Prospects & Peer Moves
Going forward, per the report from the Markets and Markets firm, the global ammunition market is poised to witness a CAGR of 3.7% over the 2021-2026 period. This could lead to additional contracts for arms and ammunition procurement for General Dynamics. Such a consistent order inflow is likely to boost GD’s order book and backlog.
Other defense majors poised to benefit from the expanding ammunition market are Lockheed Martin LMT, RTX Corporation RTX and Northrop Grumman NOC.
Lockheed Martin provides a wide variety of highly effective and reliable weapon systems. These weapon systems include precision strike weapons with long standoff ranges and smart submunitions to give the warfighter maximum flexibility and fire support mobile artillery and guided munitions to dominate the battlefield.
Lockheed boasts a long-term earnings growth rate of 8.6%. The Zacks Consensus Estimate for its 2023 sales suggests a growth rate of 0.9% from the prior-year reported figure.
RTX manufactures ammunition ranging from shoulder-fired weapons to extended-range precision munitions. Its product portfolio includes Excalibur projectile and a few more.
RTX’s long-term earnings growth rate is pegged at 9.4%. The Zacks Consensus Estimate for its 2023 sales suggests a growth rate of 10.5% from the prior-year reported figure.
Northrop’s ammunition includes air-bursting, proximity and guided munitions, which provide greater precision and the ability to counter unmanned threats and defeat advanced armor. Its portfolio of ammunition includes M865 kinetic energy and the M1002, 120mm M829, M830, M908, M1028 and M1147 cartridges and a few more.
Northrop boasts a long-term earnings growth rate of 2.4%. NOC stock has appreciated 9.1% in the past three months.
Price Performance
Shares of General Dynamics have increased 18% in the past six months against the industry’s 6.2% decline.
Image Source: Zacks Investment Research
Zacks Rank
General Dynamics currently carries a Zacks Rank #3 (Hold). You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lockheed Martin Corporation (LMT) : Free Stock Analysis Report
Northrop Grumman Corporation (NOC) : Free Stock Analysis Report
General Dynamics Corporation (GD) : Free Stock Analysis Report
RTX Corporation (RTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Such increased defense spending on military arms and ammunition often translates to a boost for companies like General Dynamics, renowned for their extensive expertise in the designing, engineering and production of munitions, energetics, weapons, armaments and missile subsystems worldwide. The latest order win for M1128, which is an eight-wheeled assault mobile gun system for the Stryker family, reflects the significant demand that this product enjoys, thereby boosting the revenue generation prospects of General Dynamics. Northrop’s ammunition includes air-bursting, proximity and guided munitions, which provide greater precision and the ability to counter unmanned threats and defeat advanced armor.
|
Other defense majors poised to benefit from the expanding ammunition market are Lockheed Martin LMT, RTX Corporation RTX and Northrop Grumman NOC. Image Source: Zacks Investment Research Zacks Rank General Dynamics currently carries a Zacks Rank #3 (Hold). Click to get this free report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report Northrop Grumman Corporation (NOC) : Free Stock Analysis Report General Dynamics Corporation (GD) : Free Stock Analysis Report RTX Corporation (RTX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Such increased defense spending on military arms and ammunition often translates to a boost for companies like General Dynamics, renowned for their extensive expertise in the designing, engineering and production of munitions, energetics, weapons, armaments and missile subsystems worldwide. Image Source: Zacks Investment Research Zacks Rank General Dynamics currently carries a Zacks Rank #3 (Hold). Click to get this free report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report Northrop Grumman Corporation (NOC) : Free Stock Analysis Report General Dynamics Corporation (GD) : Free Stock Analysis Report RTX Corporation (RTX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Consequently, the company witnesses a consistent order inflow for its manufactured arms and ammunition, like the latest one. This could lead to additional contracts for arms and ammunition procurement for General Dynamics. Image Source: Zacks Investment Research Zacks Rank General Dynamics currently carries a Zacks Rank #3 (Hold).
|
1bb089ab-09fb-4392-b5d4-3975f4b281a8
|
715343.0
|
2023-12-01 00:00:00 UTC
|
5 Low-Vol Dividend Stocks Yielding Up to 10.4%
|
DCOMP
|
https://www.nasdaq.com/articles/5-low-vol-dividend-stocks-yielding-up-to-10.4
|
nan
|
nan
|
First-level investors think the key to retiring on dividends alone is to find the largest yields they can and ride them into the sunset.
But while it's important to lock down fat yields--like the five-pack of 5.5%-10.4% yielders I'll share with you today--that's only part of the puzzle. We need two more things from our long-term income holdings:
Dividend safety. A 10.4% payout is only helpful if it's actually going to get paid for quarters and years to come. No dividend cuts, please.
Principal safety. We're also not looking to lose 10.4% per year in price. Or anything in price, for that matter. We want our principal to stay steady or better.
One of the best ways to find safe dividends that will protect our principal is in "low-beta" stocks. We could call them "low-heartburn" just as well. These are equities that move less than the broader market.
Perfect for us payout-focused investors.
Here's a quick example of beta. Let's say a stock has a beta of 0.5. It moves half as fast as the market.
If the S&P drops 10%, we would expect our 0.5 beta stock to be down only 5%. Less bad, in other words.
A low volatility (beta) strategy has performed well since the bear market started in 2022. A popular "low vol" ETF beat the market with--wouldn't you know it--less heartburn.
Low Vol ETF Beats Broader Market
But as you know, we can do better than a lazy ETF! Today we'll discuss five low-beta dividend stocks that pay between 5.5% and 10.4% to see if they meet our safe dividend and principal intact standards.
Tobacco companies like Philip Morris International (PM, 5.5% yield), somehow, keep churning cash flow. Governments hate 'em, but smokers gotta have 'em. And ol' Flip Mo actually grows faster than our average tobacco peddler.
Shares have been left behind over the past year or so as the market has found its groove. But PM has performed exceptionally during downturns as a store of safety. And that's in part because Philip Morris keeps finding ways to bring in more money.
Believe It or Not, Philip Morris is Still Growing
While cigarette sales are struggling, PM is finding ways to offset that weakness--specifically in heated and oral tobacco products, which it has bolstered by raising its stake in (and eventually outright acquiring) Swedish Match. Also, its positioning in foreign markets makes Philip Morris more attractive than its U.S.-locked peers. So while other cigarette makers might be treading water or worse, PM is expected to grow its top and bottom lines this year and next.
Philip Morris's shares boast one- and five-year betas of 6.8 and 8.0, respectively. Dividend stability is every bit as nice--the company has increased its dividend every year since splitting from Altria (MO) in 2008, by more than 7% annually.
LTC Properties (LTC, 7.0% yield) is a national real estate investment trust (REIT) that's roughly 50/50 split between senior housing and skilled nursing properties. This type of real estate was long considered can't-miss--that is, of course, until COVID wreaked havoc on the sector. The upside? Most operators (including LTC) likely have the worst of it in the rear-view, with occupancy and rent coverage generally on the upswing.
LTC's one- and five-year betas are both just under 1, so you're not getting noticeably calmer performance than the rest of the market. But that could very well mellow out as the industry's conditions continue to improve. The dividend needs to get in gear, though--LTC's 7% yield is nice, and a monthly payout schedule is even nicer, but the payout has been idling for years at 19 cents, losing a lot of ground to inflation.
Fashion retailer Buckle (BKE, 10.4% yield) is a strange name to see here, on two counts.
For one, it's generally surprising to see a retailer with consistently low beta--fashion is fickle, and as a result, fashion stocks tend to be mercurial as well.
But Buckle's five-year beta is a hair under 1.0, and it's been downright sleepy over the past year with a beta of 0.59. This is a case where beta doesn't tell the whole story, though. After a few years of boom times, Wall Street sees Buckle's earnings dropping 17% and revenues falling 6% this year; its results through three quarters are right in line with those projections. No wonder BKE shares are off double digits in 2023 while the S&P 500 has returned nearly 20%.
Buckle's Financial Results Were Flattening; Now They're Falling
If there's any silver lining, it's that Buckle's results are largely expected to stabilize next year.
The other oddity is Buckle's double-digit yield, which is extremely unusual for any stock, but especially one in retail. But BKE's payout is more than meets the eye, for better or worse. Buckle is a special dividend payer--one that prefers to augment its regular dividend with special distributions as profits allow. Of the Buckle's 10.4% yield, only 3.6% of that comes from its quarterly dole. So while Buckle does provide income potential, it's perhaps not the best source of stable income potential. Let's move on.
VICI Properties (VICI, 5.7% yield) is another eyebrow-raiser, as it's involved in one of the market's more cyclical businesses: casinos and hospitality.
VICI Properties' portfolio includes 54 gaming facilities--including Caesars Palace Las Vegas, MGM Grand, and the Venetian Resort Las Vegas--as well as 38 non-gaming experiential properties. All told, its real estate includes 60,000-plus rooms and 500-plus restaurants, bars, clubs, and sportsbooks. So VICI Properties' properties are a little more than just a place to sit down and play slots.
All of the above is discretionary nonetheless, but, then, VICI's business isn't collecting chips--it's merely collecting the rent. And that's really it, in fact. VICI is a triple-net lease property, so its tenants are responsible for taxes, insurance and maintenance.
From that perspective, business is good. In fact, so good that, despite a lukewarm forward-looking price-to-adjusted funds from operations (AFFO) of 14 or so, it's possible the market is sleeping on this REIT.
VICI's Operations Have Exploded, But Shares Haven't--Yet
VICI just barely qualifies as low-vol--its one- and five-year betas are both just under 1. Still, that's about as cool and collected as you'll get from the gaming business, and it offers a 6% yield to boot--on a dividend that has been rising since its 2018 IPO.
One REIT that screams stability is Getty Realty (GTY, 6.2% yield), which is one of the most boring landlords in America.
And boring, as I like to say, is beautiful.
Getty Boasts a History of Stable Growth
Getty Realty owns nearly 1,100 single-tenant retail properties in 40 states and the District of Columbia. Sure, the mention of brick-and-mortar retail doesn't exactly inspire confidence, but Getty's tenants will. More than two-thirds of the portfolio involves convenience store companies like 7-Eleven and gas stations from the likes of BP (BP). Its other tenants include car washes, repair shops, auto service stations, and more.
Much of the above is either recession-proof or at least recession-resistant. That said, Getty isn't exactly invincible--higher interest rates have weighed on GTY, much like other REITs. And there's an open question about whether a gradual shift to electric vehicles will weigh on its gas-station properties, though the convenience-store aspect of these locations should make them plenty resilient.
Getty will never be a font of explosive growth. But it's a smooth operator--one- and five-year betas are 0.67 and 0.91, respectively--and it boasts a well-above-average yield that keeps getting bigger as time marches on.
Give Me 4 Minutes, I'll 5X Your Retirement Income
Getty is a perfect illustration of how we want to build a high-yield retirement portfolio. We want holdings that will let us sleep through existential crises--bear markets, economic slumps, yet another Jerome Powell press conference.
And those are exactly the kind of investments I stash away in my "Perfect Income" portfolio.
My "Perfect Income" portfolio attacks retirement investing from a different angle. Rather than trying to time the market and chase trends, we target high-yield holdings (roughly 5x the S&P!) that walk their own path, no matter what the Fed, Congress or the rest of the world throws their way.
So, what makes these dividends "perfect"? Well, they have to have a few things in common:
They DO pay consistently, predictably and reliably.
They DO survive--and even thrive--in market crashes.
They DO deliver double-digit returns, with safe, secure investments.
They DO require minimal management time--just a few minutes every month!
They DON'T involve day trading, buying on margin or any other risky strategy.
They DON'T involve gambling on penny stocks, Bitcoin or buying puts and calls.
Let me show you the stocks and funds you need to stabilize your retirement. But more importantly, let me teach you more about this incredible strategy itself and make you a better investor in the process!
Take control of your financial legacy today. Click here for my newly updated briefing on the Perfect Income Portfolio!
Also see:
Warren Buffett Dividend Stocks
Dividend Growth Stocks: 25 Aristocrats
Future Dividend Aristocrats: Close Contenders
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
While cigarette sales are struggling, PM is finding ways to offset that weakness--specifically in heated and oral tobacco products, which it has bolstered by raising its stake in (and eventually outright acquiring) Swedish Match. So while other cigarette makers might be treading water or worse, PM is expected to grow its top and bottom lines this year and next. And there's an open question about whether a gradual shift to electric vehicles will weigh on its gas-station properties, though the convenience-store aspect of these locations should make them plenty resilient.
|
Philip Morris's shares boast one- and five-year betas of 6.8 and 8.0, respectively. LTC Properties (LTC, 7.0% yield) is a national real estate investment trust (REIT) that's roughly 50/50 split between senior housing and skilled nursing properties. Also see: Warren Buffett Dividend Stocks Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Today we'll discuss five low-beta dividend stocks that pay between 5.5% and 10.4% to see if they meet our safe dividend and principal intact standards. VICI Properties (VICI, 5.7% yield) is another eyebrow-raiser, as it's involved in one of the market's more cyclical businesses: casinos and hospitality. Also see: Warren Buffett Dividend Stocks Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Let's say a stock has a beta of 0.5. Today we'll discuss five low-beta dividend stocks that pay between 5.5% and 10.4% to see if they meet our safe dividend and principal intact standards. So, what makes these dividends "perfect"?
|
50b98f2a-3ba9-49c8-9404-b0573b6fe45b
|
715344.0
|
2023-12-01 00:00:00 UTC
|
Improved Traffic to Drive lululemon's (LULU) Q3 Earnings Beat
|
DCOMP
|
https://www.nasdaq.com/articles/improved-traffic-to-drive-lululemons-lulu-q3-earnings-beat
|
nan
|
nan
|
lululemon athletica inc. LULU is likely to witness top-line and bottom-line growth when it reports third-quarter fiscal 2023 results on Dec 7, after market close.
The Zacks Consensus Estimate for fiscal third-quarter sales is pegged at $2.2 billion, indicating a 17.8% increase from the year-ago quarter's reported figure. The consensus estimate for the company's fiscal third-quarter earnings is pegged at $2.27 per share, suggesting a 13.5% rise from earnings of $2.00 per share reported in the year-ago quarter. Earnings estimates have been unchanged in the past 30 days.
The company delivered an earnings surprise of 5.9% in the last reported quarter. LULU's bottom line beat estimates by 6.8%, on average, in the trailing four quarters.
lululemon athletica inc. Price and EPS Surprise
lululemon athletica inc. price-eps-surprise | lululemon athletica inc. Quote
Key Factors to Note
lululemon has been benefiting from the continued business momentum, backed by a favorable response to its products. Improvement in store traffic and a solid online show bode well. The persistence of these trends is expected to have boosted the company’s top line in the to-be-reported quarter.
LULU has been capitalizing on the importance of physical retail and the convenience of online engagement, which is expected to have boosted its top-line and bottom-line performances. The company has been focused on investments to enhance the in-store experience. It has been leveraging its stores to facilitate omnichannel capabilities, including buy online pick up in store (BOPUS) and ship from store. It has also been implementing several strategies to improve the guest experience and reduce wait time. Store expansion efforts are also expected to have acted as an upside.
lululemon has been gaining from improving online demand. Its accelerated e-commerce investments to ensure a robust shopping experience bode well. The company has been investing in developing sites, building transactional omni functionality and increasing fulfillment capabilities. Some notable efforts in this space are curbside pickups, same-day deliveries and BOPUS. Gains from these initiatives are likely to be reflected in its third-quarter fiscal 2023 top-line results.
Our model predicts company-operated stores and the direct-to-consumer channel to register year-over-year revenue growth of 19.7% and 14.7%, respectively, in the fiscal third quarter. Other sales are anticipated to increase 15.4% year over year.
On the last reported quarter’searnings call management anticipated the strong business momentum to continue throughout fiscal 2023. LULU expects net revenues to be $2.165-$2.190 billion for third-quarter fiscal 2023, indicating 17-18% year-over-year growth. The company projects earnings per share of $2.23-$2.28 for the fiscal third quarter.
Additionally, the company has been witnessing improved gross margins in recent quarters due to lower expenses. Gross margin gains have been resulting from lower air freight expenses, which have been aiding product margin, as well as a regional mix.
We expect the adjusted gross margin to expand 160 basis points (bps) year over year to 57.5% in the fiscal third quarter, driven by a decline in the cost of sales due to lower freight expenses. For the third quarter of fiscal 2023, management expects the gross margin to expand 160-180 bps, driven by lower airfreight costs.
However, the company predicted gross margin growth to be partly offset by strategic investments to support growth, including supply chain, distribution centers, product teams and modest deleverage on occupancy and depreciation. This is likely to have resulted in an elevated SG&A expense rate in the fiscal third quarter.
Management predicted SG&A expenses, as a percentage of sales, to deleverage by 200-220 bps year over year in third-quarter fiscal 2023. The increase is likely to have been driven by its strategic decision to invest in growth initiatives, including efforts to improve global brand awareness. Operating margin is predicted to contract 40 bps year over year.
Our model predicts an adjusted operating margin of 18.6%, down 40 bps from the year-ago quarter’s actual. In dollar terms, adjusted operating income is likely to increase 14.9% year over year.
Additionally, lululemon has been witnessing elevated inventory levels, which have been concerning. Although the inventory growth rate moderated to 14% year-over-year growth in the fiscal second quarter, management expects inventory growth of high-single-digit to low-double-digits at the end of the fiscal third quarter.
What the Zacks Model Unveils
Our proven model conclusively predicts an earnings beat for lululemon this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
lululemon has an Earnings ESP of +0.19% and a Zacks Rank #3 .
Other Stocks Poised to Beat Earnings Estimates
Here are some other stocks, which according our model, have the right combination of elements to post an earnings beat:
Ollie's Bargain Outlet OLLI currently has an Earnings ESP of +0.57% and a Zacks Rank of 2. The company is anticipated to register top-line and bottom-line growth in third-quarter fiscal 2023. The Zacks Consensus Estimate for OLLI’s quarterly revenues is pegged at $470 million, suggesting growth of 12.4% from the figure reported in the prior-year quarter. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Ollie's quarterly earnings moved up by a penny in the last seven days to 44 cents per share, suggesting 18.9% growth from the year-ago quarter's reported number. OLLI delivered an earnings surprise of 1.3%, on average, in the trailing four quarters.
Campbell Soup CPB currently has an Earnings ESP of +0.07% and a Zacks Rank of 3. The company is expected to register top-line and bottom-line declines when it reports first-quarter fiscal 2024 numbers. The Zacks Consensus Estimate for CPB’s quarterly earnings was unchanged in the last 30 days at 87 cents per share, suggesting a decline of 14.7% from the year-ago quarter's reported number.
The Zacks Consensus Estimate for Campbell Soup’s quarterly revenues is pegged at $2.5 billion, which suggests a decline of 2.7% from the figure reported in the prior-year quarter. CPB delivered an earnings surprise of 8.6%, on average, in the trailing four quarters.
AutoZone AZO currently has an Earnings ESP of +0.34% and a Zacks Rank of 3. The company is expected to register top and bottom-line growth when it reports first-quarter fiscal 2024 results. The Zacks Consensus Estimate for AZO’s quarterly revenues is pegged at $4.2 billion, which suggests growth of 4.5% from the figure reported in the prior-year quarter.
The consensus estimate for AutoZone’s bottom line has moved down 0.1% in the last 30 days to $30.78 per share, which suggests growth of 12.1% from the figure reported in the prior-year quarter. AZO has delivered an earnings surprise of 9.9%, on average, in the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Campbell Soup Company (CPB) : Free Stock Analysis Report
AutoZone, Inc. (AZO) : Free Stock Analysis Report
lululemon athletica inc. (LULU) : Free Stock Analysis Report
Ollie's Bargain Outlet Holdings, Inc. (OLLI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
lululemon athletica inc. LULU is likely to witness top-line and bottom-line growth when it reports third-quarter fiscal 2023 results on Dec 7, after market close. The Zacks Consensus Estimate for fiscal third-quarter sales is pegged at $2.2 billion, indicating a 17.8% increase from the year-ago quarter's reported figure. The consensus estimate for AutoZone’s bottom line has moved down 0.1% in the last 30 days to $30.78 per share, which suggests growth of 12.1% from the figure reported in the prior-year quarter.
|
The Zacks Consensus Estimate for fiscal third-quarter sales is pegged at $2.2 billion, indicating a 17.8% increase from the year-ago quarter's reported figure. We expect the adjusted gross margin to expand 160 basis points (bps) year over year to 57.5% in the fiscal third quarter, driven by a decline in the cost of sales due to lower freight expenses. Click to get this free report Campbell Soup Company (CPB) : Free Stock Analysis Report AutoZone, Inc. (AZO) : Free Stock Analysis Report lululemon athletica inc. (LULU) : Free Stock Analysis Report Ollie's Bargain Outlet Holdings, Inc. (OLLI) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The consensus estimate for the company's fiscal third-quarter earnings is pegged at $2.27 per share, suggesting a 13.5% rise from earnings of $2.00 per share reported in the year-ago quarter. The Zacks Consensus Estimate for Ollie's quarterly earnings moved up by a penny in the last seven days to 44 cents per share, suggesting 18.9% growth from the year-ago quarter's reported number. Click to get this free report Campbell Soup Company (CPB) : Free Stock Analysis Report AutoZone, Inc. (AZO) : Free Stock Analysis Report lululemon athletica inc. (LULU) : Free Stock Analysis Report Ollie's Bargain Outlet Holdings, Inc. (OLLI) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Store expansion efforts are also expected to have acted as an upside. Management predicted SG&A expenses, as a percentage of sales, to deleverage by 200-220 bps year over year in third-quarter fiscal 2023. The company is expected to register top and bottom-line growth when it reports first-quarter fiscal 2024 results.
|
2d5d1820-55cb-4ef9-a834-5800e6170693
|
715345.0
|
2023-12-01 00:00:00 UTC
|
Emerging Markets ETFs Could Surprise in 2024
|
DCOMP
|
https://www.nasdaq.com/articles/emerging-markets-etfs-could-surprise-in-2024
|
nan
|
nan
|
S
tarting with a disclaimer, it’s been awhile since the MSCI Emerging Markets beat the S&P 500 on an annual basis and it’s not going to happen this year.
The last time the emerging markets benchmark beat the domestic equities was 2017, meaning this year will be the sixth consecutive in which it’s lagged major U.S. equity indexes. Making that scenario all the more vexing is that stocks in developing are more volatile than U.S. equivalents. Between the heightened turbulence and slack performance, there haven’t been many good reasons for investors to embrace the risks associated with emerging markets equities and the corresponding exchange traded funds.
Problematic for investors is the fact that many developing economies, including some of the larger ones, continue notching growth rates that far outpace those seen in more mature economies. In other words, some emerging markets’ equity markets aren’t keeping pace with the economies’ growth rates.
Of course, “it’s time” or an asset being overdue to outperform aren’t credible investment theses, but there are areas of opportunity that could be compelling in 2024. Here are some of the ETFs to consider.
Global X MSCI Argentina ETF (ARGT)
A word of caution regarding the Global X MSCI Argentina ETF (ARGT). The original ETF dedicated to stocks in the South American county is higher by 8.63% over the past week and 31.37% over the past month on the back of populist Javier Milei’s victory in the recent presidential election in that country. As of yet, ARGT hasn’t experience a “sell the news” retrenchment. Perhaps that’s a sign that markets continue to be enthusiastic about Milei’s win.
While the right-leaning Milei has predictably been vilified in the global media, a strong case can be made that he’s likely a stark improvement over previous regimes in the country and, at worst, won’t be any worse than those regimes. After all, Argentina has experienced five sovereign defaults over the past 50 years.
Additionally, Milei is likely to moderate his tone because his La Libertad Avanza party wields little power in either house of Argentina’s Congress. A more middle-of-the-road posture from the new president could be to the delight of investors.
“We have been impressed with Milei’s actions on this front since the first round of voting,” according to Global X research. “His negotiations with the Juntos coalition showed flexibility within his ideological framework, easing fears that he would not moderate. Milei’s victory also proves that he can maintain support from his core voters while coming to the middle. As a result, we see declining execution risks surrounding his ability to successfully implement orthodox fiscal and economic policies while maintaining public support.”
WisdonTree India Earnings Fund (EPI)
The WisdonTree India Earnings Fund (EPI) merits consideration in the “emerging markets ETFs for 2024” due in part to that fact that Indian stocks have been trouncing broader developing world indexes for several years. Past performance isn’t a guarantee of future returns and India holds national elections next year, which could boost volatility. However, some major global banks are already forecasting another year of out-performance by Indian equities.
Specific to EPI, the first U.S.-listed ETF to buy local Indian stocks, this emerging markets ETFs has some perks. Those include helping investors stay away from money-losing companies and those that are richly valued – an important point given the current state of affairs regarding Indian stocks.
“We optimize valuation, by weighting by earnings and eliminating unprofitable companies, allowing the most profitable companies to occupy more weight in the Index. This allows EPI to provide investors with access to the broad market, but at a more reasonable price,” notes WisdomTree.
VanEck Vietnam ETF (VNM)
The VanEck Vietnam ETF (VNM) – the original ETF to focus on Vietnamese shares – is up an admirable 10.64% year-to-date, but things could be even better in 2024 as Vietnam continues its quest for emerging markets status. It’s currently classified as a frontier.
Part of that quest includes continued liberalization of local financial markets, which are driving robust levels of foreign direct investment. Another source of allure with VNM is Vietnam’s rise as a tech hub. That could benefit VNM’s financial services holdings and potentially set the ETF up for more long-term growth.
“Vietnam has the fastest-growing digital economy in Southeast Asia. By 2025 it could be worth $49 billion, with an average annual growth rate of 31%, by 2025. Nearly three-quarters (73%) of the population are internet-enabled, rising from around 2% in 2002, making Vietnam the 12th biggest internet user worldwide,” according to Dragon Capital.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Between the heightened turbulence and slack performance, there haven’t been many good reasons for investors to embrace the risks associated with emerging markets equities and the corresponding exchange traded funds. As a result, we see declining execution risks surrounding his ability to successfully implement orthodox fiscal and economic policies while maintaining public support.” WisdonTree India Earnings Fund (EPI) The WisdonTree India Earnings Fund (EPI) merits consideration in the “emerging markets ETFs for 2024” due in part to that fact that Indian stocks have been trouncing broader developing world indexes for several years. Those include helping investors stay away from money-losing companies and those that are richly valued – an important point given the current state of affairs regarding Indian stocks.
|
In other words, some emerging markets’ equity markets aren’t keeping pace with the economies’ growth rates. As a result, we see declining execution risks surrounding his ability to successfully implement orthodox fiscal and economic policies while maintaining public support.” WisdonTree India Earnings Fund (EPI) The WisdonTree India Earnings Fund (EPI) merits consideration in the “emerging markets ETFs for 2024” due in part to that fact that Indian stocks have been trouncing broader developing world indexes for several years. VanEck Vietnam ETF (VNM) The VanEck Vietnam ETF (VNM) – the original ETF to focus on Vietnamese shares – is up an admirable 10.64% year-to-date, but things could be even better in 2024 as Vietnam continues its quest for emerging markets status.
|
Global X MSCI Argentina ETF (ARGT) A word of caution regarding the Global X MSCI Argentina ETF (ARGT). As a result, we see declining execution risks surrounding his ability to successfully implement orthodox fiscal and economic policies while maintaining public support.” WisdonTree India Earnings Fund (EPI) The WisdonTree India Earnings Fund (EPI) merits consideration in the “emerging markets ETFs for 2024” due in part to that fact that Indian stocks have been trouncing broader developing world indexes for several years. VanEck Vietnam ETF (VNM) The VanEck Vietnam ETF (VNM) – the original ETF to focus on Vietnamese shares – is up an admirable 10.64% year-to-date, but things could be even better in 2024 as Vietnam continues its quest for emerging markets status.
|
Global X MSCI Argentina ETF (ARGT) A word of caution regarding the Global X MSCI Argentina ETF (ARGT). Specific to EPI, the first U.S.-listed ETF to buy local Indian stocks, this emerging markets ETFs has some perks. VanEck Vietnam ETF (VNM) The VanEck Vietnam ETF (VNM) – the original ETF to focus on Vietnamese shares – is up an admirable 10.64% year-to-date, but things could be even better in 2024 as Vietnam continues its quest for emerging markets status.
|
78a69abb-b6d5-45b9-9bab-1225952301f1
|
715346.0
|
2023-12-01 00:00:00 UTC
|
Stock Market News for Dec 1, 2023
|
DCOMP
|
https://www.nasdaq.com/articles/stock-market-news-for-dec-1-2023
|
nan
|
nan
|
U.S. stocks ended mostly higher on Thursday, with the Dow recording its highest close since January 2022, while the Nasdaq and S&P 500 registered their best monthly gains since July 2022 as fresh data showed inflation cooled further in October. The Dow and the S&P 500 ended in positive territory, while the Nasdaq edged slightly lower.
How Did The Benchmarks Perform?
The Dow Jones Industrial Average (DJI) advanced 1.5% or 520.47 points to finish at 35,950.89 points, recording its highest close since January 13, 2023.
The S&P 500 gained 0.4% or 17.22 points, to end at 4,567.80 points. Consumer staples, industrials, healthcare and financial stocks were the best performers.
The Consumer Staples Select Sector SPDR (XLP) and the Industrials Select Sector SPDR (XLI) gained 1% and 1.1%, respectively. The Health Care Select Sector SPDR (XLV) and Financials Select Sector SPDR (XLF) rose 1.3% and 1.1%, respectively. Nine of the 11 sectors of the benchmark index ended in positive territory.
The tech-heavy Nasdaq lost 0.2% or 32.27 points to close at 14,226.22 points.
The fear-gauge CBOE Volatility Index (VIX) was down 0.46% to 12.92. A total of 13.22 billion shares were traded on Thursday, higher than the last 20-session average of 10.55 billion. Advancers outnumbered decliners on the NYSE by a 1.62-to-1 ratio. On the Nasdaq, a 1.01-to-1 ratio favored advancing issues.
Inflation Eases Further
All three major indexes recorded their best monthly gains in nearly a year as the Wall Street rally continued on the last day of November. The Dow surged ahead of the closing bell on Thursday to clinch its biggest daily percentage gain in the past four weeks.
The blue-chip index not only ended the month with gains but also recorded its highest close for the year. Leading the rally was cloud software giant Salesforce, Inc. (CRM) which surged 9.4% after the company reported an earnings beat.
Salesforces reported third-quarter 2023 earnings of $2.11 per share, surpassing the Zacks Consensus Estimate of 2.06 per share. Salesforce has a Zacks Rank #3 3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Thursday’s rally came amid impressive economic data that showed inflation continued to ease in October. Data released on Thursday showed that core Personal Consumption Expenditure (PCE), which strips out the volatile food and energy prices, rose 3.5% year over year in October compared with 3.7% in September. Month over month core PCE increased 0.2% in October.
Headline inflation came in flat month over month in October, while year over year it increased 3%.
The 10-year Treasury yield which crossed the 5% mark in October retreated in November. However, it inched marginally higher on Thursday to close at 4.34%. Tech stocks, which led the rally in November took a breather as the month came to a close. Shares of NVIDIA Corporation (NVDA) fell 2.9%. Also, Tesla, Inc. (TSLA) declined 1.7%.
Economic Data
In other economic data released on Thursday, personal income increased 0.2% in October. Also, personal spending increased 0.2%.
The Labor Department said that jobless claims totaled 218,000 for the week ending Nov 25, an increase from the previous week’s revised level of 211,000 from 209,000. The four-week moving average was 220,000, an increase of 500 from the previous week’s revised average of 220,500.
Continuing claims came in at 1,927,000, an increase of 86,000 from the previous week’s revised level of 1,841,000. The 4-week moving average was 1,865,750 an increase of 250 from the previous week's revised average of 1,837,000.
Monthly Roundup
For the month, the Dow gained 8.9%, snapping its three-month losing streak. The S&P 500 also closed out with an 8.9% gain. The Nasdaq jumped 10.7% in November. Both the S&P 500 and Nasdaq recorded their biggest monthly gains since July 2022.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Salesforce Inc. (CRM) : Free Stock Analysis Report
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
U.S. stocks ended mostly higher on Thursday, with the Dow recording its highest close since January 2022, while the Nasdaq and S&P 500 registered their best monthly gains since July 2022 as fresh data showed inflation cooled further in October. Inflation Eases Further All three major indexes recorded their best monthly gains in nearly a year as the Wall Street rally continued on the last day of November. The Dow surged ahead of the closing bell on Thursday to clinch its biggest daily percentage gain in the past four weeks.
|
The Consumer Staples Select Sector SPDR (XLP) and the Industrials Select Sector SPDR (XLI) gained 1% and 1.1%, respectively. The Health Care Select Sector SPDR (XLV) and Financials Select Sector SPDR (XLF) rose 1.3% and 1.1%, respectively. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
U.S. stocks ended mostly higher on Thursday, with the Dow recording its highest close since January 2022, while the Nasdaq and S&P 500 registered their best monthly gains since July 2022 as fresh data showed inflation cooled further in October. Headline inflation came in flat month over month in October, while year over year it increased 3%. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
U.S. stocks ended mostly higher on Thursday, with the Dow recording its highest close since January 2022, while the Nasdaq and S&P 500 registered their best monthly gains since July 2022 as fresh data showed inflation cooled further in October. Nine of the 11 sectors of the benchmark index ended in positive territory. The Nasdaq jumped 10.7% in November.
|
9bf2865c-2256-4f7d-bb8c-d0908e6daabf
|
715347.0
|
2023-12-01 00:00:00 UTC
|
Is Rambus (RMBS) a Buy as Wall Street Analysts Look Optimistic?
|
DCOMP
|
https://www.nasdaq.com/articles/is-rambus-rmbs-a-buy-as-wall-street-analysts-look-optimistic
|
nan
|
nan
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Rambus (RMBS).
Rambus currently has an average brokerage recommendation (ABR) of 1.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by five brokerage firms. An ABR of 1.00 indicates Strong Buy.
Of the five recommendations that derive the current ABR, five are Strong Buy, representing 100% of all recommendations.
Brokerage Recommendation Trends for RMBS
Check price target & stock forecast for Rambus here>>>
While the ABR calls for buying Rambus, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is RMBS a Good Investment?
Looking at the earnings estimate revisions for Rambus, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $1.76.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Rambus. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Rambus.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Rambus, Inc. (RMBS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
|
Rambus currently has an average brokerage recommendation (ABR) of 1.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance.
|
Rambus currently has an average brokerage recommendation (ABR) of 1.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
|
An ABR of 1.00 indicates Strong Buy. Brokerage Recommendation Trends for RMBS Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
|
9b07ef7a-4151-4ac4-bee8-102af1fcfe73
|
715348.0
|
2023-12-01 00:00:00 UTC
|
Wall Street Bulls Look Optimistic About Meta Platforms (META): Should You Buy?
|
DCOMP
|
https://www.nasdaq.com/articles/wall-street-bulls-look-optimistic-about-meta-platforms-meta%3A-should-you-buy-0
|
nan
|
nan
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Meta Platforms (META).
Meta Platforms currently has an average brokerage recommendation (ABR) of 1.18, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 39 brokerage firms. An ABR of 1.18 approximates between Strong Buy and Buy.
Of the 39 recommendations that derive the current ABR, 36 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 92.3% and 2.6% of all recommendations.
Brokerage Recommendation Trends for META
Check price target & stock forecast for Meta Platforms here>>>
While the ABR calls for buying Meta Platforms, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is META a Good Investment?
Looking at the earnings estimate revisions for Meta Platforms, the Zacks Consensus Estimate for the current year has increased 0.3% over the past month to $14.26.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Meta Platforms. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Meta Platforms may serve as a useful guide for investors.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Meta Platforms, Inc. (META) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for Meta Platforms may serve as a useful guide for investors.
|
Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. Looking at the earnings estimate revisions for Meta Platforms, the Zacks Consensus Estimate for the current year has increased 0.3% over the past month to $14.26.
|
Meta Platforms currently has an average brokerage recommendation (ABR) of 1.18, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for Meta Platforms may serve as a useful guide for investors.
|
Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. Looking at the earnings estimate revisions for Meta Platforms, the Zacks Consensus Estimate for the current year has increased 0.3% over the past month to $14.26. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for Meta Platforms may serve as a useful guide for investors.
|
ce67d6e8-c063-499e-afd4-1c581969b36a
|
715349.0
|
2023-12-01 00:00:00 UTC
|
Should You Invest in Goldman (GS) Based on Bullish Wall Street Views?
|
DCOMP
|
https://www.nasdaq.com/articles/should-you-invest-in-goldman-gs-based-on-bullish-wall-street-views
|
nan
|
nan
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Goldman Sachs (GS).
Goldman currently has an average brokerage recommendation (ABR) of 1.72, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 18 brokerage firms. An ABR of 1.72 approximates between Strong Buy and Buy.
Of the 18 recommendations that derive the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 61.1% and 5.6% of all recommendations.
Brokerage Recommendation Trends for GS
Check price target & stock forecast for Goldman here>>>
While the ABR calls for buying Goldman, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is GS a Good Investment?
Looking at the earnings estimate revisions for Goldman, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $22.98.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Goldman. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Goldman.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
|
Goldman currently has an average brokerage recommendation (ABR) of 1.72, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance.
|
Goldman currently has an average brokerage recommendation (ABR) of 1.72, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
|
Brokerage Recommendation Trends for GS Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. Looking at the earnings estimate revisions for Goldman, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $22.98.
|
d7379235-f594-44b5-a1ec-ca19c35a1090
|
715350.0
|
2023-12-01 00:00:00 UTC
|
Brokers Suggest Investing in Graphic Packaging (GPK): Read This Before Placing a Bet
|
DCOMP
|
https://www.nasdaq.com/articles/brokers-suggest-investing-in-graphic-packaging-gpk%3A-read-this-before-placing-a-bet
|
nan
|
nan
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Graphic Packaging (GPK).
Graphic Packaging currently has an average brokerage recommendation (ABR) of 2.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by nine brokerage firms. An ABR of 2.00 indicates Buy.
Of the nine recommendations that derive the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.6% and 11.1% of all recommendations.
Brokerage Recommendation Trends for GPK
Check price target & stock forecast for Graphic Packaging here>>>
While the ABR calls for buying Graphic Packaging, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is GPK a Good Investment?
Looking at the earnings estimate revisions for Graphic Packaging, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $2.85.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Graphic Packaging. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Graphic Packaging.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Graphic Packaging Holding Company (GPK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Graphic Packaging.
|
Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. Click to get this free report Graphic Packaging Holding Company (GPK) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Graphic Packaging currently has an average brokerage recommendation (ABR) of 2.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
|
Brokerage Recommendation Trends for GPK Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Graphic Packaging.
|
d20f909f-7783-4024-88e1-4d834c87ad07
|
715351.0
|
2023-12-01 00:00:00 UTC
|
Dick's Sporting Goods (DKS) Just Overtook the 200-Day Moving Average
|
DCOMP
|
https://www.nasdaq.com/articles/dicks-sporting-goods-dks-just-overtook-the-200-day-moving-average-0
|
nan
|
nan
|
Dick's Sporting Goods (DKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DKS broke through the 200-day moving average, which suggests a long-term bullish trend.
The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level.
DKS could be on the verge of another rally after moving 17.6% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.
Looking at DKS's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 8 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.
With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on DKS for more gains in the near future.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DICK'S Sporting Goods, Inc. (DKS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on DKS for more gains in the near future. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Dick's Sporting Goods (DKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Looking at DKS's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. Click to get this free report DICK'S Sporting Goods, Inc. (DKS) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Click to get this free report DICK'S Sporting Goods, Inc. (DKS) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level. Plus, the company is currently a Zacks Rank #3 (Hold) stock. Looking at DKS's earnings estimate revisions, investors will be even more convinced of the bullish uptrend.
|
54d24aa2-bbcd-4916-add2-6ddd7090659b
|
715352.0
|
2023-12-01 00:00:00 UTC
|
Why ICF International (ICFI) is a Top Stock for the Long-Term
|
DCOMP
|
https://www.nasdaq.com/articles/why-icf-international-icfi-is-a-top-stock-for-the-long-term-4
|
nan
|
nan
|
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium service, which provides daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter, makes these more manageable goals. All of the features can help you identify what stocks to buy, what to sell, and what are today's hottest industries.
Also included in Zacks Premium is the Focus List. This is a long-term portfolio of top stocks that have all the traits to beat the market.
Breaking Down the Zacks Focus List
Building an investment portfolio from scratch can be difficult, so if you could, wouldn't you take a peek at a curated list of top stocks?
Enter the Zacks Focus List. It's a portfolio made up of 50 stocks that are set to beat the market over the next 12 months; each company selected serves as a foundation for long-term investors looking to create an individual portfolio.
Additionally, each selection is accompanied by a full Zacks Analyst Report, something that makes the Focus List even more valuable. The report explains in detail why each stock was picked and why we believe it's good for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List Methodology
When stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Earnings estimates, or expectations of growth and profitability, come from brokerage analysts who track publicly traded companies; these analysts work together with company management to analyze every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
Investors also need to look at what a company will earn down the road. This is why earnings estimate revisions are so important.
The stocks that receive positive changes to earnings estimates are more likely to receive even more upward changes in the future. Take this example: if an analyst raised their estimates last month, they'll probably do so again this month, and other analysts will follow.
Utilizing the power of earnings estimate revisions is when the Zacks Rank joins the party. A unique, proprietary stock-rating model, the Zacks Rank uses changes to quarterly earnings expectations to help investors create a winning portfolio.
There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise. Each one of these features is then given a raw score that's recalculated every night and compiled into the Rank. Using this data, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell."
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
Because stock prices react to revisions, buying stocks with rising earnings estimates can be very profitable. Focus List stocks offer investors a great opportunity to get into companies whose future earnings estimates will be raised, potentially leading to price momentum.
Focus List Spotlight: ICF International (ICFI)
Headquartered in Fairfax, VA, ICF International, Inc. is a provider of professional services and technology-based solutions to government and commercial clients. The company’s primary services include advisory, analytics, digital, engagement and program implementation services. These services are offered in four markets namely, energy, environment and infrastructure; health, education, and social programs; safety and security, and consumer and financial.
Since being added to the Focus List on April 23, 2018 at $66.60 per share, shares of ICFI have increased 110.14% to $139.95. The stock is currently a #3 (Hold) on the Zacks Rank.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.14 to $6.45. ICFI boasts an average earnings surprise of 6.6%.
Additionally, ICFI's earnings are expected to grow 11.8% for the current fiscal year.
Reveal Winning Stocks
Unlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICF International, Inc. (ICFI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success. Focus List stocks offer investors a great opportunity to get into companies whose future earnings estimates will be raised, potentially leading to price momentum. These services are offered in four markets namely, energy, environment and infrastructure; health, education, and social programs; safety and security, and consumer and financial.
|
The Zacks Premium service, which provides daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter, makes these more manageable goals. Reveal Winning Stocks Unlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Click to get this free report ICF International, Inc. (ICFI) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
The Zacks Premium service, which provides daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter, makes these more manageable goals. The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts. Reveal Winning Stocks Unlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium.
|
Focus List Methodology When stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions. The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023.
|
d11a3841-54ec-4608-b312-e5fa89e5a5d1
|
715353.0
|
2023-12-01 00:00:00 UTC
|
Chico's (CHS) Reports Q3 Earnings: What Key Metrics Have to Say
|
DCOMP
|
https://www.nasdaq.com/articles/chicos-chs-reports-q3-earnings%3A-what-key-metrics-have-to-say
|
nan
|
nan
|
For the quarter ended October 2023, Chico's FAS (CHS) reported revenue of $505.13 million, down 2.6% over the same period last year. EPS came in at $0.11, compared to $0.20 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $512.65 million, representing a surprise of -1.47%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.10.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Chico's performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Number of stores - Total (EOP): 1,256 versus the two-analyst average estimate of 1,258.
Number of stores - Total Chicos: 602 compared to the 603 average estimate based on two analysts.
Number of stores - Total WH/BM: 374 compared to the 374 average estimate based on two analysts.
Number of stores - Total Soma: 280 versus 281 estimated by two analysts on average.
Net sales- Chico?s: $252.22 million compared to the $252.30 million average estimate based on two analysts. The reported number represents a change of -1.2% year over year.
Net sales- Soma: $105.41 million compared to the $105.35 million average estimate based on two analysts. The reported number represents a change of -0.1% year over year.
Net sales- White House Black Market: $147.50 million compared to the $155 million average estimate based on two analysts. The reported number represents a change of -6.3% year over year.
View all Key Company Metrics for Chico's here>>>
Shares of Chico's have returned +0.3% over the past month versus the Zacks S&P 500 composite's +9.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chico's FAS, Inc. (CHS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Here is how Chico's performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Number of stores - Total (EOP): 1,256 versus the two-analyst average estimate of 1,258. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Here is how Chico's performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Number of stores - Total (EOP): 1,256 versus the two-analyst average estimate of 1,258. Net sales- Chico?s: $252.22 million compared to the $252.30 million average estimate based on two analysts. Net sales- Soma: $105.41 million compared to the $105.35 million average estimate based on two analysts.
|
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Chico's performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Number of stores - Total (EOP): 1,256 versus the two-analyst average estimate of 1,258. Net sales- Chico?s: $252.22 million compared to the $252.30 million average estimate based on two analysts.
|
For the quarter ended October 2023, Chico's FAS (CHS) reported revenue of $505.13 million, down 2.6% over the same period last year. The reported revenue compares to the Zacks Consensus Estimate of $512.65 million, representing a surprise of -1.47%. Here is how Chico's performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Number of stores - Total (EOP): 1,256 versus the two-analyst average estimate of 1,258.
|
ed2bdfbb-51d0-40ee-93c4-d3a3dae7966e
|
715354.0
|
2023-12-01 00:00:00 UTC
|
3 Struggling Stocks That Could Rise More Than 50%, According to Wall Street. But Should You Listen?
|
DCOMP
|
https://www.nasdaq.com/articles/3-struggling-stocks-that-could-rise-more-than-50-according-to-wall-street.-but-should-you
|
nan
|
nan
|
Analysts' price targets can give you a good gauge of where a stock might be headed in the months ahead -- but that's not always the case. In some situations, a stock that's in free fall can decline faster than analysts can downgrade it. The result is a price target that looks high, with the stock looking as though it has plenty of upside. That, however, can sometimes be a dangerous assumption for investors to make.
Three stocks that have been struggling this year and that analysts think have more than 50% upside right now are Plug Power (NASDAQ: PLUG), Medical Properties Trust (NYSE: MPW), and Warner Bros. Discovery (NASDAQ: WBD). Here's a closer look at whether these are indeed good stocks to buy, or if investors should brace for more downgrades.
Plug Power: 187% upside
Plug Power is a green energy stock with a consensus analyst price target of nearly $10. For it to get to that level, shares of the hydrogen cell company would have to nearly triple in value. But that upside has more to do with the stock's rapid fall this year, as Plug Power's valuation has plunged 72% since January.
The hydrogen fuel cell company is a big play for investors expecting hydrogen to be a key part of the world's green energy solutions. But even if that's the case, it doesn't mean Plug Power will be the company to lead the industry there. Regardless of the long-term potential, the business needs to survive long enough to realize those opportunities, and that isn't a sure thing at all.
This month, the company released its latest earnings numbers along with a "going concern" warning, saying that there is doubt about its ability to survive. As of the end of September, the company reported cash, cash equivalents, and restricted cash of less than $337 million. Meanwhile, its current liabilities -- what it has to pay over the course of the next 12 months -- total $931 million. It could sell inventory and available-for-sale securities, but overall, it's not a pretty picture, as this is a cash-burning business.
Investors should be careful not to get caught up looking at Plug Power's Wall Street price targets as they are likely to come down in the weeks and months ahead. This isn't a stock to risk your hard-earned money on.
Medical Properties Trust: 84% upside
Medical Properties Trust (MPT) is a real estate investment trust (REIT) that has been struggling for the past few years due to the pandemic. Its tenants, which are mainly hospitals, have been enduring some challenging conditions in the industry. Labor costs have risen, and that has put a strain on their bottom lines -- and their ability to pay rent.
The situation deteriorated so much for Medical Properties that it had to slash its dividend payments earlier this year. Although its yield remains incredibly high at more than 12%, that's more indicative of just how bearish investors have been on the stock. Year to date, shares of Medical Properties Trust are down 57%, and the stock can't seem to catch a break.
The consensus analyst price target for the stock is $8.83, which implies an upside of more than 80% from where it trades today. There is a bullish case to be made for MPT. The REIT reported funds from operations per share of $0.36 in its latest quarterly results (which ended Sept. 30)
That's enough to support its quarterly dividend of $0.15 -- but there is still plenty of risk with the stock as interest rates remain high. And the company is looking to potentially sell assets to free up liquidity, which isn't exactly a sign of confidence.
The future remains hazy for Medical Properties, and investors should be careful not to rely too heavily on the stock's price target, as analysts are likely to downgrade it further. It may be an appealing contrarian investment, but this isn't a dividend stock that most investors should get their hopes up for now.
Warner Bros. Discovery: 55% upside
The actors' and writers' strikes in Hollywood are over, but Warner Bros. Discovery is still going to feel the effects of them into next year. That could amount to hundreds of millions of dollars on this year's earnings before interest, taxes, depreciation, and amortization (EBITDA). There have been delays in releasing content due to the strikes. And to make matters worse, the ad market hasn't been particularly strong of late, either.
The stock is up 14% this year, and it has been the best-performing investment on this list. In the past three months, however, shares of Warner Bros. Discovery have fallen by 12%. The good news is that at least the worst news is out of the way -- the strikes have been resolved.
Analysts have been lowering their price targets for Warner Bros. stock, but with the consensus price target still at nearly $17, there's more than 50% upside for the stock, according to analysts.
The company reported a net loss of $407 million for the most recent quarter, which ended on Sept. 30. The big challenge is what looms ahead for the business. More downgrades could be coming for the stock, but despite a possibly difficult year ahead for the company, Warner Bros.
Discovery is the only stock on this list that investors may want to buy. With some quality media assets and brands, including HBO and Warner Bros., this could still be a good long-term play.
10 stocks we like better than Medical Properties Trust
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Medical Properties Trust wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 27, 2023
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Warner Bros. Discovery. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Analysts' price targets can give you a good gauge of where a stock might be headed in the months ahead -- but that's not always the case. Investors should be careful not to get caught up looking at Plug Power's Wall Street price targets as they are likely to come down in the weeks and months ahead. The future remains hazy for Medical Properties, and investors should be careful not to rely too heavily on the stock's price target, as analysts are likely to downgrade it further.
|
Three stocks that have been struggling this year and that analysts think have more than 50% upside right now are Plug Power (NASDAQ: PLUG), Medical Properties Trust (NYSE: MPW), and Warner Bros. Plug Power: 187% upside Plug Power is a green energy stock with a consensus analyst price target of nearly $10. Medical Properties Trust: 84% upside Medical Properties Trust (MPT) is a real estate investment trust (REIT) that has been struggling for the past few years due to the pandemic.
|
Three stocks that have been struggling this year and that analysts think have more than 50% upside right now are Plug Power (NASDAQ: PLUG), Medical Properties Trust (NYSE: MPW), and Warner Bros. Analysts have been lowering their price targets for Warner Bros. stock, but with the consensus price target still at nearly $17, there's more than 50% upside for the stock, according to analysts. 10 stocks we like better than Medical Properties Trust When our analyst team has a stock tip, it can pay to listen.
|
Three stocks that have been struggling this year and that analysts think have more than 50% upside right now are Plug Power (NASDAQ: PLUG), Medical Properties Trust (NYSE: MPW), and Warner Bros. Discovery: 55% upside The actors' and writers' strikes in Hollywood are over, but Warner Bros. Discovery is the only stock on this list that investors may want to buy.
|
94f02429-6b18-4e41-a7c2-75067a79e1d3
|
715355.0
|
2023-12-01 00:00:00 UTC
|
After Plunging -12.22% in 4 Weeks, Here's Why the Trend Might Reverse for MGP (MGPI)
|
DCOMP
|
https://www.nasdaq.com/articles/after-plunging-12.22-in-4-weeks-heres-why-the-trend-might-reverse-for-mgp-mgpi
|
nan
|
nan
|
MGP (MGPI) has been beaten down lately with too much selling pressure. While the stock has lost 12.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
How to Determine if a Stock is Oversold
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
Why a Trend Reversal is Due for MGPI
The RSI reading of 29.42 for MGPI is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for MGPI has increased 3.3%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, MGPI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MGP Ingredients, Inc. (MGPI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
While the stock has lost 12.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Moreover, MGPI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. Click to get this free report MGP Ingredients, Inc. (MGPI) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. Why a Trend Reversal is Due for MGPI The RSI reading of 29.42 for MGPI is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come.
|
RSI oscillates between zero and 100. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
15926b28-a264-49bd-b0d2-27f803679a05
|
715356.0
|
2023-12-01 00:00:00 UTC
|
Tesla falls on long wait for Cybertruck payoff, hefty price tag
|
DCOMP
|
https://www.nasdaq.com/articles/tesla-falls-on-long-wait-for-cybertruck-payoff-hefty-price-tag
|
nan
|
nan
|
By Samrhitha A and Chavi Mehta
Dec 1 (Reuters) - Tesla shares TSLA.O fell more than 3% on Friday after the highly anticipated launch of its Cybertruck left analysts concerned about the electric vehicle's steep price tag and a longer wait for significant financial payoff.
The $60,990 starting price for the long-delayed Cybertruck is more than 50% higher than what CEO Elon Musk had touted in 2019 and a cost analysts have said will draw select, affluent buyers.
"Cybertruck does not significantly move the financial needle for Tesla in FY24..," Wedbush said in a note, while Bernstein analysts forecast 250 deliveries this year and 75,000 for next year, saying both "may be ambitious".
Musk has said Tesla was likely to reach a production rate of roughly 250,000 Cybertrucks a year in 2025.
The company has repeatedly warned that it would face significant challenges in ramping the product and becoming free cash flow positive - likely not until mid-2025 - which could negatively impact profitability.
"Tesla has a product problem - i.e., an older line-up that does not address enough of the market, and has no new mass market offerings until likely late 2025," Bernstein analysts added.
The Cybertruck, Tesla's first new model in nearly four years, is critical to its reputation as a maker of innovative vehicles, especially at a time when the company is battling softening electric-vehicle demand and rising competition.
The electric vehicle maker is on course to lose nearly $23.4 billion of its value on Friday if premarket losses hold. The stock has nearly doubled this year, after having fallen more than 65% in 2022.
The Cybertruck, two years behind schedule, enters a hot pickup truck market to compete with the likes of Ford's F.N F150 Lightning, Rivian Automotive's RIVN.O R1T and General Motors' GM.N Hummer EV.
"Cybertruck is more of a 'halo' product, in our view, to attract consumers to the brand for the mainstream vehicles Model 3 and Model Y," RBC Capital Markets analyst Tom Narayan said.
(Reporting by Samrhitha Arunasalam and Chavi Mehta in Bengaluru; Editing by Devika Syamnath)
((Samrhitha.A@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
By Samrhitha A and Chavi Mehta Dec 1 (Reuters) - Tesla shares TSLA.O fell more than 3% on Friday after the highly anticipated launch of its Cybertruck left analysts concerned about the electric vehicle's steep price tag and a longer wait for significant financial payoff. The Cybertruck, Tesla's first new model in nearly four years, is critical to its reputation as a maker of innovative vehicles, especially at a time when the company is battling softening electric-vehicle demand and rising competition. The Cybertruck, two years behind schedule, enters a hot pickup truck market to compete with the likes of Ford's F.N F150 Lightning, Rivian Automotive's RIVN.O R1T and General Motors' GM.N Hummer EV.
|
By Samrhitha A and Chavi Mehta Dec 1 (Reuters) - Tesla shares TSLA.O fell more than 3% on Friday after the highly anticipated launch of its Cybertruck left analysts concerned about the electric vehicle's steep price tag and a longer wait for significant financial payoff. The electric vehicle maker is on course to lose nearly $23.4 billion of its value on Friday if premarket losses hold. "Cybertruck is more of a 'halo' product, in our view, to attract consumers to the brand for the mainstream vehicles Model 3 and Model Y," RBC Capital Markets analyst Tom Narayan said.
|
By Samrhitha A and Chavi Mehta Dec 1 (Reuters) - Tesla shares TSLA.O fell more than 3% on Friday after the highly anticipated launch of its Cybertruck left analysts concerned about the electric vehicle's steep price tag and a longer wait for significant financial payoff. "Cybertruck does not significantly move the financial needle for Tesla in FY24..," Wedbush said in a note, while Bernstein analysts forecast 250 deliveries this year and 75,000 for next year, saying both "may be ambitious". "Cybertruck is more of a 'halo' product, in our view, to attract consumers to the brand for the mainstream vehicles Model 3 and Model Y," RBC Capital Markets analyst Tom Narayan said.
|
By Samrhitha A and Chavi Mehta Dec 1 (Reuters) - Tesla shares TSLA.O fell more than 3% on Friday after the highly anticipated launch of its Cybertruck left analysts concerned about the electric vehicle's steep price tag and a longer wait for significant financial payoff. The $60,990 starting price for the long-delayed Cybertruck is more than 50% higher than what CEO Elon Musk had touted in 2019 and a cost analysts have said will draw select, affluent buyers. "Cybertruck is more of a 'halo' product, in our view, to attract consumers to the brand for the mainstream vehicles Model 3 and Model Y," RBC Capital Markets analyst Tom Narayan said.
|
c68a946c-f732-4537-b450-5007d191d823
|
715357.0
|
2023-12-01 00:00:00 UTC
|
Energy Sector Update for 12/01/2023: GEL, TTE, XLE, USO, UNG
|
DCOMP
|
https://www.nasdaq.com/articles/energy-sector-update-for-12-01-2023%3A-gel-tte-xle-uso-ung
|
nan
|
nan
|
Energy stocks were slipping pre-bell Friday with the Energy Select Sector SPDR Fund (XLE) recently declining by 0.02%.
The United States Oil Fund (USO) was nearly 1% higher and the United States Natural Gas Fund (UNG) was down 1.1%.
Front-month US West Texas Intermediate crude oil was down 2.6% at $75.83 per barrel at the New York Mercantile Exchange. Global benchmark North Sea Brent crude oil lost 0.3% to $80.63 per barrel. Natural gas futures were 0.8% lower at $2.780 per 1 million British Thermal Units.
Genesis Energy (GEL) was down more than 4% after it announced a cash tender offer to repurchase any and all of the 6.50% senior unsecured notes due 2025 that were co-issued with its Genesis Energy Finance subsidiary.
TotalEnergies (TTE) was 0.6% lower after saying it signed an agreement to divest its roughly 36.4% minority stake in National Petroleum Refiners of South Africa to the Prax Group.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Front-month US West Texas Intermediate crude oil was down 2.6% at $75.83 per barrel at the New York Mercantile Exchange. Global benchmark North Sea Brent crude oil lost 0.3% to $80.63 per barrel. TotalEnergies (TTE) was 0.6% lower after saying it signed an agreement to divest its roughly 36.4% minority stake in National Petroleum Refiners of South Africa to the Prax Group.
|
The United States Oil Fund (USO) was nearly 1% higher and the United States Natural Gas Fund (UNG) was down 1.1%. Front-month US West Texas Intermediate crude oil was down 2.6% at $75.83 per barrel at the New York Mercantile Exchange. Genesis Energy (GEL) was down more than 4% after it announced a cash tender offer to repurchase any and all of the 6.50% senior unsecured notes due 2025 that were co-issued with its Genesis Energy Finance subsidiary.
|
The United States Oil Fund (USO) was nearly 1% higher and the United States Natural Gas Fund (UNG) was down 1.1%. Genesis Energy (GEL) was down more than 4% after it announced a cash tender offer to repurchase any and all of the 6.50% senior unsecured notes due 2025 that were co-issued with its Genesis Energy Finance subsidiary. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Energy stocks were slipping pre-bell Friday with the Energy Select Sector SPDR Fund (XLE) recently declining by 0.02%. The United States Oil Fund (USO) was nearly 1% higher and the United States Natural Gas Fund (UNG) was down 1.1%. Front-month US West Texas Intermediate crude oil was down 2.6% at $75.83 per barrel at the New York Mercantile Exchange.
|
2784b8fd-d12f-4e70-9d17-e99af442e6cf
|
715358.0
|
2023-12-01 00:00:00 UTC
|
AIG Prices Secondary Offering Of Corebridge Financial Common Stock At $20.50/shr
|
DCOMP
|
https://www.nasdaq.com/articles/aig-prices-secondary-offering-of-corebridge-financial-common-stock-at-%2420.50-shr-0
|
nan
|
nan
|
(RTTNews) - American International Group, Inc. (AIG) announced Friday it has priced the secondary offering of Corebridge Financial, Inc. (CRBG) common stock at $20.50 per share. The offering is expected to close on December 5, 2023, subject to customary closing conditions.
AIG, as the selling stockholder, has offered 35 million existing shares of common stock of Corebridge, corresponding to approximately $718 million of gross proceeds.
AIG has also granted a 30-day option to the underwriter to purchase up to an additional 5.25 million shares.
AIG will remain a majority shareholder of Corebridge Financial upon completion of this offering. All of the net proceeds from the offering will go to AIG.
J.P. Morgan is acting as the underwriter for the offering. The underwriter may offer the shares of common stock from time to time for sale in one or more transactions on the NYSE.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - American International Group, Inc. (AIG) announced Friday it has priced the secondary offering of Corebridge Financial, Inc. (CRBG) common stock at $20.50 per share. AIG has also granted a 30-day option to the underwriter to purchase up to an additional 5.25 million shares. AIG will remain a majority shareholder of Corebridge Financial upon completion of this offering.
|
(RTTNews) - American International Group, Inc. (AIG) announced Friday it has priced the secondary offering of Corebridge Financial, Inc. (CRBG) common stock at $20.50 per share. AIG, as the selling stockholder, has offered 35 million existing shares of common stock of Corebridge, corresponding to approximately $718 million of gross proceeds. The underwriter may offer the shares of common stock from time to time for sale in one or more transactions on the NYSE.
|
(RTTNews) - American International Group, Inc. (AIG) announced Friday it has priced the secondary offering of Corebridge Financial, Inc. (CRBG) common stock at $20.50 per share. AIG, as the selling stockholder, has offered 35 million existing shares of common stock of Corebridge, corresponding to approximately $718 million of gross proceeds. The underwriter may offer the shares of common stock from time to time for sale in one or more transactions on the NYSE.
|
(RTTNews) - American International Group, Inc. (AIG) announced Friday it has priced the secondary offering of Corebridge Financial, Inc. (CRBG) common stock at $20.50 per share. The offering is expected to close on December 5, 2023, subject to customary closing conditions. AIG, as the selling stockholder, has offered 35 million existing shares of common stock of Corebridge, corresponding to approximately $718 million of gross proceeds.
|
ec27ae63-1456-4bb5-86e9-74468954efc9
|
715359.0
|
2023-12-01 00:00:00 UTC
|
Financial Sector Update for 12/01/2023: BMO, GBDC, XLF, FAS, FAZ
|
DCOMP
|
https://www.nasdaq.com/articles/financial-sector-update-for-12-01-2023%3A-bmo-gbdc-xlf-fas-faz
|
nan
|
nan
|
Financial stocks were declining premarket Friday with the Financial Select Sector SPDR Fund (XLF) down 0.2%.
The Direxion Daily Financial Bull 3X Shares (FAS) was 0.4% lower and bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was up 0.4%.
Bank of Montreal (BMO) was declining 0.4% after it reported fiscal Q4 adjusted earnings of 2.02 billion Canadian dollars ($1.49 billion), or CA$2.81 per diluted share, down from CA$2.06 billion, or CA$3.04 per share, a year earlier.
Golub Capital BDC (GBDC) was 0.2% lower after it priced an underwritten public offering of $450 million of 7.05% notes due Dec. 5, 2028.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Direxion Daily Financial Bull 3X Shares (FAS) was 0.4% lower and bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was up 0.4%. Bank of Montreal (BMO) was declining 0.4% after it reported fiscal Q4 adjusted earnings of 2.02 billion Canadian dollars ($1.49 billion), or CA$2.81 per diluted share, down from CA$2.06 billion, or CA$3.04 per share, a year earlier. Golub Capital BDC (GBDC) was 0.2% lower after it priced an underwritten public offering of $450 million of 7.05% notes due Dec. 5, 2028.
|
The Direxion Daily Financial Bull 3X Shares (FAS) was 0.4% lower and bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was up 0.4%. Bank of Montreal (BMO) was declining 0.4% after it reported fiscal Q4 adjusted earnings of 2.02 billion Canadian dollars ($1.49 billion), or CA$2.81 per diluted share, down from CA$2.06 billion, or CA$3.04 per share, a year earlier. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Direxion Daily Financial Bull 3X Shares (FAS) was 0.4% lower and bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was up 0.4%. Bank of Montreal (BMO) was declining 0.4% after it reported fiscal Q4 adjusted earnings of 2.02 billion Canadian dollars ($1.49 billion), or CA$2.81 per diluted share, down from CA$2.06 billion, or CA$3.04 per share, a year earlier. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Financial stocks were declining premarket Friday with the Financial Select Sector SPDR Fund (XLF) down 0.2%. The Direxion Daily Financial Bull 3X Shares (FAS) was 0.4% lower and bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was up 0.4%. Bank of Montreal (BMO) was declining 0.4% after it reported fiscal Q4 adjusted earnings of 2.02 billion Canadian dollars ($1.49 billion), or CA$2.81 per diluted share, down from CA$2.06 billion, or CA$3.04 per share, a year earlier.
|
eb08850c-2fd8-4d00-8d6c-96c814b6b47b
|
715360.0
|
2023-12-01 00:00:00 UTC
|
Health Care Sector Update for 12/01/2023: PFE, BIOR, AZN, XLV, IBB
|
DCOMP
|
https://www.nasdaq.com/articles/health-care-sector-update-for-12-01-2023%3A-pfe-bior-azn-xlv-ibb
|
nan
|
nan
|
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was a slight 0.1% lower and iShares Biotechnology ETF (IBB) was recently inactive.
Pfizer (PFE) was slipping nearly 5% after saying topline data from a phase 2 study of danuglipron met its primary endpoint, but it will not pursue phase 3 studies for a twice-daily dosage of the weight-loss drug.
Biora Therapeutics (BIOR) was rallying 33% after saying the US Food and Drug Administration has cleared the company's Investigational New Drug application for BT-600 for the treatment of moderate to severe ulcerative colitis.
AstraZeneca (AZN) was up 0.1% after saying it has discontinued two phase 3 trials of Lokelma that are part of a program assessing the clinical data and real-world evidence of the potential benefit of the drug in managing hyperkalemia across the cardiorenal spectrum.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was a slight 0.1% lower and iShares Biotechnology ETF (IBB) was recently inactive. Pfizer (PFE) was slipping nearly 5% after saying topline data from a phase 2 study of danuglipron met its primary endpoint, but it will not pursue phase 3 studies for a twice-daily dosage of the weight-loss drug. AstraZeneca (AZN) was up 0.1% after saying it has discontinued two phase 3 trials of Lokelma that are part of a program assessing the clinical data and real-world evidence of the potential benefit of the drug in managing hyperkalemia across the cardiorenal spectrum.
|
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was a slight 0.1% lower and iShares Biotechnology ETF (IBB) was recently inactive. Pfizer (PFE) was slipping nearly 5% after saying topline data from a phase 2 study of danuglipron met its primary endpoint, but it will not pursue phase 3 studies for a twice-daily dosage of the weight-loss drug. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was a slight 0.1% lower and iShares Biotechnology ETF (IBB) was recently inactive. Pfizer (PFE) was slipping nearly 5% after saying topline data from a phase 2 study of danuglipron met its primary endpoint, but it will not pursue phase 3 studies for a twice-daily dosage of the weight-loss drug. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was a slight 0.1% lower and iShares Biotechnology ETF (IBB) was recently inactive. Pfizer (PFE) was slipping nearly 5% after saying topline data from a phase 2 study of danuglipron met its primary endpoint, but it will not pursue phase 3 studies for a twice-daily dosage of the weight-loss drug. Biora Therapeutics (BIOR) was rallying 33% after saying the US Food and Drug Administration has cleared the company's Investigational New Drug application for BT-600 for the treatment of moderate to severe ulcerative colitis.
|
0a127d8b-0dfd-4b44-8a2f-e570fecf8658
|
715361.0
|
2023-12-01 00:00:00 UTC
|
Consumer Sector Update for 12/01/2023: ULTA, AOUT, XLP, XLY
|
DCOMP
|
https://www.nasdaq.com/articles/consumer-sector-update-for-12-01-2023%3A-ulta-aout-xlp-xly
|
nan
|
nan
|
Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was unchanged while the Consumer Discretionary Select Sector SPDR Fund (XLY) was 0.6% lower recently.
Ulta Beauty (ULTA) was 23% higher after it reported fiscal Q3 net sales of $2.49 billion, up from $2.34 billion a year earlier. Analysts surveyed by Capital IQ expected $2.47 billion.
American Outdoor Brands (AOUT) was advancing by more than 3% after it reported fiscal Q2 sales of $57.9 million, up from $54.4 million a year earlier. Three analysts surveyed by Capital IQ expected $53 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was unchanged while the Consumer Discretionary Select Sector SPDR Fund (XLY) was 0.6% lower recently. Analysts surveyed by Capital IQ expected $2.47 billion. Three analysts surveyed by Capital IQ expected $53 million.
|
Analysts surveyed by Capital IQ expected $2.47 billion. American Outdoor Brands (AOUT) was advancing by more than 3% after it reported fiscal Q2 sales of $57.9 million, up from $54.4 million a year earlier. Three analysts surveyed by Capital IQ expected $53 million.
|
Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was unchanged while the Consumer Discretionary Select Sector SPDR Fund (XLY) was 0.6% lower recently. Ulta Beauty (ULTA) was 23% higher after it reported fiscal Q3 net sales of $2.49 billion, up from $2.34 billion a year earlier. American Outdoor Brands (AOUT) was advancing by more than 3% after it reported fiscal Q2 sales of $57.9 million, up from $54.4 million a year earlier.
|
Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was unchanged while the Consumer Discretionary Select Sector SPDR Fund (XLY) was 0.6% lower recently. Ulta Beauty (ULTA) was 23% higher after it reported fiscal Q3 net sales of $2.49 billion, up from $2.34 billion a year earlier. Analysts surveyed by Capital IQ expected $2.47 billion.
|
707ec00b-c39f-4198-87c1-23c55c981f3b
|
715362.0
|
2023-12-01 00:00:00 UTC
|
Datadog, Inc. (DDOG) Hits Fresh High: Is There Still Room to Run?
|
DCOMP
|
https://www.nasdaq.com/articles/datadog-inc.-ddog-hits-fresh-high%3A-is-there-still-room-to-run
|
nan
|
nan
|
Have you been paying attention to shares of Datadog (DDOG)? Shares have been on the move with the stock up 47.1% over the past month. The stock hit a new 52-week high of $120.26 in the previous session. Datadog has gained 58.6% since the start of the year compared to the 46% move for the Zacks Computer and Technology sector and the 57% return for the Zacks Internet - Software industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2023, Datadog reported EPS of $0.45 versus consensus estimate of $0.34 while it beat the consensus revenue estimate by 4.63%.
For the current fiscal year, Datadog is expected to post earnings of $1.53 per share on $2.11 billion in revenues. This represents a 56.12% change in EPS on a 25.69% change in revenues. For the next fiscal year, the company is expected to earn $1.71 per share on $2.55 billion in revenues. This represents a year-over-year change of 11.86% and 21.32%, respectively.
Valuation Metrics
Datadog may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Datadog has a Value Score of F. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 76.3X current fiscal year EPS estimates, which is a premium to the peer industry average of 36.6X. On a trailing cash flow basis, the stock currently trades at 1180.8X versus its peer group's average of 17.5X. Additionally, the stock has a PEG ratio of 2.68. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Datadog currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Datadog meets the list of requirements. Thus, it seems as though Datadog shares could still be poised for more gains ahead.
How Does DDOG Stack Up to the Competition?
Shares of DDOG have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is CrowdStrike (CRWD). CRWD has a Zacks Rank of # 2 (Buy) and a Value Score of F, a Growth Score of A, and a Momentum Score of A.
Earnings were strong last quarter. CrowdStrike beat our consensus estimate by 10.81%, and for the current fiscal year, CRWD is expected to post earnings of $3.48 per share on revenue of $3.05 billion.
Shares of CrowdStrike have gained 29.6% over the past month, and currently trade at a forward P/E of 83.52X and a P/CF of 524.73X.
The Internet - Software industry is in the top 13% of all the industries we have in our universe, so it looks like there are some nice tailwinds for DDOG and CRWD, even beyond their own solid fundamental situation.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Datadog, Inc. (DDOG) : Free Stock Analysis Report
CrowdStrike (CRWD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. CrowdStrike beat our consensus estimate by 10.81%, and for the current fiscal year, CRWD is expected to post earnings of $3.48 per share on revenue of $3.05 billion. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
In its last earnings report on November 7, 2023, Datadog reported EPS of $0.45 versus consensus estimate of $0.34 while it beat the consensus revenue estimate by 4.63%. In terms of its value breakdown, the stock currently trades at 76.3X current fiscal year EPS estimates, which is a premium to the peer industry average of 36.6X. Click to get this free report Datadog, Inc. (DDOG) : Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Datadog has a Value Score of F. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B. Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Click to get this free report Datadog, Inc. (DDOG) : Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
For the next fiscal year, the company is expected to earn $1.71 per share on $2.55 billion in revenues. One industry peer that looks good is CrowdStrike (CRWD). Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
dc9f3f41-80fd-4aaf-b5fb-0400dead3652
|
715363.0
|
2023-12-01 00:00:00 UTC
|
PVH Corp. (PVH) Soars to 52-Week High, Time to Cash Out?
|
DCOMP
|
https://www.nasdaq.com/articles/pvh-corp.-pvh-soars-to-52-week-high-time-to-cash-out
|
nan
|
nan
|
Have you been paying attention to shares of PVH (PVH)? Shares have been on the move with the stock up 31% over the past month. The stock hit a new 52-week high of $99.05 in the previous session. PVH has gained 38.5% since the start of the year compared to the 11.3% move for the Zacks Consumer Discretionary sector and the 8.8% return for the Zacks Textile - Apparel industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 29, 2023, PVH reported EPS of $2.9 versus consensus estimate of $2.72.
For the current fiscal year, PVH is expected to post earnings of $10.34 per share on $9.34 billion in revenues. This represents a 15.27% change in EPS on a 3.5% change in revenues. For the next fiscal year, the company is expected to earn $11.40 per share on $9.64 billion in revenues. This represents a year-over-year change of 10.32% and 3.2%, respectively.
Valuation Metrics
PVH may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
PVH has a Value Score of A. The stock's Growth and Momentum Scores are B and D, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 9.5X current fiscal year EPS estimates, which is not in-line with the peer industry average of 16.5X. On a trailing cash flow basis, the stock currently trades at 4.7X versus its peer group's average of 8.2X. Additionally, the stock has a PEG ratio of 0.71. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, PVH currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if PVH fits the bill. Thus, it seems as though PVH shares could still be poised for more gains ahead.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PVH Corp. (PVH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
On a trailing cash flow basis, the stock currently trades at 4.7X versus its peer group's average of 8.2X. Fortunately, PVH currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
In its last earnings report on November 29, 2023, PVH reported EPS of $2.9 versus consensus estimate of $2.72. In terms of its value breakdown, the stock currently trades at 9.5X current fiscal year EPS estimates, which is not in-line with the peer industry average of 16.5X. Click to get this free report PVH Corp. (PVH) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). Zacks Rank We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if PVH fits the bill.
|
For the next fiscal year, the company is expected to earn $11.40 per share on $9.64 billion in revenues. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style. PVH has a Value Score of A.
|
cddd4cff-a95d-4c98-8078-06a2b289fb08
|
715364.0
|
2023-12-01 00:00:00 UTC
|
PACCAR Inc. (PCAR) Soars to 52-Week High, Time to Cash Out?
|
DCOMP
|
https://www.nasdaq.com/articles/paccar-inc.-pcar-soars-to-52-week-high-time-to-cash-out-0
|
nan
|
nan
|
Have you been paying attention to shares of Paccar (PCAR)? Shares have been on the move with the stock up 8.8% over the past month. The stock hit a new 52-week high of $92.2 in the previous session. Paccar has gained 39.2% since the start of the year compared to the 34.2% move for the Zacks Auto-Tires-Trucks sector and the 47.5% return for the Zacks Automotive - Domestic industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 24, 2023, Paccar reported EPS of $2.34 versus consensus estimate of $2.07 while it beat the consensus revenue estimate by 2.1%.
For the current fiscal year, Paccar is expected to post earnings of $8.99 per share on $32.81 billion in revenues. This represents a 56.35% change in EPS on a 20.12% change in revenues. For the next fiscal year, the company is expected to earn $7.39 per share on $30.93 billion in revenues. This represents a year-over-year change of -17.75% and -5.71%, respectively.
Valuation Metrics
Paccar may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Paccar has a Value Score of A. The stock's Growth and Momentum Scores are B and F, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 10.2X current fiscal year EPS estimates, which is a premium to the peer industry average of 9.3X. On a trailing cash flow basis, the stock currently trades at 12.6X versus its peer group's average of 5X. Additionally, the stock has a PEG ratio of 1.02. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Paccar currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Paccar fits the bill. Thus, it seems as though Paccar shares could have potential in the weeks and months to come.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PACCAR Inc. (PCAR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself. On a trailing cash flow basis, the stock currently trades at 12.6X versus its peer group's average of 5X. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
In its last earnings report on October 24, 2023, Paccar reported EPS of $2.34 versus consensus estimate of $2.07 while it beat the consensus revenue estimate by 2.1%. In terms of its value breakdown, the stock currently trades at 10.2X current fiscal year EPS estimates, which is a premium to the peer industry average of 9.3X. Click to get this free report PACCAR Inc. (PCAR) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Paccar fits the bill.
|
For the next fiscal year, the company is expected to earn $7.39 per share on $30.93 billion in revenues. Paccar has a Value Score of A. Free: See Our Top Stock and 4 Runners Up >> Want the latest recommendations from Zacks Investment Research?
|
90865827-3da2-4654-bac6-ab1be9cc4c5a
|
715365.0
|
2023-12-01 00:00:00 UTC
|
Does Adeia (ADEA) Have the Potential to Rally 66.81% as Wall Street Analysts Expect?
|
DCOMP
|
https://www.nasdaq.com/articles/does-adeia-adea-have-the-potential-to-rally-66.81-as-wall-street-analysts-expect
|
nan
|
nan
|
Shares of Adeia (ADEA) have gained 4.4% over the past four weeks to close the last trading session at $9.19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 66.8%.
The mean estimate comprises three short-term price targets with a standard deviation of $1.15. While the lowest estimate of $14 indicates a 52.3% increase from the current price level, the most optimistic analyst expects the stock to surge 74.1% to reach $16. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for ADEA, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You May Not Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why ADEA Could Witness a Solid Upside
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 6.7%.
Moreover, ADEA currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much ADEA could gain, the direction of price movement it implies does appear to be a good guide.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adeia Inc. (ADEA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Adeia (ADEA) have gained 4.4% over the past four weeks to close the last trading session at $9.19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
|
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ADEA could gain, the direction of price movement it implies does appear to be a good guide.
|
Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ADEA could gain, the direction of price movement it implies does appear to be a good guide.
|
Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 66.8%. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ADEA could gain, the direction of price movement it implies does appear to be a good guide.
|
4d39252a-b7bc-46a9-bbce-cc0c646195fc
|
715366.0
|
2023-12-01 00:00:00 UTC
|
ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?
|
DCOMP
|
https://www.nasdaq.com/articles/immunogen-imgn-just-flashed-golden-cross-signal%3A-do-you-buy-0
|
nan
|
nan
|
From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. IMGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages.
Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend.
Over the past four weeks, IMGN has gained 89.4%. The company is currently ranked a Zacks Rank #2 (Buy), another strong indication the stock could move even higher.
Looking at IMGN's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 9 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.
Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on IMGN for more gains in the near future.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on IMGN for more gains in the near future. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend. Looking at IMGN's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. Click to get this free report ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. Similar to other SMAs, if a stock's price moves above the 20-day, the trend is considered positive, while price falling below the moving average can signal a downward trend. Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on IMGN for more gains in the near future.
|
IMGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend. Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on IMGN for more gains in the near future. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
|
aca117d0-489f-49ab-9bd5-d0addb32a9d4
|
715367.0
|
2023-12-01 00:00:00 UTC
|
Udemy, Inc. (UDMY) Soars to 52-Week High, Time to Cash Out?
|
DCOMP
|
https://www.nasdaq.com/articles/udemy-inc.-udmy-soars-to-52-week-high-time-to-cash-out
|
nan
|
nan
|
Have you been paying attention to shares of Udemy, Inc. (UDMY)? Shares have been on the move with the stock up 65% over the past month. The stock hit a new 52-week high of $14.9 in the previous session. Udemy, Inc. has gained 41% since the start of the year compared to the 46% move for the Zacks Computer and Technology sector and the 57% return for the Zacks Internet - Software industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 2, 2023, Udemy, Inc. reported EPS of $0.05 versus consensus estimate of $-0.02.
For the current fiscal year, Udemy, Inc. is expected to post earnings of -$0.04 per share on $725.06 million in revenues. This represents a 91.67% change in EPS on a 15.25% change in revenues. For the next fiscal year, the company is expected to earn $0.06 per share on $833.51 million in revenues. This represents a year-over-year change of 268.75% and 14.96%, respectively.
Valuation Metrics
Udemy, Inc. may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Udemy, Inc. has a Value Score of D. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Udemy, Inc. currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Udemy, Inc. passes the test. Thus, it seems as though Udemy, Inc. shares could have a bit more room to run in the near term.
How Does UDMY Stack Up to the Competition?
Shares of UDMY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is PubMatic, Inc. (PUBM). PUBM has a Zacks Rank of # 2 (Buy) and a Value Score of B, a Growth Score of C, and a Momentum Score of A.
Earnings were strong last quarter. PubMatic, Inc. beat our consensus estimate by 137.50%, and for the current fiscal year, PUBM is expected to post earnings of $0.15 per share on revenue of $260.56 million.
Shares of PubMatic, Inc. have gained 41.6% over the past month, and currently trade at a forward P/E of 696.25X and a P/CF of 12.69X.
The Internet - Software industry is in the top 13% of all the industries we have in our universe, so it looks like there are some nice tailwinds for UDMY and PUBM, even beyond their own solid fundamental situation.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Udemy, Inc. (UDMY) : Free Stock Analysis Report
PubMatic, Inc. (PUBM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. PubMatic, Inc. beat our consensus estimate by 137.50%, and for the current fiscal year, PUBM is expected to post earnings of $0.15 per share on revenue of $260.56 million. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
For the current fiscal year, Udemy, Inc. is expected to post earnings of -$0.04 per share on $725.06 million in revenues. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Udemy, Inc. passes the test. Click to get this free report Udemy, Inc. (UDMY) : Free Stock Analysis Report PubMatic, Inc. (PUBM) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Udemy, Inc. has a Value Score of D. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B. Zacks Rank We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Udemy, Inc. passes the test. Click to get this free report Udemy, Inc. (UDMY) : Free Stock Analysis Report PubMatic, Inc. (PUBM) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Fortunately, Udemy, Inc. currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates. Shares of UDMY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? PubMatic, Inc. beat our consensus estimate by 137.50%, and for the current fiscal year, PUBM is expected to post earnings of $0.15 per share on revenue of $260.56 million.
|
14e1a05c-8972-4736-b3a6-f5ee6d03d184
|
715368.0
|
2023-12-01 00:00:00 UTC
|
Crypto stocks set to start December on a high note as bitcoin hits near 19-month high
|
DCOMP
|
https://www.nasdaq.com/articles/crypto-stocks-set-to-start-december-on-a-high-note-as-bitcoin-hits-near-19-month-high
|
nan
|
nan
|
Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies climbed in premarket trading on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite.
Bitcoin BTC=BTSP, up 2% at $38,410, has been gaining since October on optimism that a potential approval of a spot exchange-traded fund is likely to unleash more capital investments in the digital asset sector.
"Tailwinds have been gathering strength all year, especially in recent months, as spot ETF expectations build, the Binance uncertainty is resolved, and 2024's accelerated money printing becomes more inevitable," crypto-focused economist Noelle Acheson said, referring to the bitcoin rally.
Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O, Cipher Mining CIFR.O and TeraWulf WULF.O rose between 2.4% and 4% in trading before the bell.
J.P.Morgan raised its price targets on Cipher Mining, CleanSpark CLSK.O, Iris Energy IREN.O, Marathon Digital and Riot Platforms to reflect the rally in bitcoin.
Shares of bitcoin mining machine maker Canaan CAN.O added nearly 4%.
The mining companies are also increasing production before bitcoin's "halving" event next year, when rewards for producing the tokens are cut in half.
Coinbase's shares COIN.O rose 2.6% following the 62% jump in November that outperformed bitcoin's 11% climb even as the U.S. crypto exchange reported a decline in trading volume earlier in the month.
"Higher crypto prices should lead to a boost in transaction volume and transaction revenues for Coinbase as we enter 2024," said CFRA Research analyst Michael Elliott.
However, Elliott cautioned the crypto exchange faces both legal challenges and new regulations that are likely to take time to play out and will continue to result in volatility for the stock.
The ETF approval bets have helped counter latest concerns after Changpeng Zhao, the founder of the world's largest crypto exchange, stepped down and pleaded guilty to breaking U.S. anti-money laundering laws.
Among other premarket gainers were U.S. software developer and bitcoin investor Microstrategy MSTR.O, up nearly 5%, and ProShares Bitcoin Strategy ETF BITO.P, which added 2%.
(Reporting by Medha Singh in Bengaluru; Editing by Sriraj Kalluvila)
((Medha.Singh@thomsonreuters.com; +91 80 6210 0592; X, formerly Twitter: @medhasinghs;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies climbed in premarket trading on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite. "Tailwinds have been gathering strength all year, especially in recent months, as spot ETF expectations build, the Binance uncertainty is resolved, and 2024's accelerated money printing becomes more inevitable," crypto-focused economist Noelle Acheson said, referring to the bitcoin rally. The ETF approval bets have helped counter latest concerns after Changpeng Zhao, the founder of the world's largest crypto exchange, stepped down and pleaded guilty to breaking U.S. anti-money laundering laws.
|
Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies climbed in premarket trading on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite. Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O, Cipher Mining CIFR.O and TeraWulf WULF.O rose between 2.4% and 4% in trading before the bell. J.P.Morgan raised its price targets on Cipher Mining, CleanSpark CLSK.O, Iris Energy IREN.O, Marathon Digital and Riot Platforms to reflect the rally in bitcoin.
|
Dec 1 (Reuters) - Shares of crypto miners and bitcoin-tracking companies climbed in premarket trading on Friday as the world's largest cryptocurrency extended a recent rally to touch a near 19-month high on improving risk appetite. Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O, Cipher Mining CIFR.O and TeraWulf WULF.O rose between 2.4% and 4% in trading before the bell. Coinbase's shares COIN.O rose 2.6% following the 62% jump in November that outperformed bitcoin's 11% climb even as the U.S. crypto exchange reported a decline in trading volume earlier in the month.
|
Bitcoin BTC=BTSP, up 2% at $38,410, has been gaining since October on optimism that a potential approval of a spot exchange-traded fund is likely to unleash more capital investments in the digital asset sector. Shares of bitcoin miners - whose profitability improves as bitcoin climbs - including Riot Platforms RIOT.O, Marathon Digital MARA.O, Cipher Mining CIFR.O and TeraWulf WULF.O rose between 2.4% and 4% in trading before the bell. Coinbase's shares COIN.O rose 2.6% following the 62% jump in November that outperformed bitcoin's 11% climb even as the U.S. crypto exchange reported a decline in trading volume earlier in the month.
|
6119410f-9ece-4879-9fd9-bf00c5ab94f5
|
715369.0
|
2023-12-01 00:00:00 UTC
|
Broadcom Inc. (AVGO) is Attracting Investor Attention: Here is What You Should Know
|
DCOMP
|
https://www.nasdaq.com/articles/broadcom-inc.-avgo-is-attracting-investor-attention%3A-here-is-what-you-should-know-9
|
nan
|
nan
|
Broadcom Inc. (AVGO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this chipmaker have returned +6.3%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks Electronics - Semiconductors industry, which Broadcom Inc. falls in, has gained 14.1%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Broadcom Inc. is expected to post earnings of $10.95 per share, indicating a change of +4.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.1% over the last 30 days.
The consensus earnings estimate of $42.14 for the current fiscal year indicates a year-over-year change of +12%. This estimate has changed -0.6% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $45.75 indicates a change of +8.6% from what Broadcom Inc. is expected to report a year ago. Over the past month, the estimate has changed +0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Broadcom Inc. is rated Zacks Rank #2 (Buy).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Broadcom Inc. the consensus sales estimate for the current quarter of $9.28 billion indicates a year-over-year change of +3.9%. For the current and next fiscal years, $35.8 billion and $38.39 billion estimates indicate +7.8% and +7.2% changes, respectively.
Last Reported Results and Surprise History
Broadcom Inc. reported revenues of $8.88 billion in the last reported quarter, representing a year-over-year change of +4.9%. EPS of $10.54 for the same period compares with $9.73 a year ago.
Compared to the Zacks Consensus Estimate of $8.86 billion, the reported revenues represent a surprise of +0.22%. The EPS surprise was +1.15%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Broadcom Inc. is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Broadcom Inc. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Broadcom Inc. (AVGO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Broadcom Inc.
|
A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
|
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. EPS of $10.54 for the same period compares with $9.73 a year ago. The company topped consensus revenue estimates each time over this period.
|
8f569885-8ca2-4b3c-b0da-3acb5df94228
|
715370.0
|
2023-12-01 00:00:00 UTC
|
Here's Why EOG Resources (EOG) is an Attractive Investment Bet
|
DCOMP
|
https://www.nasdaq.com/articles/heres-why-eog-resources-eog-is-an-attractive-investment-bet-3
|
nan
|
nan
|
EOG Resources, Inc. EOG has witnessed upward earnings estimate revisions for 2023 and 2024 over the past 30 days.
Factors Working in Favor
The price of West Texas Intermediate crude, at more than the $75 per barrel mark again, is highly favorable for upstream operations. EOG Resources, currently carrying a Zacks Rank #2 (Buy), is well-placed to capitalize on the promising business scenario. It has significant undrilled premium locations, resulting in a brightened production outlook.
EOG Resources is strongly committed to returning capital to shareholders. Since transitioning to premium drilling, the company has returned significant cash to its stockholders. Notably, from 1999 through 2024, the company has committed to raise its regular dividend at a compound annual growth rate of 21%. It has never suspended or lowered its dividend, even during business turmoil, reflecting solid underlying business.
With the employment of premium drilling, EOG will be able to reduce its cash operating costs per barrel of oil equivalent, aiding its bottom line.
Other Stocks to Consider
Other prospective energy companies include Southwest Gas Holdings Inc. SWX, Weatherford International plc WFRD and Transportadora de Gas del Sur SA TGS. While Southwest Gas Holdings sports a Zacks Rank #1 (Strong Buy), Weatherford International and Transportadora de Gas carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Southwest Gas Holdings is making progress in its transition to a pure-play natural gas leader. The company's affordable energy solutions are witnessing heightened demand from its growing customer base.
Weatherfordis a key energy player and is engaged in offering exclusive drilling technologies that will maximize clients’ reservoir exposure. Weatherford is also involved in well construction and completion activities in an efficient manner.
Transportadora’s midstream asset portfolio has the most extensive natural gas pipeline network in Latin America. It generates stable fee-based revenues since its pipeline assets transport more than 60% of the gas consumed in Argentina.
Transportadora has witnessed upward estimate revisions for its 2024 bottom line in the past 30 days. The upward revisions are backed by the company’s stable business model and a strong focus on creating differential value for shareholders. Also, TGS has lower debt exposure than the composite stocks belonging to the industry.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EOG Resources, Inc. (EOG) : Free Stock Analysis Report
Southwest Gas Corporation (SWX) : Free Stock Analysis Report
Transportadora De Gas Sa Ord B (TGS) : Free Stock Analysis Report
Weatherford International PLC (WFRD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
With the employment of premium drilling, EOG will be able to reduce its cash operating costs per barrel of oil equivalent, aiding its bottom line. Weatherfordis a key energy player and is engaged in offering exclusive drilling technologies that will maximize clients’ reservoir exposure. The upward revisions are backed by the company’s stable business model and a strong focus on creating differential value for shareholders.
|
Other Stocks to Consider Other prospective energy companies include Southwest Gas Holdings Inc. SWX, Weatherford International plc WFRD and Transportadora de Gas del Sur SA TGS. While Southwest Gas Holdings sports a Zacks Rank #1 (Strong Buy), Weatherford International and Transportadora de Gas carry a Zacks Rank #2. Click to get this free report EOG Resources, Inc. (EOG) : Free Stock Analysis Report Southwest Gas Corporation (SWX) : Free Stock Analysis Report Transportadora De Gas Sa Ord B (TGS) : Free Stock Analysis Report Weatherford International PLC (WFRD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Other Stocks to Consider Other prospective energy companies include Southwest Gas Holdings Inc. SWX, Weatherford International plc WFRD and Transportadora de Gas del Sur SA TGS. While Southwest Gas Holdings sports a Zacks Rank #1 (Strong Buy), Weatherford International and Transportadora de Gas carry a Zacks Rank #2. Click to get this free report EOG Resources, Inc. (EOG) : Free Stock Analysis Report Southwest Gas Corporation (SWX) : Free Stock Analysis Report Transportadora De Gas Sa Ord B (TGS) : Free Stock Analysis Report Weatherford International PLC (WFRD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
EOG Resources, Inc. EOG has witnessed upward earnings estimate revisions for 2023 and 2024 over the past 30 days. EOG Resources is strongly committed to returning capital to shareholders. You can see the complete list of today’s Zacks #1 Rank stocks here.
|
ec1ffee3-70a5-45b9-8826-37362e998c26
|
715371.0
|
2023-12-01 00:00:00 UTC
|
ExxonMobil (XOM) Commences Fawley Oil Refinery Work in UK
|
DCOMP
|
https://www.nasdaq.com/articles/exxonmobil-xom-commences-fawley-oil-refinery-work-in-uk
|
nan
|
nan
|
Exxon Mobil Corporation XOM is set to complete a $1-billion expansion project for diesel production at its Fawley oil refinery in 2024.
Located near Southampton, Hampshire, on England’s south coast, the Fawley oil refinery stands as the largest and oldest among the six operational refinery sites in the UK. The facility processes 270,000 barrels of crude per day.
ExxonMobil plans to incorporate a new hydrogen plant into Britain’s largest oil-processing complex, a move that could open avenues for the development of sustainable aviation fuel. The unit is designed to operate on natural gas.
The refinery is poised to increase low-sulfur diesel production by 40%. Referred to as the Fast project, it is expected to achieve full production in 2025, coinciding with the planned cessation of low-sulfur diesel production at the Grangemouth refinery in Scotland.
ExxonMobil has been working for years on the Fawley diesel facility. The company paused work on the Fawley diesel facility due to Covid-induced drop in fuel demand. In Europe, diesel profits now exceed historical averages due to Russia sanctions impacting the region’s major external supplier.
Although UK diesel demand has not fully recovered to pre-pandemic levels, the country depends on imports for approximately half of its consumption. The Fawley project has the potential to reduce imports by up to a quarter.
The expanded facility is expected to commence production in 2024. ExxonMobil initially projected nearly 45% increase, equivalent to 38,000 barrels per day, in ultra-low sulfur diesel production when it made the final investment decision in 2019.
Earlier this month, XOM obtained funding from the UK government to investigate sustainable aviation fuel production at Fawley. If the project progresses, it could meet 20% of the UK’s sustainable aviation fuel requirements by 2030.
The hydrogen plant at Fawley is set to be part of the Solent cluster, a collaborative effort among companies focused on decarbonizing the industry. XOM’s significant investment aims to decrease Britain’s dependence on imported fuel and reduce emissions linked to global transport.
Zacks Rank & Stocks to Consider
ExxonMobil currently carries a Zack Rank #3 (Hold).
Investors interested in the energy sector might look at the following companies that presently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Murphy Oil Corporation MUR possesses one of the best upstream portfolios among the domestic oil and natural gas integrated companies, and independent E&P group.
The company has a long history of increasing the value of its shareholders, courtesy of steady cash flows. Its board of directors approved a 10% increase in the quarterly dividend rate beginning in the first quarter of 2023, taking the total annualized figure to $1.10 per share. MUR’s current dividend yield is 2.57%, better than the Zacks S&P 500 Composite's average of 1.7%.
Suncor Energy, Inc. SU is Canada’s premier integrated energy company. Suncor boasts an impressive supply-chain network, owning significant oil sands and conventional production platforms.
Suncor's robust liquidity position will allow it to sustain its dividend, even if oil prices stay lower for longer. Notably, SU recently hiked its dividend by 5% to 54.5 Canadian cents per share (over the prior quarter) and increased the buyback authorization to roughly 10% of its public float.
Liberty Energy LBRT reported third-quarter 2023 earnings of 85 cents per share, which beat the Zacks Consensus Estimate of earnings of 74 cents. The Denver, CO-based oil and gas equipment company’s outperformance reflects the impacts of strong execution and increased service pricing.
Liberty’s board of directors announced a cash dividend of seven cents per common share, payable Dec 20, 2023, to stockholders of record as of Dec 6, 2023. This dividend reflects a 40% rise from the previous quarter’s level. As part of its shareholder return policy, LBRT repurchased shares worth $29 million at an average price of $16.38 per share.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exxon Mobil Corporation (XOM) : Free Stock Analysis Report
Murphy Oil Corporation (MUR) : Free Stock Analysis Report
Suncor Energy Inc. (SU) : Free Stock Analysis Report
Liberty Energy Inc. (LBRT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ExxonMobil plans to incorporate a new hydrogen plant into Britain’s largest oil-processing complex, a move that could open avenues for the development of sustainable aviation fuel. ExxonMobil initially projected nearly 45% increase, equivalent to 38,000 barrels per day, in ultra-low sulfur diesel production when it made the final investment decision in 2019. Notably, SU recently hiked its dividend by 5% to 54.5 Canadian cents per share (over the prior quarter) and increased the buyback authorization to roughly 10% of its public float.
|
Exxon Mobil Corporation XOM is set to complete a $1-billion expansion project for diesel production at its Fawley oil refinery in 2024. Liberty Energy LBRT reported third-quarter 2023 earnings of 85 cents per share, which beat the Zacks Consensus Estimate of earnings of 74 cents. Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Murphy Oil Corporation (MUR) : Free Stock Analysis Report Suncor Energy Inc. (SU) : Free Stock Analysis Report Liberty Energy Inc. (LBRT) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Exxon Mobil Corporation XOM is set to complete a $1-billion expansion project for diesel production at its Fawley oil refinery in 2024. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year. Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Murphy Oil Corporation (MUR) : Free Stock Analysis Report Suncor Energy Inc. (SU) : Free Stock Analysis Report Liberty Energy Inc. (LBRT) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Exxon Mobil Corporation XOM is set to complete a $1-billion expansion project for diesel production at its Fawley oil refinery in 2024. ExxonMobil has been working for years on the Fawley diesel facility. Liberty Energy LBRT reported third-quarter 2023 earnings of 85 cents per share, which beat the Zacks Consensus Estimate of earnings of 74 cents.
|
4efb8157-cb8f-44fd-b42f-2407929e04fb
|
715372.0
|
2023-12-01 00:00:00 UTC
|
Investors Heavily Search Energy Transfer LP (ET): Here is What You Need to Know
|
DCOMP
|
https://www.nasdaq.com/articles/investors-heavily-search-energy-transfer-lp-et%3A-here-is-what-you-need-to-know-7
|
nan
|
nan
|
Energy Transfer LP (ET) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this energy-related services provider have returned +1.8% over the past month versus the Zacks S&P 500 composite's +9.2% change. The Zacks Oil and Gas - Production Pipeline - MLB industry, to which Energy Transfer LP belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Energy Transfer LP is expected to post earnings of $0.28 per share for the current quarter, representing a year-over-year change of -17.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -15.2%.
The consensus earnings estimate of $1.09 for the current fiscal year indicates a year-over-year change of -22.7%. This estimate has changed -3.7% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $1.16 indicates a change of +5.8% from what Energy Transfer LP is expected to report a year ago. Over the past month, the estimate has changed -14.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Energy Transfer LP is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Energy Transfer LP, the consensus sales estimate for the current quarter of $23.44 billion indicates a year-over-year change of +14.3%. For the current and next fiscal years, $81.96 billion and $96.49 billion estimates indicate -8.8% and +17.7% changes, respectively.
Last Reported Results and Surprise History
Energy Transfer LP reported revenues of $20.74 billion in the last reported quarter, representing a year-over-year change of -9.6%. EPS of $0.31 for the same period compares with $0.30 a year ago.
Compared to the Zacks Consensus Estimate of $21.68 billion, the reported revenues represent a surprise of -4.34%. The EPS surprise was +6.9%.
Over the last four quarters, the company surpassed EPS estimates just once. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Energy Transfer LP is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Energy Transfer LP. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Energy Transfer LP (ET) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Zacks Oil and Gas - Production Pipeline - MLB industry, to which Energy Transfer LP belongs, has gained 5.2% over this period. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Energy Transfer LP.
|
For the next fiscal year, the consensus earnings estimate of $1.16 indicates a change of +5.8% from what Energy Transfer LP is expected to report a year ago. Last Reported Results and Surprise History Energy Transfer LP reported revenues of $20.74 billion in the last reported quarter, representing a year-over-year change of -9.6%. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
|
For the next fiscal year, the consensus earnings estimate of $1.16 indicates a change of +5.8% from what Energy Transfer LP is expected to report a year ago. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Energy Transfer LP is rated Zacks Rank #3 (Hold). While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. For the next fiscal year, the consensus earnings estimate of $1.16 indicates a change of +5.8% from what Energy Transfer LP is expected to report a year ago. For Energy Transfer LP, the consensus sales estimate for the current quarter of $23.44 billion indicates a year-over-year change of +14.3%.
|
f70f2470-ef3c-4871-8509-ce121aa6993e
|
715373.0
|
2023-12-01 00:00:00 UTC
|
Fortinet, Inc. (FTNT) Is a Trending Stock: Facts to Know Before Betting on It
|
DCOMP
|
https://www.nasdaq.com/articles/fortinet-inc.-ftnt-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-2
|
nan
|
nan
|
Fortinet (FTNT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this network security company have returned -8.7%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks Internet - Software industry, which Fortinet falls in, has gained 11.6%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Fortinet is expected to post earnings of $0.43 per share for the current quarter, representing a year-over-year change of -2.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +4.4%.
The consensus earnings estimate of $1.56 for the current fiscal year indicates a year-over-year change of +31.1%. This estimate has changed +3.8% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $1.67 indicates a change of +6.7% from what Fortinet is expected to report a year ago. Over the past month, the estimate has changed -3.7%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Fortinet.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Fortinet, the consensus sales estimate of $1.41 billion for the current quarter points to a year-over-year change of +9.7%. The $5.3 billion and $5.94 billion estimates for the current and next fiscal years indicate changes of +19.9% and +12.1%, respectively.
Last Reported Results and Surprise History
Fortinet reported revenues of $1.33 billion in the last reported quarter, representing a year-over-year change of +16.1%. EPS of $0.41 for the same period compares with $0.33 a year ago.
Compared to the Zacks Consensus Estimate of $1.35 billion, the reported revenues represent a surprise of -1%. The EPS surprise was +10.81%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates just once over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Fortinet is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Fortinet. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fortinet, Inc. (FTNT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Fortinet.
|
For the next fiscal year, the consensus earnings estimate of $1.67 indicates a change of +6.7% from what Fortinet is expected to report a year ago. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Last Reported Results and Surprise History Fortinet reported revenues of $1.33 billion in the last reported quarter, representing a year-over-year change of +16.1%.
|
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
When earnings estimates for a company go up, the fair value for its stock goes up as well. EPS of $0.41 for the same period compares with $0.33 a year ago. Compared to the Zacks Consensus Estimate of $1.35 billion, the reported revenues represent a surprise of -1%.
|
5c0abf12-9474-44e2-a300-7c6e80b3c9db
|
715374.0
|
2023-12-01 00:00:00 UTC
|
Investors Heavily Search Palo Alto Networks, Inc. (PANW): Here is What You Need to Know
|
DCOMP
|
https://www.nasdaq.com/articles/investors-heavily-search-palo-alto-networks-inc.-panw%3A-here-is-what-you-need-to-know-4
|
nan
|
nan
|
Palo Alto Networks (PANW) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this security software maker have returned +17.9% over the past month versus the Zacks S&P 500 composite's +9.2% change. The Zacks Internet - Software industry, to which Palo Alto belongs, has gained 11.6% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Palo Alto is expected to post earnings of $1.30 per share for the current quarter, representing a year-over-year change of +23.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +3.2%.
The consensus earnings estimate of $5.48 for the current fiscal year indicates a year-over-year change of +23.4%. This estimate has changed +4.5% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $6.43 indicates a change of +17.4% from what Palo Alto is expected to report a year ago. Over the past month, the estimate has changed +0.6%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Palo Alto is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Palo Alto, the consensus sales estimate for the current quarter of $1.97 billion indicates a year-over-year change of +19.1%. For the current and next fiscal years, $8.17 billion and $9.65 billion estimates indicate +18.6% and +18.1% changes, respectively.
Last Reported Results and Surprise History
Palo Alto reported revenues of $1.88 billion in the last reported quarter, representing a year-over-year change of +20.1%. EPS of $1.38 for the same period compares with $0.83 a year ago.
Compared to the Zacks Consensus Estimate of $1.84 billion, the reported revenues represent a surprise of +1.98%. The EPS surprise was +18.97%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Palo Alto is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Palo Alto. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Palo Alto.
|
For the next fiscal year, the consensus earnings estimate of $6.43 indicates a change of +17.4% from what Palo Alto is expected to report a year ago. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
|
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Palo Alto is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. The consensus earnings estimate of $5.48 for the current fiscal year indicates a year-over-year change of +23.4%. The company topped consensus revenue estimates three times over this period.
|
6b9bfa50-d85e-4fd5-85fb-995d2cd4ac04
|
715375.0
|
2023-12-01 00:00:00 UTC
|
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
|
DCOMP
|
https://www.nasdaq.com/articles/eli-lilly-and-company-lly-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-6
|
nan
|
nan
|
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +1.9%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has gained 3.9%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Lilly is expected to post earnings of $2.79 per share for the current quarter, representing a year-over-year change of +33.5%. Over the last 30 days, the Zacks Consensus Estimate has changed -9.2%.
For the current fiscal year, the consensus earnings estimate of $6.62 points to a change of -16.6% from the prior year. Over the last 30 days, this estimate has changed -0.5%.
For the next fiscal year, the consensus earnings estimate of $12.57 indicates a change of +89.9% from what Lilly is expected to report a year ago. Over the past month, the estimate has changed -4.5%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lilly.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Lilly, the consensus sales estimate of $8.87 billion for the current quarter points to a year-over-year change of +21.5%. The $33.64 billion and $39.29 billion estimates for the current and next fiscal years indicate changes of +17.9% and +16.8%, respectively.
Last Reported Results and Surprise History
Lilly reported revenues of $9.5 billion in the last reported quarter, representing a year-over-year change of +36.8%. EPS of $0.10 for the same period compares with $1.98 a year ago.
Compared to the Zacks Consensus Estimate of $8.88 billion, the reported revenues represent a surprise of +6.97%. The EPS surprise was +225%.
Over the last four quarters, Lilly surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Lilly is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Lilly. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Lilly.
|
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue Growth While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Click to get this free report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue Growth While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
For the next fiscal year, the consensus earnings estimate of $12.57 indicates a change of +89.9% from what Lilly is expected to report a year ago. EPS of $0.10 for the same period compares with $1.98 a year ago. Compared to the Zacks Consensus Estimate of $8.88 billion, the reported revenues represent a surprise of +6.97%.
|
8d03b0cf-aba4-4e6f-b3f4-c81bc45e2991
|
715376.0
|
2023-12-01 00:00:00 UTC
|
Enterprise Products Partners L.P. (EPD) Is a Trending Stock: Facts to Know Before Betting on It
|
DCOMP
|
https://www.nasdaq.com/articles/enterprise-products-partners-l.p.-epd-is-a-trending-stock%3A-facts-to-know-before-betting-7
|
nan
|
nan
|
Enterprise Products Partners (EPD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this provider of midstream energy services have returned +1.6% over the past month versus the Zacks S&P 500 composite's +9.2% change. The Zacks Oil and Gas - Production Pipeline - MLB industry, to which Enterprise Products belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Enterprise Products is expected to post earnings of $0.67 per share for the current quarter, representing a year-over-year change of +3.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.6%.
For the current fiscal year, the consensus earnings estimate of $2.50 points to a change of -0.8% from the prior year. Over the last 30 days, this estimate has changed -0.5%.
For the next fiscal year, the consensus earnings estimate of $2.64 indicates a change of +5.7% from what Enterprise Products is expected to report a year ago. Over the past month, the estimate has changed -1.1%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Enterprise Products is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Enterprise Products, the consensus sales estimate of $12.86 billion for the current quarter points to a year-over-year change of -5.8%. The $48.5 billion and $52.47 billion estimates for the current and next fiscal years indicate changes of -16.6% and +8.2%, respectively.
Last Reported Results and Surprise History
Enterprise Products reported revenues of $12 billion in the last reported quarter, representing a year-over-year change of -22.4%. EPS of $0.60 for the same period compares with $0.63 a year ago.
Compared to the Zacks Consensus Estimate of $12.34 billion, the reported revenues represent a surprise of -2.78%. The EPS surprise was -4.76%.
Over the last four quarters, Enterprise Products surpassed consensus EPS estimates two times. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Enterprise Products is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Enterprise Products. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Enterprise Products Partners L.P. (EPD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Enterprise Products.
|
For the next fiscal year, the consensus earnings estimate of $2.64 indicates a change of +5.7% from what Enterprise Products is expected to report a year ago. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
For the next fiscal year, the consensus earnings estimate of $2.64 indicates a change of +5.7% from what Enterprise Products is expected to report a year ago. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Enterprise Products is rated Zacks Rank #3 (Hold). While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. Over the last four quarters, Enterprise Products surpassed consensus EPS estimates two times. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
dfea5c86-f029-4ec2-b970-03b89854320c
|
715377.0
|
2023-12-01 00:00:00 UTC
|
Diversified Healthcare Trust (DHC) Is a Trending Stock: Facts to Know Before Betting on It
|
DCOMP
|
https://www.nasdaq.com/articles/diversified-healthcare-trust-dhc-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-0
|
nan
|
nan
|
Diversified Healthcare (DHC) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this residential care real estate investment trust have returned +5.4%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks REIT and Equity Trust - Other industry, which Diversified Healthcare falls in, has gained 13.4%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Diversified Healthcare is expected to post earnings of $0.07 per share for the current quarter, representing a year-over-year change of +133.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -22.2%.
For the current fiscal year, the consensus earnings estimate of $0.25 points to a change of +256.3% from the prior year. Over the last 30 days, this estimate has changed -7.6%.
For the next fiscal year, the consensus earnings estimate of $0.40 indicates a change of +60% from what Diversified Healthcare is expected to report a year ago. Over the past month, the estimate has changed -11.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Diversified Healthcare.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Diversified Healthcare, the consensus sales estimate of $360.14 million for the current quarter points to a year-over-year change of +6.9%. The $1.41 billion and $1.51 billion estimates for the current and next fiscal years indicate changes of +9.8% and +6.9%, respectively.
Last Reported Results and Surprise History
Diversified Healthcare reported revenues of $356.52 million in the last reported quarter, representing a year-over-year change of +10.4%. EPS of -$0.28 for the same period compares with -$0.06 a year ago.
Compared to the Zacks Consensus Estimate of $359.63 million, the reported revenues represent a surprise of -0.86%. The EPS surprise was -57.14%.
Over the last four quarters, the company surpassed EPS estimates just once. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Diversified Healthcare is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Diversified Healthcare. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Diversified Healthcare Trust (DHC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Over the past month, shares of this residential care real estate investment trust have returned +5.4%, compared to the Zacks S&P 500 composite's +9.2% change. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Diversified Healthcare.
|
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue Growth While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Click to get this free report Diversified Healthcare Trust (DHC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Diversified Healthcare. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
For the next fiscal year, the consensus earnings estimate of $0.40 indicates a change of +60% from what Diversified Healthcare is expected to report a year ago. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Diversified Healthcare. EPS of -$0.28 for the same period compares with -$0.06 a year ago.
|
5bc14cdf-95e6-46e0-a280-2efa4a83cb62
|
715378.0
|
2023-12-01 00:00:00 UTC
|
Technology Sector Update for 12/01/2023: ESTC, IOT, DELL, XLK, XSD
|
DCOMP
|
https://www.nasdaq.com/articles/technology-sector-update-for-12-01-2023%3A-estc-iot-dell-xlk-xsd
|
nan
|
nan
|
Technology stocks were leaning lower pre-bell Friday, with the Technology Select Sector SPDR Fund (XLK) was down 0.3% and the SPDR S&P Semiconductor ETF (XSD) recently declining by 0.3%.
Elastic (ESTC) was gaining more than 21% in value after it reported fiscal Q2 non-GAAP diluted earnings of $0.37 per share, compared with a breakeven a year earlier. Analysts polled by Capital IQ expected $0.24.
Samsara (IOT) was more than 14% higher after it reported fiscal Q3 non-GAAP diluted EPS of $0.04, compared with a loss of $0.02 a year earlier. Analysts polled by Capital IQ expected normalized earnings of $0.01.
Dell Technologies (DELL) was slipping past 4% after it reported fiscal Q3 non-GAAP diluted EPS of $1.88, down from $2.30 a year earlier.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Technology stocks were leaning lower pre-bell Friday, with the Technology Select Sector SPDR Fund (XLK) was down 0.3% and the SPDR S&P Semiconductor ETF (XSD) recently declining by 0.3%. Elastic (ESTC) was gaining more than 21% in value after it reported fiscal Q2 non-GAAP diluted earnings of $0.37 per share, compared with a breakeven a year earlier. Samsara (IOT) was more than 14% higher after it reported fiscal Q3 non-GAAP diluted EPS of $0.04, compared with a loss of $0.02 a year earlier.
|
Samsara (IOT) was more than 14% higher after it reported fiscal Q3 non-GAAP diluted EPS of $0.04, compared with a loss of $0.02 a year earlier. Analysts polled by Capital IQ expected normalized earnings of $0.01. Dell Technologies (DELL) was slipping past 4% after it reported fiscal Q3 non-GAAP diluted EPS of $1.88, down from $2.30 a year earlier.
|
Elastic (ESTC) was gaining more than 21% in value after it reported fiscal Q2 non-GAAP diluted earnings of $0.37 per share, compared with a breakeven a year earlier. Samsara (IOT) was more than 14% higher after it reported fiscal Q3 non-GAAP diluted EPS of $0.04, compared with a loss of $0.02 a year earlier. Dell Technologies (DELL) was slipping past 4% after it reported fiscal Q3 non-GAAP diluted EPS of $1.88, down from $2.30 a year earlier.
|
Technology stocks were leaning lower pre-bell Friday, with the Technology Select Sector SPDR Fund (XLK) was down 0.3% and the SPDR S&P Semiconductor ETF (XSD) recently declining by 0.3%. Elastic (ESTC) was gaining more than 21% in value after it reported fiscal Q2 non-GAAP diluted earnings of $0.37 per share, compared with a breakeven a year earlier. Analysts polled by Capital IQ expected $0.24.
|
cf5f0b3d-fd6b-4e8a-9716-4c9ac0370f3f
|
715379.0
|
2023-12-01 00:00:00 UTC
|
Investors Heavily Search HCA Healthcare, Inc. (HCA): Here is What You Need to Know
|
DCOMP
|
https://www.nasdaq.com/articles/investors-heavily-search-hca-healthcare-inc.-hca%3A-here-is-what-you-need-to-know
|
nan
|
nan
|
HCA Healthcare (HCA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this hospital operator have returned +9.9%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks Medical - Hospital industry, which HCA falls in, has gained 10.9%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
HCA is expected to post earnings of $5.02 per share for the current quarter, representing a year-over-year change of +8.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.7%.
The consensus earnings estimate of $18.17 for the current fiscal year indicates a year-over-year change of +7.6%. This estimate has changed -0.4% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $19.47 indicates a change of +7.2% from what HCA is expected to report a year ago. Over the past month, the estimate has changed -1.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, HCA is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For HCA, the consensus sales estimate for the current quarter of $16.55 billion indicates a year-over-year change of +6.8%. For the current and next fiscal years, $64.21 billion and $67.49 billion estimates indicate +6.6% and +5.1% changes, respectively.
Last Reported Results and Surprise History
HCA reported revenues of $16.21 billion in the last reported quarter, representing a year-over-year change of +8.3%. EPS of $3.91 for the same period compares with $3.93 a year ago.
Compared to the Zacks Consensus Estimate of $15.77 billion, the reported revenues represent a surprise of +2.8%. The EPS surprise was -1.51%.
Over the last four quarters, HCA surpassed consensus EPS estimates two times. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
HCA is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about HCA. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about HCA.
|
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue Growth Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Click to get this free report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, HCA is rated Zacks Rank #3 (Hold). Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
For the next fiscal year, the consensus earnings estimate of $19.47 indicates a change of +7.2% from what HCA is expected to report a year ago. EPS of $3.91 for the same period compares with $3.93 a year ago. The company topped consensus revenue estimates three times over this period.
|
dfcf1366-e0cb-4703-997d-bff0e3f61b41
|
715380.0
|
2023-12-01 00:00:00 UTC
|
Investors Heavily Search Graphic Packaging Holding Company (GPK): Here is What You Need to Know
|
DCOMP
|
https://www.nasdaq.com/articles/investors-heavily-search-graphic-packaging-holding-company-gpk%3A-here-is-what-you-need-to-0
|
nan
|
nan
|
Graphic Packaging (GPK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this packaging company have returned +3.6% over the past month versus the Zacks S&P 500 composite's +9.2% change. The Zacks Containers - Paper and Packaging industry, to which Graphic Packaging belongs, has gained 9% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Graphic Packaging is expected to post earnings of $0.69 per share for the current quarter, representing a year-over-year change of +17%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.6%.
For the current fiscal year, the consensus earnings estimate of $2.85 points to a change of +22.3% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $2.78 indicates a change of -2.5% from what Graphic Packaging is expected to report a year ago. Over the past month, the estimate has remained unchanged.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Graphic Packaging is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Graphic Packaging, the consensus sales estimate of $2.4 billion for the current quarter points to a year-over-year change of +0.7%. The $9.58 billion and $9.82 billion estimates for the current and next fiscal years indicate changes of +1.5% and +2.5%, respectively.
Last Reported Results and Surprise History
Graphic Packaging reported revenues of $2.35 billion in the last reported quarter, representing a year-over-year change of -4.2%. EPS of $0.74 for the same period compares with $0.67 a year ago.
Compared to the Zacks Consensus Estimate of $2.46 billion, the reported revenues represent a surprise of -4.58%. The EPS surprise was +2.78%.
Over the last four quarters, Graphic Packaging surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Graphic Packaging is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Graphic Packaging. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Graphic Packaging Holding Company (GPK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Graphic Packaging.
|
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Graphic Packaging is rated Zacks Rank #3 (Hold). Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Click to get this free report Graphic Packaging Holding Company (GPK) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Graphic Packaging is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. Over the last four quarters, Graphic Packaging surpassed consensus EPS estimates three times. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
6ed031e9-f3d8-40d8-9b14-59fa9713b973
|
715381.0
|
2023-12-01 00:00:00 UTC
|
Market Slump Got You Down? 1 Supercharged Stock to Buy Now
|
DCOMP
|
https://www.nasdaq.com/articles/market-slump-got-you-down-1-supercharged-stock-to-buy-now
|
nan
|
nan
|
Now may finally be the time for investors to book a position in Booking Holdings (NASDAQ: BKNG). After years of range-bound trading, the former Priceline.com has risen more than 55% this year and the stock achieved a record high earlier this fall.
After a pandemic that nearly brought the travel industry to a standstill, Booking has benefited from pent-up demand for travel. Even with a nominal stock price of over $3,100 per share, this supercharged travel stock looks positioned to continue achieving new highs. Here's why.
Who is Booking Holdings?
Admittedly, the company may have a name recognition problem. As Priceline.com, the company was one of the darlings of the dot-com era until the stock lost nearly all of its value in a sell-off.
However, the stock recovered over time, and the company acquired other travel sites such as Booking.com, Agoda.com, Kayak.com, and OpenTable. Although it adopted the Priceline Group name in 2014, the company felt it needed to improve brand awareness, so in 2018, it became Booking Holdings.
Dropping the Priceline name may have had the opposite effect. As late as the fall of 2022, Booking Holdings traded at a lower price than the day the company changed its name in February 2018. It was only with the latest move that the stock achieved record highs.
BKNG data by YCharts
The Booking Holdings share price
Another perception-related challenge may pertain to its massive share price. Admittedly, many small investors cannot afford a full share with the price exceeding $3,100 per share. The company's continuing avoidance of a stock split may baffle some investors.
This curiosity is understandable as Booking approved a 1-for-6 reverse stock split during the dot-com bust to boost a then-lagging share price. Since that time, it has made no effort to reverse the reverse split. However, most brokerages will sell fractional shares of this company, making it available to investors with small budgets.
Moreover, investors may benefit from the smaller share count. The number of outstanding shares has steadily fallen since 2014, when the share count peaked at over 52 million. In just the past year, share buybacks have taken the count from just under 39 million shares to less than 35 million. That lower supply has likely contributed to the increased stock price.
Booking Holdings' business recovery
A lower supply of shares is not the only reason to consider Booking Holdings. In the third quarter of 2023 alone, customers booked over 276 million nights on the site, a 15% yearly increase. Also, about 33% of those room nights were for alternative accommodations, indicating it has not conceded this market to Airbnb. Booking has also further developed its flight offerings. Consequently, Its sites booked 57% more flights over the last year.
Given such improvements, Booking grew revenue for the first nine months of the year to nearly $17 billion, a 28% increase from the same period last year. Between slower growth in operating expenses and its interest and dividend income, net income for the first three quarters of the year came in at almost $4.1 billion. In comparison, net income was $1.8 billion in the year-ago period.
That higher net income has also taken the P/E ratio to 22, a level near multiyear lows. With its low earnings multiple, business recovery, and share price growth, investors may finally see this stock in a different light.
Consider Booking Holdings stock
Given its business and share price recovery, Booking Holdings may have already begun a long-awaited bull market. Indeed, moving away from the Priceline name may not have helped the company. Also, its share price strongly indicates it needs to initiate a stock split.
Nonetheless, its underlying businesses have shown meaningful signs of recovery. Also, the stock sells at a low P/E ratio even after significant share price growth. Given such conditions, the stock looks poised to fly higher for the foreseeable future.
10 stocks we like better than Booking Holdings
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Booking Holdings wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 27, 2023
Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Airbnb and Booking Holdings. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Although it adopted the Priceline Group name in 2014, the company felt it needed to improve brand awareness, so in 2018, it became Booking Holdings. This curiosity is understandable as Booking approved a 1-for-6 reverse stock split during the dot-com bust to boost a then-lagging share price. With its low earnings multiple, business recovery, and share price growth, investors may finally see this stock in a different light.
|
Now may finally be the time for investors to book a position in Booking Holdings (NASDAQ: BKNG). Booking Holdings' business recovery A lower supply of shares is not the only reason to consider Booking Holdings. Consider Booking Holdings stock Given its business and share price recovery, Booking Holdings may have already begun a long-awaited bull market.
|
Even with a nominal stock price of over $3,100 per share, this supercharged travel stock looks positioned to continue achieving new highs. Booking Holdings' business recovery A lower supply of shares is not the only reason to consider Booking Holdings. Consider Booking Holdings stock Given its business and share price recovery, Booking Holdings may have already begun a long-awaited bull market.
|
Even with a nominal stock price of over $3,100 per share, this supercharged travel stock looks positioned to continue achieving new highs. Booking Holdings' business recovery A lower supply of shares is not the only reason to consider Booking Holdings. Consider Booking Holdings stock Given its business and share price recovery, Booking Holdings may have already begun a long-awaited bull market.
|
7cdb650e-2159-41d5-90ee-54d9a7d24255
|
715382.0
|
2023-12-01 00:00:00 UTC
|
Here is What to Know Beyond Why Opendoor Technologies Inc. (OPEN) is a Trending Stock
|
DCOMP
|
https://www.nasdaq.com/articles/here-is-what-to-know-beyond-why-opendoor-technologies-inc.-open-is-a-trending-stock-1
|
nan
|
nan
|
Opendoor Technologies Inc. (OPEN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this company have returned +36.8% over the past month versus the Zacks S&P 500 composite's +9.2% change. The Zacks Technology Services industry, to which Opendoor Technologies Inc. belongs, has gained 15% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Opendoor Technologies Inc. is expected to post a loss of $0.18 per share for the current quarter, representing a year-over-year change of +75.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.5%.
For the current fiscal year, the consensus earnings estimate of -$1.21 points to a change of -31.5% from the prior year. Over the last 30 days, this estimate has changed +3.2%.
For the next fiscal year, the consensus earnings estimate of -$0.60 indicates a change of +50.4% from what Opendoor Technologies Inc. is expected to report a year ago. Over the past month, the estimate has changed +11.1%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Opendoor Technologies Inc. is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Opendoor Technologies Inc. the consensus sales estimate of $830.43 million for the current quarter points to a year-over-year change of -70.9%. The $6.91 billion and $6.15 billion estimates for the current and next fiscal years indicate changes of -55.6% and -10.9%, respectively.
Last Reported Results and Surprise History
Opendoor Technologies Inc. reported revenues of $980 million in the last reported quarter, representing a year-over-year change of -70.8%. EPS of -$0.11 for the same period compares with -$0.52 a year ago.
Compared to the Zacks Consensus Estimate of $985.97 million, the reported revenues represent a surprise of -0.61%. The EPS surprise was +35.29%.
Over the last four quarters, Opendoor Technologies Inc. surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Opendoor Technologies Inc. is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Opendoor Technologies Inc. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Opendoor Technologies Inc. (OPEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Opendoor Technologies Inc.
|
For the next fiscal year, the consensus earnings estimate of -$0.60 indicates a change of +50.4% from what Opendoor Technologies Inc. is expected to report a year ago. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
For the next fiscal year, the consensus earnings estimate of -$0.60 indicates a change of +50.4% from what Opendoor Technologies Inc. is expected to report a year ago. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Opendoor Technologies Inc. is rated Zacks Rank #3 (Hold). While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. For the next fiscal year, the consensus earnings estimate of -$0.60 indicates a change of +50.4% from what Opendoor Technologies Inc. is expected to report a year ago. Over the last four quarters, Opendoor Technologies Inc. surpassed consensus EPS estimates three times.
|
51b4bede-74a8-4d41-859d-417afe88c236
|
715383.0
|
2023-12-01 00:00:00 UTC
|
Wingstop Inc. (WING) Is a Trending Stock: Facts to Know Before Betting on It
|
DCOMP
|
https://www.nasdaq.com/articles/wingstop-inc.-wing-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-2
|
nan
|
nan
|
Wingstop (WING) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this restaurant chain have returned +21% over the past month versus the Zacks S&P 500 composite's +9.2% change. The Zacks Retail - Restaurants industry, to which Wingstop belongs, has gained 7.6% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Wingstop is expected to post earnings of $0.54 per share, indicating a change of -10% from the year-ago quarter. The Zacks Consensus Estimate has changed +4% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $2.39 points to a change of +29.2% from the prior year. Over the last 30 days, this estimate has changed +8.6%.
For the next fiscal year, the consensus earnings estimate of $2.80 indicates a change of +17.2% from what Wingstop is expected to report a year ago. Over the past month, the estimate has changed +9.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Wingstop is rated Zacks Rank #1 (Strong Buy).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Wingstop, the consensus sales estimate for the current quarter of $118.37 million indicates a year-over-year change of +12.9%. For the current and next fiscal years, $451.36 million and $521.91 million estimates indicate +26.3% and +15.6% changes, respectively.
Last Reported Results and Surprise History
Wingstop reported revenues of $117.1 million in the last reported quarter, representing a year-over-year change of +26.4%. EPS of $0.69 for the same period compares with $0.45 a year ago.
Compared to the Zacks Consensus Estimate of $109.01 million, the reported revenues represent a surprise of +7.43%. The EPS surprise was +32.69%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Wingstop is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Wingstop. However, its Zacks Rank #1 does suggest that it may outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Wingstop Inc. (WING) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Wingstop.
|
A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Wingstop is rated Zacks Rank #1 (Strong Buy). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues.
|
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Wingstop is rated Zacks Rank #1 (Strong Buy). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. EPS of $0.69 for the same period compares with $0.45 a year ago. The company topped consensus revenue estimates each time over this period.
|
950ae50c-ce12-4b5d-a32c-a7d1fa9356f3
|
715384.0
|
2023-12-01 00:00:00 UTC
|
Axcelis Technologies, Inc. (ACLS) Is a Trending Stock: Facts to Know Before Betting on It
|
DCOMP
|
https://www.nasdaq.com/articles/axcelis-technologies-inc.-acls-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-3
|
nan
|
nan
|
Axcelis Technologies (ACLS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this semiconductor services company have returned -2.9%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks Electronics - Manufacturing Machinery industry, which Axcelis falls in, has gained 16.3%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Axcelis is expected to post earnings of $1.98 per share for the current quarter, representing a year-over-year change of +15.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.9%.
The consensus earnings estimate of $7.25 for the current fiscal year indicates a year-over-year change of +32.8%. This estimate has changed +3.5% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $7.83 indicates a change of +8% from what Axcelis is expected to report a year ago. Over the past month, the estimate has changed -3.7%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Axcelis is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Axcelis, the consensus sales estimate for the current quarter of $295.2 million indicates a year-over-year change of +11%. For the current and next fiscal years, $1.12 billion and $1.2 billion estimates indicate +21.3% and +7.8% changes, respectively.
Last Reported Results and Surprise History
Axcelis reported revenues of $292.33 million in the last reported quarter, representing a year-over-year change of +27.6%. EPS of $1.99 for the same period compares with $1.21 a year ago.
Compared to the Zacks Consensus Estimate of $281.3 million, the reported revenues represent a surprise of +3.92%. The EPS surprise was +15.03%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Axcelis is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axcelis. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Axcelis Technologies, Inc. (ACLS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axcelis.
|
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue Growth Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Click to get this free report Axcelis Technologies, Inc. (ACLS) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Axcelis is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue Growth Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
When earnings estimates for a company go up, the fair value for its stock goes up as well. EPS of $1.99 for the same period compares with $1.21 a year ago. The company topped consensus revenue estimates each time over this period.
|
0d01c40a-6e57-43b2-9429-5c11f62d309e
|
715385.0
|
2023-12-01 00:00:00 UTC
|
2 Retail Stocks That Could Outperform Amazon in 2024
|
DCOMP
|
https://www.nasdaq.com/articles/2-retail-stocks-that-could-outperform-amazon-in-2024
|
nan
|
nan
|
This year has been a strong one for online retail giant Amazon, whose shares are up an impressive 75%. But a repeat performance may be unlikely next year, especially as concerns about the economy haven't exactly disappeared. One market that has been hot of late is China, and there are two Chinese retail stocks that may outperform Amazon next year: PDD Holdings (NASDAQ: PDD) and JD.com (NASDAQ: JD)
Plus, the Chinese economy could be looking up. According to estimates from the Federal Reserve Bank of Atlanta, the U.S. economy is growing at a rate of 2.1% rate. Concerns of a recession next year suggest a slowdown in the months ahead. China's economy could see a slowdown as well, but the International Monetary Fund projects that its gross domestic product may still grow at a 4.6% rate next year.
Here's a closer look at these two businesses and why they may be worth investing in right now.
1. PDD Holdings
PDD Holdings owns some promising e-commerce assets that make it an attractive option for investors who are looking for a solid growth stock to own for 2024. It owns one of the most popular e-commerce marketplaces in the country, Pinduoduo.
It also owns Temu, which earlier this year became the most downloaded app in the U.S. Temu has grown in popularity due to social media and its incredibly low-priced items. And unlike many similar e-commerce platforms, it accepts returns within 90 days.
On Tuesday, the company reported its latest earnings numbers. Revenue of $9.4 billion for the period ended Sept. 30 was up an impressive 94% year over year. The company achieved such strong numbers while also seeing its net income soar by 47% to $2.2 billion.
PDD is showing the big advantage it has over other retailers as it has been effective in luring shoppers to buy its low-priced items while not having to compromise earnings growth to do so. It's an impressive accomplishment. And with shoppers becoming increasingly price-sensitive amid inflation and a possible recession in the U.S. next year, that can lead to even better growth numbers for PDD next year.
Although PDD has not been a bad stock to own this year, with its shares up over 40% heading into the release of earnings this week, it can build on those strong results next year as it may be in a better position than Amazon to continue delivering strong growth. And with the stock trading at less than 20 times its estimated future earnings, investors are getting some good value with the stock.
2. JD.com
Another top Chinese e-commerce company is JD.com. Consumers can find a variety of goods on its website, including food, apparel, electronics, cosmetics, and other areas. The company says its vast fulfillment network reaches 99% of the Chinese population, and it offers same-day and next-day delivery options. In this sense, it's more of a direct comparison to Amazon than PDD, as it operates through a direct sales model where it controls the inventory and delivery of products.
JD.com posted its latest numbers recently, and revenue for the period ended Sept. 30 totaled $34 billion, up 1.7% year over year. Operating income of just under $1.3 billion also rose by 6.6%, while net income rose by 38% as the company benefited from an increase in other income (e.g., gains and losses on investments).
While JD.com's business isn't nearly as fast-growing as PDD Holdings, it's still a top online retailer in China. It also has a diverse business that features its retail segment, logistics, Dada (an on-demand delivery platform), and other smaller businesses it houses under its "new businesses" segment. However, it's the company's retail and logistics segments that account for nearly the entire top line.
Although JD.com's growth rate hasn't been all that strong of late, and it has been declining over the years, this is another stock that offers some good value for investors, given its wide reach into the Chinese market. The stock has taken a beating in 2023, falling by 50% year to date. It hasn't been a great growth stock, as is evident from its underwhelming growth rate; geopolitical tensions involving China and the U.S. certainly haven't helped things. But with the stock trading at only 13 times its trailing earnings and less than nine times its estimated future profits, investors can get some good value here.
JD.com is bigger and more diversified than PDD Holdings. While it hasn't been generating the exciting growth numbers that PDD has been posting, it still stands to benefit from a growing Chinese economy. And if there's a slowdown in the U.S. economy next year and investors look for better-valued growth stocks than, say, Amazon, for example, both JD.com and PDD Holdings could become much more attractive buys, which is why they could outperform the tech giant in 2024.
10 stocks we like better than Pdd
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Pdd wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 27, 2023
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and JD.com. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
PDD is showing the big advantage it has over other retailers as it has been effective in luring shoppers to buy its low-priced items while not having to compromise earnings growth to do so. Although JD.com's growth rate hasn't been all that strong of late, and it has been declining over the years, this is another stock that offers some good value for investors, given its wide reach into the Chinese market. And if there's a slowdown in the U.S. economy next year and investors look for better-valued growth stocks than, say, Amazon, for example, both JD.com and PDD Holdings could become much more attractive buys, which is why they could outperform the tech giant in 2024.
|
One market that has been hot of late is China, and there are two Chinese retail stocks that may outperform Amazon next year: PDD Holdings (NASDAQ: PDD) and JD.com (NASDAQ: JD) Plus, the Chinese economy could be looking up. JD.com posted its latest numbers recently, and revenue for the period ended Sept. 30 totaled $34 billion, up 1.7% year over year. Operating income of just under $1.3 billion also rose by 6.6%, while net income rose by 38% as the company benefited from an increase in other income (e.g., gains and losses on investments).
|
One market that has been hot of late is China, and there are two Chinese retail stocks that may outperform Amazon next year: PDD Holdings (NASDAQ: PDD) and JD.com (NASDAQ: JD) Plus, the Chinese economy could be looking up. Although PDD has not been a bad stock to own this year, with its shares up over 40% heading into the release of earnings this week, it can build on those strong results next year as it may be in a better position than Amazon to continue delivering strong growth. And if there's a slowdown in the U.S. economy next year and investors look for better-valued growth stocks than, say, Amazon, for example, both JD.com and PDD Holdings could become much more attractive buys, which is why they could outperform the tech giant in 2024.
|
JD.com Another top Chinese e-commerce company is JD.com. While JD.com's business isn't nearly as fast-growing as PDD Holdings, it's still a top online retailer in China. Although JD.com's growth rate hasn't been all that strong of late, and it has been declining over the years, this is another stock that offers some good value for investors, given its wide reach into the Chinese market.
|
0cc967f9-fac4-4350-a223-4abc34a1f4ea
|
715386.0
|
2023-12-01 00:00:00 UTC
|
Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio
|
DCOMP
|
https://www.nasdaq.com/articles/wealth-from-wellness%3A-7-healthcare-stocks-to-inoculate-your-portfolio
|
nan
|
nan
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With concerns about a slowdown in the global economy rising, investors may be better served considering the top healthcare hidden-gem stocks. To be sure, no guarantees exist in the market; otherwise, everyone would pour money into the guaranteed space. However, over the long run, the healthcare sector may be as close to a sure thing as you can get.
Primarily, healthcare stocks inherently carry a defensive posture. Many other sectors face volatility as the major indices print red ink due to fading discretionary spending directly impacting underlying businesses. However, healthcare providers and specialists represent a “permanent” necessity. Basically, when you get sick or injured, you’ve got to do whatever it takes to get better. It’s a cynical argument but it works.
Also, demographic trends may help healthcare stocks. According to the Population Reference Bureau, in 2016, baby boomers hit the ages of between 52 and 70. As this demographic continues to get older, their personal care needs will likely increase. Therefore, whatever red ink may be impacting this sector now may turn black soon enough.
On that note, below are top healthcare hidden-gem stocks to add to your portfolio.
Hidden-Gem Stocks: Spok (SPOK)
Source: Supavadee butradee / Shutterstock.com
A healthcare communications specialist, Spok (NASDAQ:SPOK) provides a secure platform to automate clinical workflows for various activities. These include patient alerts, clinician consults, code calls, and test results. It’s not the most well-known enterprise, featuring a market capitalization of about $344 million. Nevertheless, SPOK has more than doubled since the beginning of this year and is one of the top hidden-gem stocks to consider.
So, what’s behind this incredible performance? Generally, Spok tends to either meet or exceed analysts’ expectations for earnings. In its last disclosure for the third quarter, the company posted earnings per share of 22 cents. However, analysts were looking for an EPS of 18 cents. Also, revenue landed at $35.43 million, noticeably above the consensus view of $33.7 million.
Also, in Q2, Spok saw a 90% increase in software bookings, representing a stunning print. While it’s not the most consistently profitable company, it features strong trailing-year margins. Right now, Spok carries a massive forward dividend yield of 7.28% (albeit with a high payout ratio of almost 123%).
As long as Spok maintains momentum, this could be one of the top healthcare hidden-gem stocks available.
Patterson Companies (PDCO)
Source: IgorGolovniov / Shutterstock.com
Based in Saint Paul, Minnesota, Patterson Companies (NASDAQ:PDCO) is another one of the top hidden-gem stocks that provides products, technologies, services, and business solutions to oral and animal health customers in North America and the U.K. With fears of COVID-19 dropping sharply, more people are returning to the dentists’ offices. Also, with the employment market stabilizing (for now), workers are likely to take advantage of their health plans.
In theory, these dynamics should help boost demand for Patterson. Oh yeah, Americans love their four-legged family members, spending a total of nearly $137 billion on them last year. So, PDCO enjoys a massive total addressable market, making it one of the most attractive healthcare stocks to buy. Sure enough, PDCO posted a modest double-digit return since the beginning of this year.
Financially, Patterson also benefits by being out of the spotlight, thus offering a deal to investors. Presently, shares trade at 12.35x forward earnings, below the sector median of 15.65x. Enticingly, the company also offers a forward yield of 3.31% with a payout ratio of only 38.86%.
Hidden-Gem Stocks: Premier (PINC)
Source: Roman Zaiets / Shutterstock.com
Headquartered in Charlotte, North Carolina, Premier (NASDAQ:PINC) primarily represents a group purchasing entity. Per its website, Premier was among the first companies to translate the purchasing power of a healthcare alliance into significant cost savings. In addition, the enterprise offers a performance improvement technology and analytics platform along with a consultancy service, among other relevancies.
While Premier offers a pertinent business, Wall Street has a difficult time trusting PNC. Since the start of the year, the company suffered a heavy loss of equity value. What hasn’t helped the cause is earnings performance. While Premier generally meets or exceeds EPS estimates, it has disappointed with revenue in recent quarters. Most notably, in fiscal Q3 2023, Premier posted sales of $322.23 million against a consensus view of $350.53 million.
Still, a patient approach could be key to this troubled but compelling example among healthcare stocks. Specifically, its consistently profitable while trading at a lowly 9.07x forward earnings. Additionally, Premier offers a forward yield of 4.06% and a payout ratio of only 39.61%.
Kenvue (KVUE)
Source: Giovanni Nastukov / Shutterstock.com
While I may be talking about Kenvue (NYSE:KVUE) a bit too much, I can’t help myself. From a fundamental point of view, KVUE easily symbolizes one of the top healthcare stocks. Spun off from Johnson & Johnson (NYSE:JNJ), Kevnue focuses on the consumer and personal care product segment. In my opinion, that’s valuable real estate heading into an unknown economic future.
Frankly, during difficult circumstances, it might not be possible for many patients to afford the latest and greatest in pharmaceutical and medical technologies. However, everyone can (reasonably) afford bottles of Tylenol for various aches and pains. And since these nuisances always pop up, Kenvue should theoretically benefit from a predictable revenue stream.
Moreover, with KVUE suffering a steep loss since its first public trading session, it may be ripe for a comeback rally. In the meantime, investors can enjoy the company’s generous forward yield of 3.97%. Yes, its payout ratio is elevated at 62.47% but it’s not anything truly out of the ordinary. In my opinion, it’s worth a shot.
Hidden-Gem Stocks: CVS Health (CVS)
Source: Susan Montgomery / Shutterstock.com
One of the riskiest ideas among top healthcare stocks, CVS Health (NYSE:CVS) may be worth a look for astute speculators; that is, gamblers who don’t mind taking calculated risks in fundamentally relevant enterprises. To be sure, the pharmacy retailer faces disruption from the usual suspects like Amazon (NASDAQ:AMZN). However, the company is also well aware of the challenges and has been responding in kind.
For me, it’s difficult to see CVS being disrupted. Yeah, certain segments of the business may face some headwinds. But when you combine the holistic advantages of CVS – infrastructure, convenience and brand awareness and trust, among other attributes – the bear case could arguably be overblown. Still, you do want to acknowledge the heavy loss on a 52-week basis.
At the same time, shares appear to have stabilized since mid-May. Also, the market prices CVS at a discount, only 8.22x forward earnings compared to the sector average of 12.88x. Significantly, the company offers a forward yield of 3.49% along with a very sustainable payout ratio of 28.43%.
US Physical Therapy (USPH)
Source: Microgen / Shutterstock
Hailing from Houston, Texas, US Physical Therapy (NYSE:USPH) bills itself as one of the largest publicly traded pure-play operators of outpatient physical and occupational therapy clinics. While not the most talked-about space among healthcare stocks, it’s crucially important to overall wellness. According to Grand View Research, the U.S. physical therapy services market reached a value of $44.8 billion last year.
What’s more, experts project that by 2030, the sector will print revenue of $58.6 billion. That comes out to a compound annual growth rate (CAGR) of 3.56% from 2023. Now, even though it’s up modestly for the year and is down quite sharply during the trailing half-year period, USPH features a premium multiple. That might not be the greatest news ever.
However, the company is consistently profitable. In turn, it offers a forward yield of 2.01%. At first glance, that might not seem like much. Nevertheless, Wall Street analysts peg USPH a unanimous strong buy. Also, their average price target lands at a lofty $110.
Select Medical (SEM)
Source: THICHA SATAPITANON / Shutterstock
Based in Pennsylvania, Select Medical (NYSE:SEM) is a leader in poste-acute recovery and rehabilitation. Per its website, Select Medical is one of the largest providers of critical illness recovery hospitals, inpatient rehabilitation hospitals, outpatient rehabilitation centers and occupational health clinics in the U.S. Also, the company commands an army of 54,000 healthcare professionals to help restore patients’ quality of life.
That said, the Street is looking for something to kick SEM into a higher gear. Since the beginning of the year, shares are down modestly on a year-to-date and trailing-52-week basis. Still, it’s possible that the market is being too harsh on Select. In the three quarters this year, the company handily analysts’ EPS estimates. And that applies to the revenue front as well, although with less bravado.
Another compelling factor to keep in mind is that unlike US Physical Therapy above, Select is undervalued against traditional metrics. For example, SEM trades at only 9.55x forward earnings, below the sector median of 23.78x.
Finally, analysts also rate SEM a unanimous strong buy with a $32.67 average price target.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.
More From InvestorPlace
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
The #1 AI Investment Might Be This Company You’ve Never Heard Of
The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
The post Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Many other sectors face volatility as the major indices print red ink due to fading discretionary spending directly impacting underlying businesses. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio appeared first on InvestorPlace.
|
Hidden-Gem Stocks: Spok (SPOK) Source: Supavadee butradee / Shutterstock.com A healthcare communications specialist, Spok (NASDAQ:SPOK) provides a secure platform to automate clinical workflows for various activities. Select Medical (SEM) Source: THICHA SATAPITANON / Shutterstock Based in Pennsylvania, Select Medical (NYSE:SEM) is a leader in poste-acute recovery and rehabilitation. Per its website, Select Medical is one of the largest providers of critical illness recovery hospitals, inpatient rehabilitation hospitals, outpatient rehabilitation centers and occupational health clinics in the U.S. Also, the company commands an army of 54,000 healthcare professionals to help restore patients’ quality of life.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With concerns about a slowdown in the global economy rising, investors may be better served considering the top healthcare hidden-gem stocks. Patterson Companies (PDCO) Source: IgorGolovniov / Shutterstock.com Based in Saint Paul, Minnesota, Patterson Companies (NASDAQ:PDCO) is another one of the top hidden-gem stocks that provides products, technologies, services, and business solutions to oral and animal health customers in North America and the U.K. With fears of COVID-19 dropping sharply, more people are returning to the dentists’ offices. Hidden-Gem Stocks: CVS Health (CVS) Source: Susan Montgomery / Shutterstock.com One of the riskiest ideas among top healthcare stocks, CVS Health (NYSE:CVS) may be worth a look for astute speculators; that is, gamblers who don’t mind taking calculated risks in fundamentally relevant enterprises.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With concerns about a slowdown in the global economy rising, investors may be better served considering the top healthcare hidden-gem stocks. What’s more, experts project that by 2030, the sector will print revenue of $58.6 billion. For example, SEM trades at only 9.55x forward earnings, below the sector median of 23.78x.
|
028822a7-038e-4007-a0ac-0183e4fcea6f
|
715387.0
|
2023-12-01 00:00:00 UTC
|
Banks get carbon emissions standard they sought for stock, bond deals
|
DCOMP
|
https://www.nasdaq.com/articles/banks-get-carbon-emissions-standard-they-sought-for-stock-bond-deals
|
nan
|
nan
|
By Tommy Wilkes
LONDON, Dec 1 (Reuters) - Banks will need to account for a third of the emissions linked to their capital markets deals when they report their carbon footprint, after an industry-led standard setter launched a long-awaited methodology on Friday.
Disagreement between banks over how much of the emissions should be apportioned to them delayed a decision, considered a crucial part of making emissions reporting credible.
The Partnership for Carbon Accounting Financials (PCAF) had been trying since last year to finalise the standard for facilitated emissions - those generated by activities such as a lender helping a company issue a bond.
Pending the methodology, banks including Citi C.N and Morgan Stanley MS.N have excluded the emissions from their reduction targets.
Environmental groups welcomed PCAF's new standard, although ShareAction said it was disappointed banks would only have to account for 33% of the emissions linked to their capital markets businesses.
Reuters reported in July that banks working to develop the standard had voted to exclude the other two-thirds.
"Of course it wasn’t easy. Finding the number was complex. The most important objective of PCAF was to find a harmonising methodology that all banks can use," PCAF Executive Director Angélica Afanador told Reuters.
Under the new standard, lenders have the option of disclosing 100% of their facilitated emissions as well as the 33% weighting.
Afanador said it was important to distinguish between banks as providers of capital via a loan kept on their balance sheets, and as facilitators for capital from investors in a stock or bond deal.
Banks signed up to PCAF must already account for 100% of the emissions from any financing that is kept on balance sheet - and so must investors for the emissions generated by the stocks and bonds they own.
UNDERWRITING FOSSIL FUELS
Two thirds of U.S. bank financing for fossil fuel expansion came via underwriting stocks and bonds, Sierra Club said in a July report.
"Banks have an enormous and overlooked climate impact from underwriting investments in big polluters, and disclosure of these impacts is long overdue," said Adele Shraiman, senior strategist for the Sierra Club's Fossil-Free Finance campaign.
Shraiman said banks needed to set targets for reducing their facilitated emissions and follow through on their pledges.
Jeanne Martin, Head of the Banking Programme at ShareAction, said PCAF had given banks a "get-out-of-transparency-free card" by using a 33% weighting.
"While we strongly welcome PCAF encouraging banks to go further, the guidelines published today are further proof that voluntary climate initiatives cannot deliver what is needed for people and planet," she said.
In explaining its approach, Afanador said PCAF had decided on the 33% weighting because the Basel Committee on Banking Supervision, which assesses the importance of global systemically important banks (G-SIB), previously considered balance sheet exposures such as bank lending as three times more impactful than underwriting.
Not all big banks have joined PCAF. Several including JP Morgan JPM.N and Goldman Sachs GS.N have developed their own methodologies for facilitated emissions.
PCAF's new standard is designed for emissions from the bonds and stocks that are sold to investors. If the bank puts its own capital at risk when underwriting, it is treated differently.
For daily comprehensive coverage on COP28 in your inbox, sign up for the Reuters Sustainable Switch newsletter here.
(Reporting by Tommy Reggiori Wilkes; Editing by Jamie Freed and Barbara Lewis)
((thomas.wilkes@tr.com; +44 (0) 7769 955711;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
By Tommy Wilkes LONDON, Dec 1 (Reuters) - Banks will need to account for a third of the emissions linked to their capital markets deals when they report their carbon footprint, after an industry-led standard setter launched a long-awaited methodology on Friday. The Partnership for Carbon Accounting Financials (PCAF) had been trying since last year to finalise the standard for facilitated emissions - those generated by activities such as a lender helping a company issue a bond. "While we strongly welcome PCAF encouraging banks to go further, the guidelines published today are further proof that voluntary climate initiatives cannot deliver what is needed for people and planet," she said.
|
By Tommy Wilkes LONDON, Dec 1 (Reuters) - Banks will need to account for a third of the emissions linked to their capital markets deals when they report their carbon footprint, after an industry-led standard setter launched a long-awaited methodology on Friday. Afanador said it was important to distinguish between banks as providers of capital via a loan kept on their balance sheets, and as facilitators for capital from investors in a stock or bond deal. Two thirds of U.S. bank financing for fossil fuel expansion came via underwriting stocks and bonds, Sierra Club said in a July report.
|
By Tommy Wilkes LONDON, Dec 1 (Reuters) - Banks will need to account for a third of the emissions linked to their capital markets deals when they report their carbon footprint, after an industry-led standard setter launched a long-awaited methodology on Friday. Banks signed up to PCAF must already account for 100% of the emissions from any financing that is kept on balance sheet - and so must investors for the emissions generated by the stocks and bonds they own. In explaining its approach, Afanador said PCAF had decided on the 33% weighting because the Basel Committee on Banking Supervision, which assesses the importance of global systemically important banks (G-SIB), previously considered balance sheet exposures such as bank lending as three times more impactful than underwriting.
|
Pending the methodology, banks including Citi C.N and Morgan Stanley MS.N have excluded the emissions from their reduction targets. Afanador said it was important to distinguish between banks as providers of capital via a loan kept on their balance sheets, and as facilitators for capital from investors in a stock or bond deal. Banks signed up to PCAF must already account for 100% of the emissions from any financing that is kept on balance sheet - and so must investors for the emissions generated by the stocks and bonds they own.
|
9dcf4833-6d4c-4d43-a741-6504fb5ab34a
|
715388.0
|
2023-12-01 00:00:00 UTC
|
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
|
DCOMP
|
https://www.nasdaq.com/articles/acadia-acad-begins-study-on-acp-101-for-hyperphagia-in-pws
|
nan
|
nan
|
Acadia Pharmaceuticals Inc. ACAD announced that it has initiated a late-stage study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
Acadia had previously acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022.
PWS is a rare neurobehavioral genetic disorder that affects approximately 8,000 to 10,000 patients in the United States. PWS affects the functioning of the hypothalamus and other aspects of the brain giving rise to a variety of behavioral problems among different individuals.
The most common symptom of PWS is hyperphagia. Notably, hyperphagia is described as a false and unrelenting state of starvation, which is a characteristic of PWS. The patients of PWS require constant supervision to prevent life-threatening risks, including gastric rupture, irregular swallowing and choking.
There is currently no FDA-approved treatment for the hyperphagia associated with PWS, constituting a serious unmet medical need.
Year to date, shares of Acadia have gained 39.9% against the industry’s 23.2% fall.
Image Source: Zacks Investment Research
The planned phase III COMPASS PWS study will be conducted over 12 weeks to evaluate the safety and efficacy of carbetocin nasal spray 3.2 mg, which will be administered thrice daily in 170 PWS patients. The intended patient population will comprise both pediatric and adult patients aged five to 30 years.
The primary efficacy endpoint of the COMPASS PWS study is the change from baseline to week 12 on the hyperphagia questionnaire for clinical trials (HQ-CT) score. The HQ-CT is a caregiver’s assessment for hyperphagia-related behaviors.
Enrolled patients who complete the late-stage study will be given the option to participate in a long-term extension study, which is designed to investigate the safety and tolerability of long-term treatment with ACP-101.
In a previously conducted phase III study by Levo (before getting acquired by Acadia), carbetocin nasal spray 3.2 mg was observed to reduce hyperphagia-related behaviors.
Subject to the success of the phase III COMPASS PWS study, Acadia plans to submit a new drug application for the treatment of hyperphagia in PWS to the FDA.
Currently, carbetocin nasal spray enjoys the FDA’s Orphan Drug, Fast Track and Rare Pediatric Disease designations in the United States.
ACADIA Pharmaceuticals Inc. Price and Consensus
ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank and Other Stocks to Consider
Acadia currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks worth mentioning are Puma Biotechnology, Inc. PBYI, ADMA Biologics ADMA and Agenus AGEN. While PBYI sports a Zacks Rank #1 (Strong Buy), ADMA and AGEN carry a Zacks Rank #2 each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share has increased from 67 cents to 73 cents. During the same time frame, the estimate for Puma Biotech’s 2024 earnings per share has increased from 56 cents to 62 cents. Year to date, shares of PBYI have lost 7.8%.
PBYI’s earnings beat estimates in three of the last four quarters while missing on one occasion, delivering a four-quarter average earnings surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has narrowed from 6 cents to 3 cents. The estimate for ADMA Biologics’ 2024 earnings per share is pegged at 16 cents. Year to date, shares of ADMA have lost 4.6%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 63.57%.
In the past 30 days, the Zacks Consensus Estimate for Agenus’ 2023 loss per share has narrowed from 77 cents to 63 cents. During the same time frame, the estimate for Agenus’ 2024 loss per share has narrowed from 70 cents to 45 cents. Year to date, shares of AGEN have plunged 67.6%.
AGEN beat estimates in one of the trailing four quarters, matching in one and missing the mark on the other two occasions, delivering an average earnings surprise of 0.49%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Acadia Pharmaceuticals Inc. ACAD announced that it has initiated a late-stage study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). The primary efficacy endpoint of the COMPASS PWS study is the change from baseline to week 12 on the hyperphagia questionnaire for clinical trials (HQ-CT) score. In a previously conducted phase III study by Levo (before getting acquired by Acadia), carbetocin nasal spray 3.2 mg was observed to reduce hyperphagia-related behaviors.
|
Image Source: Zacks Investment Research The planned phase III COMPASS PWS study will be conducted over 12 weeks to evaluate the safety and efficacy of carbetocin nasal spray 3.2 mg, which will be administered thrice daily in 170 PWS patients. In a previously conducted phase III study by Levo (before getting acquired by Acadia), carbetocin nasal spray 3.2 mg was observed to reduce hyperphagia-related behaviors. Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Image Source: Zacks Investment Research The planned phase III COMPASS PWS study will be conducted over 12 weeks to evaluate the safety and efficacy of carbetocin nasal spray 3.2 mg, which will be administered thrice daily in 170 PWS patients. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Acadia Pharmaceuticals Inc. ACAD announced that it has initiated a late-stage study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare neurobehavioral genetic disorder that affects approximately 8,000 to 10,000 patients in the United States. The estimate for ADMA Biologics’ 2024 earnings per share is pegged at 16 cents.
|
4fe57e6f-b3ec-43f2-b3a3-ba8c02b29312
|
715389.0
|
2023-12-01 00:00:00 UTC
|
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?
|
DCOMP
|
https://www.nasdaq.com/articles/apellis-pharmaceuticals-inc.-apls-up-9.2-since-last-earnings-report%3A-can-it-continue
|
nan
|
nan
|
It has been about a month since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS). Shares have added about 9.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Apellis Pharmaceuticals, Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Apellis’ Q3 Loss Wider Than Expected, Syfovre Drives Sales
Apellis reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of $1.75 per share in the year-ago quarter.
Total revenues amounted to $110.4 million in the third quarter, surpassing the Zacks Consensus Estimate of $101 million. In the year-ago quarter, the company had reported revenues of $22.1 million. The top line jumped almost 400% year over year owing to higher sales of Syfovre (pegcetacoplan injection) in the reported quarter.
Quarter in Detail
Revenues in the reported quarter included product sales of the marketed drugs — Empaveli (pegcetacoplan) and Syfovre — and licensing and other revenues under the collaboration agreement with Sobi.
Syfovre recorded sales of $75.3 million in the third quarter, up around 12% sequentially.
Apellis delivered more than 37,000 commercial vials and nearly 10,000 samples of Syfovre to doctors in the third quarter. As of Oct 5, 2023, the total number of vials of the drug delivered since launch was reportedly more than 100,000.
Empaveli recorded sales of $23.9 million in the reported quarter, up 35% from the year-ago quarter’s figure owing to the increasing number of patient switches from AstraZeneca’s Ultomiris (ravulizumab).
Licensing and other revenues came in at $11.2 million, up 154.5% from the year-ago quarter’s figure.
Research and development expenses decreased 16.6% to $79.4 million from the prior-year quarter’s level. This was due to a decrease in contract manufacturing expenses and lower personnel-related as well as other developmental costs.
General and administrative expenses totaled $145.6 million, up 85.7% from the year-ago quarter’s figure. This was driven by higher employee-related costs and an increase in professional and consulting fees.
As of Sep 30, 2023, Apellis had cash, cash equivalents and marketable securities worth $452.4 million compared with $616.3 million as of Jun 30, 2023. APLS expects its cash balance, combined with cash anticipated to be generated from sales of marketed products as well as Sobi reimbursements, to fund its operations into the second quarter of 2025.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision.
VGM Scores
At this time, Apellis Pharmaceuticals, Inc. has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Apellis Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Will the recent positive trend continue leading up to its next earnings release, or is Apellis Pharmaceuticals, Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
|
Apellis’ Q3 Loss Wider Than Expected, Syfovre Drives Sales Apellis reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. Quarter in Detail Revenues in the reported quarter included product sales of the marketed drugs — Empaveli (pegcetacoplan) and Syfovre — and licensing and other revenues under the collaboration agreement with Sobi. Empaveli recorded sales of $23.9 million in the reported quarter, up 35% from the year-ago quarter’s figure owing to the increasing number of patient switches from AstraZeneca’s Ultomiris (ravulizumab).
|
Apellis’ Q3 Loss Wider Than Expected, Syfovre Drives Sales Apellis reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. Quarter in Detail Revenues in the reported quarter included product sales of the marketed drugs — Empaveli (pegcetacoplan) and Syfovre — and licensing and other revenues under the collaboration agreement with Sobi. Empaveli recorded sales of $23.9 million in the reported quarter, up 35% from the year-ago quarter’s figure owing to the increasing number of patient switches from AstraZeneca’s Ultomiris (ravulizumab).
|
It has been about a month since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS). Total revenues amounted to $110.4 million in the third quarter, surpassing the Zacks Consensus Estimate of $101 million. In the year-ago quarter, the company had reported revenues of $22.1 million.
|
f09119a0-1f4d-4a55-a61e-8b805f33d587
|
715390.0
|
2023-12-01 00:00:00 UTC
|
Is Trending Stock 3M Company (MMM) a Buy Now?
|
DCOMP
|
https://www.nasdaq.com/articles/is-trending-stock-3m-company-mmm-a-buy-now-1
|
nan
|
nan
|
3M (MMM) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this maker of Post-it notes, industrial coatings and ceramics have returned +7.3%, compared to the Zacks S&P 500 composite's +9.2% change. During this period, the Zacks Diversified Operations industry, which 3M falls in, has gained 11.3%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, 3M is expected to post earnings of $2.32 per share, indicating a change of +1.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $9.12 for the current fiscal year indicates a year-over-year change of -9.7%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $9.92 indicates a change of +8.8% from what 3M is expected to report a year ago. Over the past month, the estimate has changed +0.7%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, 3M is rated Zacks Rank #2 (Buy).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For 3M, the consensus sales estimate for the current quarter of $7.68 billion indicates a year-over-year change of -5%. For the current and next fiscal years, $31.76 billion and $32.39 billion estimates indicate -7.2% and +2% changes, respectively.
Last Reported Results and Surprise History
3M reported revenues of $8.31 billion in the last reported quarter, representing a year-over-year change of -3.6%. EPS of $2.68 for the same period compares with $2.69 a year ago.
Compared to the Zacks Consensus Estimate of $7.95 billion, the reported revenues represent a surprise of +4.52%. The EPS surprise was +14.53%.
Over the last four quarters, 3M surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
3M is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about 3M. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
3M Company (MMM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Over the past month, shares of this maker of Post-it notes, industrial coatings and ceramics have returned +7.3%, compared to the Zacks S&P 500 composite's +9.2% change. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
|
A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
|
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
|
And if earnings estimates go up for a company, the fair value for its stock goes up. For the next fiscal year, the consensus earnings estimate of $9.92 indicates a change of +8.8% from what 3M is expected to report a year ago. Compared to the Zacks Consensus Estimate of $7.95 billion, the reported revenues represent a surprise of +4.52%.
|
011a2f73-9bd7-4228-9b56-a879d3b50655
|
715391.0
|
2023-12-01 00:00:00 UTC
|
3 Stocks that Could Get a Boost from the Cold Weather
|
DCOMP
|
https://www.nasdaq.com/articles/3-stocks-that-could-get-a-boost-from-the-cold-weather
|
nan
|
nan
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While it might immediately seem the most intuitive concept, investors may want to start planning stocks to buy this winter. Cooler weather and the eventfulness that it brings implies more folks stuck indoors. And that might have a negative impact on emotional wellbeing, which could dissuade investor sentiment.
On the other hand, some experts believe that enough reasonable evidence exists that cooler temperatures offer better market returns than compared to the summer season. Then again, other experts also state that the jury is still out regarding the viability of winter stocks to buy. So, who should investors believe?
If forced to render an answer, my response would be to focus on core fundamentals rather than the season. For instance, we know that the winter climate brings with it certain activities that you don’t find in the summer and vice versa.
That’s a better approach to stocks to buy this winter rather than tuning into your local weather report for market guidance and analysis.
Home Depot (HD)
Source: Jonathan Weiss / Shutterstock.com
It’s not that much of a stretch to call Home Depot (NYSE:HD). Also, you can add controversial to that description. Recently, company co-founder Bernie Marcus made his choice for president clear, angering those who felt otherwise. Subsequently, social media has been abuzz about boycotting the home improvement retailer. Put another way, Home Depot is hot this winter but perhaps not in a good way.
Then again, this controversy may be much ado about absolutely nothing. Let’s be real – we’re not a dictatorship so people are free to vote for whomever they want. On a more important note, HD makes an enticing case for stocks to buy this winter. I’m thinking about the inclement weather conditions that will materialize during this season. And that means more demand for home improvement products.
To be fair, I wouldn’t call HD a good deal on paper given its ho-hum 20x earnings multiple. Nevertheless, you’re getting predictability for a very modest premium. Its three-year revenue growth rate clocks in at 15.2% while the company commands an excellent net margin of 10.22%.
Target (TGT)
Source: Sundry Photography / Shutterstock.com
If you want to dial up the risk-reward factor for your winter stocks to buy, Target (NYSE:TGT) might be appealing. Naturally, the cold season brings us the holidays, which should enliven shoppers’ mood. As well, the cash registers should be ringing if the latest data is to be believed. According to The Wall Street Journal, Black Friday spending was strong this year.
Even better, Fortune reported that Cyber Monday was tracking for over $12 billion in sales. Now, I’m too cheap to fork over the money to climb the paywall. However, the headline clearly stated that it represented the biggest online shopping day of all time. That’s quite an endorsement and it bodes very well for Target.
To be sure, the company has its fair share of challenges. True, it more than delivered the goods regarding its third-quarter earnings. Unfortunately, theft has also increased, which has been a major thorn on its side. Indeed, I urged investors to avoid it earlier this year and I’m glad I did. However, an argument can be made that it’s de-risked. Thus, it could be one of the stocks to buy this winter.
VF Corp (VFC)
Source: rblfmr / Shutterstock.com
A global apparel and footwear company, VF Corp (NYSE:VFC) on paper represents the riskiest idea on this list. Since the beginning of this year, VFC lost more than 38% of equity value. That’s an awful performance, needless to say. On top of that, despite the Black Friday and Cyber Monday sales bump, questions remain about the viability of the consumer economy.
Can customers afford the shop-until-you-drop narrative? Consistently fading consumer sentiment suggests otherwise. Nevertheless, for extreme contrarian speculators, VFC might make a case for stocks to buy this winter. As the owner of several outdoor brands like JanSport, Timberland and especially The North Face, winter is when VF should come alive.
Of course, “alive” and “38% loss” represent two concepts that don’t mix well together. I get that. At the same time, you could make the de-risking argument here. In the trailing month, VFC returned over 16% to shareholders. On the financial side, the stock trades for 8.74x trailing-year earnings without non-recurring items (NRI). That’s practically subterranean, which might pique speculators’ interest. However, it’s a consensus hold so just watch out for that.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.
More From InvestorPlace
ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
The post 3 Stocks that Could Get a Boost from the Cold Weather appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
On the other hand, some experts believe that enough reasonable evidence exists that cooler temperatures offer better market returns than compared to the summer season. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires.
|
Home Depot (HD) Source: Jonathan Weiss / Shutterstock.com It’s not that much of a stretch to call Home Depot (NYSE:HD). Target (TGT) Source: Sundry Photography / Shutterstock.com If you want to dial up the risk-reward factor for your winter stocks to buy, Target (NYSE:TGT) might be appealing. VF Corp (VFC) Source: rblfmr / Shutterstock.com A global apparel and footwear company, VF Corp (NYSE:VFC) on paper represents the riskiest idea on this list.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it might immediately seem the most intuitive concept, investors may want to start planning stocks to buy this winter. Target (TGT) Source: Sundry Photography / Shutterstock.com If you want to dial up the risk-reward factor for your winter stocks to buy, Target (NYSE:TGT) might be appealing. Nevertheless, for extreme contrarian speculators, VFC might make a case for stocks to buy this winter.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it might immediately seem the most intuitive concept, investors may want to start planning stocks to buy this winter. Then again, other experts also state that the jury is still out regarding the viability of winter stocks to buy. Nevertheless, for extreme contrarian speculators, VFC might make a case for stocks to buy this winter.
|
be154bba-32cc-4a40-8331-cdb30957aa39
|
715392.0
|
2023-12-01 00:00:00 UTC
|
US STOCKS-Wall St set for lower open in run-up to Powell's remarks
|
DCOMP
|
https://www.nasdaq.com/articles/us-stocks-wall-st-set-for-lower-open-in-run-up-to-powells-remarks
|
nan
|
nan
|
By Shristi Achar A and Amruta Khandekar
Dec 1 (Reuters) - Wall Street's indexes were set for a subdued open on Friday as investors were on edge in the run up to Federal Reserve Chair Jerome Powell's comments that are expected to hold clues on the interest rate path.
This comes after the S&P 500 .SPX and Nasdaq .IXIC finished November with their biggest monthly gain since July 2022, while the Dow Jones .DJI rallied to close at its highest level since January 2022.
Data showing slowing U.S. consumer spending, some dovish comments from Fed officials and a strong earnings season propelled the equity indexes to a stellar November.
The recent slew of economic data, including Thursday's personal consumption expenditure index, signalled easing inflation in the world's largest economy, underscoring hopes the central bank would now end its interest rates hiking cycle.
But after recent conflicting policy remarks from some policymakers, investors are concerned that Powell could push back against the rate cut narrative. Powell is expected to speak at two separate events at 11 a.m. ET and 2 p.m. ET.
"Especially because of the ebullience of the markets over the last couple of weeks, there probably is a hawkish message that he's going to deliver today," said Kim Forrest, chief investment officer at Bokeh Capital Partners.
Forrest added markets were not expecting interest rates to stay at elevated levels for long.
A pause in rate hikes has been fully priced in for the upcoming December policy meeting, and traders also see an about 48% chance of at least a 25 basis point rate cut in March 2024 and an about 78% chance of another cut in May, according to CME Group's FedWatch tool.
Investors will also monitor comments from Fed Governors Lisa Cook and Chicago Fed President Austan Goolsbee, scheduled to speak during the day, and look out for manufacturing purchasing managers' index (PMI) data from the S&P Global and ISM.
At 8:26 a.m. ET, Dow e-minis 1YMcv1 were down 7 points, or 0.02%, S&P 500 e-minis EScv1 were down 7.5 points, or 0.16%, and Nasdaq 100 e-minis NQcv1 were down 40.75 points, or 0.25%.
TeslaTSLA.O underperformed other megacap stocks, down 2.0% before the bell, as the EV maker priced its Cybertruck above its initial forecast.
Among other stocks, U.S.-listed shares of AlibabaBABA.N slipped 1.7% premarket after Morgan Stanley downgraded the e-commerce giant, citing slower turnaround in customer management revenue (CMR).
PfizerPFE.N fell 4.3% as the drugmaker scrapped its plan to advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies.
Marvell TechnologyMRVL.O shed 4.6% after the chipmaker's fourth-quarter revenue forecast fell short of Street estimates.
Ulta BeautyULTA.O rose 10.9% after the cosmetics retailer raised the lower end of its annual net sales forecast and named Paula Oyibo its new chief financial officer.
Automation software firm UiPathPATH.N jumped 16.2% on beating third-quarter revenue estimates.
U.S. inflation is falling https://tmsnrt.rs/3R3OjrB
(Reporting by Shristi Achar A and Amruta Khandekar in Bengaluru; Editing by Shinjini Ganguli)
((Shristi.AcharA@thomsonreuters.com https://twitter.com/ShristiAchar; amruta.khandekar@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
By Shristi Achar A and Amruta Khandekar Dec 1 (Reuters) - Wall Street's indexes were set for a subdued open on Friday as investors were on edge in the run up to Federal Reserve Chair Jerome Powell's comments that are expected to hold clues on the interest rate path. Data showing slowing U.S. consumer spending, some dovish comments from Fed officials and a strong earnings season propelled the equity indexes to a stellar November. The recent slew of economic data, including Thursday's personal consumption expenditure index, signalled easing inflation in the world's largest economy, underscoring hopes the central bank would now end its interest rates hiking cycle.
|
By Shristi Achar A and Amruta Khandekar Dec 1 (Reuters) - Wall Street's indexes were set for a subdued open on Friday as investors were on edge in the run up to Federal Reserve Chair Jerome Powell's comments that are expected to hold clues on the interest rate path. ET, Dow e-minis 1YMcv1 were down 7 points, or 0.02%, S&P 500 e-minis EScv1 were down 7.5 points, or 0.16%, and Nasdaq 100 e-minis NQcv1 were down 40.75 points, or 0.25%. Marvell TechnologyMRVL.O shed 4.6% after the chipmaker's fourth-quarter revenue forecast fell short of Street estimates.
|
By Shristi Achar A and Amruta Khandekar Dec 1 (Reuters) - Wall Street's indexes were set for a subdued open on Friday as investors were on edge in the run up to Federal Reserve Chair Jerome Powell's comments that are expected to hold clues on the interest rate path. The recent slew of economic data, including Thursday's personal consumption expenditure index, signalled easing inflation in the world's largest economy, underscoring hopes the central bank would now end its interest rates hiking cycle. A pause in rate hikes has been fully priced in for the upcoming December policy meeting, and traders also see an about 48% chance of at least a 25 basis point rate cut in March 2024 and an about 78% chance of another cut in May, according to CME Group's FedWatch tool.
|
By Shristi Achar A and Amruta Khandekar Dec 1 (Reuters) - Wall Street's indexes were set for a subdued open on Friday as investors were on edge in the run up to Federal Reserve Chair Jerome Powell's comments that are expected to hold clues on the interest rate path. This comes after the S&P 500 .SPX and Nasdaq .IXIC finished November with their biggest monthly gain since July 2022, while the Dow Jones .DJI rallied to close at its highest level since January 2022. A pause in rate hikes has been fully priced in for the upcoming December policy meeting, and traders also see an about 48% chance of at least a 25 basis point rate cut in March 2024 and an about 78% chance of another cut in May, according to CME Group's FedWatch tool.
|
821e6058-f8da-4249-9062-6b984dadb0ac
|
715393.0
|
2023-12-07 00:00:00 UTC
|
Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue?
|
DCPH
|
https://www.nasdaq.com/articles/bluebird-blue-up-48.2-since-last-earnings-report%3A-can-it-continue
|
nan
|
nan
|
A month has gone by since the last earnings report for Bluebird Bio (BLUE). Shares have added about 48.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Bluebird due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
bluebird Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
bluebird delivered a loss of 66 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 69 cents per share. The company delivered a loss of $92 per share in the year-ago quarter (excluding restructuring expenses).
The company reported revenues of $12.4 million in the third quarter, up from $0.1 million in the year-ago quarter, beating the Zacks Consensus Estimate of $11 million. The increase of $5.4 million was primarily due to product revenues from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).
The FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions on Aug 17, 2022 and Skysona for treating early, active cerebral adrenoleukodystrophy on Sept 16, 2022.
Quarter in Detail
Research and development expenses declined 14.4% to $45.5 million due to manufacturing costs related to Skysona and Zynteglo (now included in inventory and cost of product revenues), reduced employee compensation, benefit and other headcount-related expenses and a decrease in information technology and facility-related costs in 2023.
Selling, general and administrative expenses increased 21.9% to $40.7 million in the year-ago quarter due to commercial costs driven by marketing activities for Skysona and Zynteglo in the United States.
As of Sep 30, 2023, bluebird had cash and cash equivalents, marketable securities and a restricted cash balance of approximately $227 million, down from $291 million at the end of the previous quarter. Based on current operating plans, bluebird expects its cash, cash equivalents and marketable securities, including anticipated cash flows from operations and excluding $53 million of restricted cash, to be sufficient for its planned operating expenses and capital expenditure requirements into the second quarter of 2024.
Other Updates
In June 2023, bluebird bio announced that the FDA accepted for priority review the company’s biologics license application seeking approval for gene therapy lovotibeglogene autotemcel (lovo-cel) for patients with sickle cell disease ages 12 and older. In August, the FDA communicated that an advisory committee meeting would not be scheduled for lovo-cel. The regulatory body has set a target action date of Dec 20, 2023.
In October 2023, bluebird entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”), if received, in connection with the potential approval of lovo-cel for sickle cell disease. Under the terms of the agreement, bluebird will receive $103 million upon closing of the sale, which is contingent upon the FDA’s approval of lovo-cel and granting of the PRV.
The priority review will shorten the FDA’s review of the application to six months from the time of filing versus a standard review timeline of 10 months. The company continues to anticipate a commercial launch in early 2024.
bluebird has made significant progress in the launch of Zynteglo with 16 patient starts (cell collections) for individuals suffering from beta-thalassemia.
The first commercial infusion for Syksona was completed in March 2023. Cell collection has been completed for six patients to be treated with Skysona. bluebird continues to anticipate 5-10 patient starts this year.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates.
The consensus estimate has shifted 16.23% due to these changes.
VGM Scores
Currently, Bluebird has a subpar Growth Score of D, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Bluebird has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Bluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 14.9% over the past month. More than a month has passed since the company reported results for the quarter ended September 2023.
Deciphera Pharmaceuticals, Inc. reported revenues of $43.31 million in the last reported quarter, representing a year-over-year change of +20.4%. EPS of -$0.58 for the same period compares with -$0.55 a year ago.
Deciphera Pharmaceuticals, Inc. is expected to post a loss of $0.59 per share for the current quarter, representing a year-over-year change of +1.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.8%.
Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
bluebird bio, Inc. (BLUE) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 14.9% over the past month. Click to get this free report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions on Aug 17, 2022 and Skysona for treating early, active cerebral adrenoleukodystrophy on Sept 16, 2022.
|
Click to get this free report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 14.9% over the past month. bluebird Q3 Earnings Top; Zynteglo, Skysona Fuel Sales bluebird delivered a loss of 66 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 69 cents per share.
|
Click to get this free report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 14.9% over the past month. bluebird Q3 Earnings Top; Zynteglo, Skysona Fuel Sales bluebird delivered a loss of 66 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 69 cents per share.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 14.9% over the past month. Click to get this free report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. A month has gone by since the last earnings report for Bluebird Bio (BLUE).
|
0c18dc62-1503-4f90-a260-39677a36b0f8
|
715394.0
|
2023-12-06 00:00:00 UTC
|
Bullish Two Hundred Day Moving Average Cross - DCPH
|
DCPH
|
https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-dcph
|
nan
|
nan
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $13.66, changing hands as high as $13.69 per share. Deciphera Pharmaceuticals Inc shares are currently trading up about 2.5% on the day. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average:
Looking at the chart above, DCPH's low point in its 52 week range is $9.90 per share, with $22.76 as the 52 week high point — that compares with a last trade of $13.74.
Free Report: Top 8%+ Dividends (paid monthly)
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
Also see:
ESE Split History
EUFN Options Chain
PLRM Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $13.66, changing hands as high as $13.69 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $9.90 per share, with $22.76 as the 52 week high point — that compares with a last trade of $13.74. Free Report: Top 8%+ Dividends (paid monthly) Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: ESE Split History EUFN Options Chain PLRM Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $13.66, changing hands as high as $13.69 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $9.90 per share, with $22.76 as the 52 week high point — that compares with a last trade of $13.74. Free Report: Top 8%+ Dividends (paid monthly) Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: ESE Split History EUFN Options Chain PLRM Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $13.66, changing hands as high as $13.69 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $9.90 per share, with $22.76 as the 52 week high point — that compares with a last trade of $13.74. Free Report: Top 8%+ Dividends (paid monthly) Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: ESE Split History EUFN Options Chain PLRM Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Wednesday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed above their 200 day moving average of $13.66, changing hands as high as $13.69 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $9.90 per share, with $22.76 as the 52 week high point — that compares with a last trade of $13.74. Deciphera Pharmaceuticals Inc shares are currently trading up about 2.5% on the day.
|
b54cf9a5-5cf1-4a69-a59a-bcf51ac2e050
|
715395.0
|
2023-12-01 00:00:00 UTC
|
Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?
|
DCPH
|
https://www.nasdaq.com/articles/exelixis-exel-up-8.4-since-last-earnings-report%3A-can-it-continue
|
nan
|
nan
|
It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 8.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Exelixis Q3 Earnings and Sales Miss, Annual View Updated
Exelixis reported earnings of 10 cents per share in the third quarter of 2023, missing the Zacks Consensus Estimate of 17 cents and down from 31 cents in the year-ago quarter.
Including stock-based compensation expense, earnings per share were breakeven compared with 23 cents per share in the year-ago quarter due to a significant increase in R&D expenses.
Net revenues came in at $471.9 million, marginally missing the Zacks Consensus Estimate of $476 million. Revenues were, however, up 14.6% year over year.
Quarter in Detail
Net product revenues came in at $426.5 million, up 16.4% year over year. The increases in net product revenues were primarily due to a rise in sales volume and the average net selling price.
Cabometyx (cabozantinib) generated revenues of $422.2 million and beat the Zacks Consensus Estimate and our model estimate of $416 million and $417.6 million, respectively. The drug is approved for advanced renal cell carcinoma (“RCC”) and previously treated hepatocellular carcinoma (“HCC”). Cometriq generated $4.3 million in net product revenues (cabozantinib capsules) for treating medullary thyroid cancer.
Collaboration revenues, comprising license revenues and collaboration services revenues, were $45.4 million in the quarter compared with $45.3 million in the year-ago quarter.
In the reported quarter, research and development expenses were $332.6 million, up 67.2% year over year. The significant surge was primarily related to the $80 million up-front payment associated with the in-licensing of XL309, increases in license and other collaboration costs, personnel expenses and manufacturing costs to support development candidates. Selling, general and administrative expenses were $138.1 million, up 20% due to an increase in personnel expenses.
In March, Exelixis announced that its board authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023. Under this program, Exelixis repurchased 16.943 million shares of the company’s common stock for a total of $344.8 million as of Sep 30.
Litigation Update
In July, Exelixis announced that it entered into a settlement and license agreement with Teva Pharmaceuticals. This settlement resolves patent litigation brought by Exelixis in response to Teva’s abbreviated new drug application seeking approval to market a generic version of Cabometyx prior to the expiration of the applicable patents. Per the settlement terms, Exelixis will grant Teva a license to market its generic version of the drug in the United States beginning on Jan 1, 2031, upon the FDA’s approval.
Consequently, both companies will terminate the ongoing litigation.
Pipeline Updates
In August, Exelixis and partner Ipsen announced that the phase III CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival (“PFS”) at the primary analysis. The study is evaluating cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (“NHT”) in patients with metastatic castration-resistant prostate cancer and measurable soft-tissue disease who have been previously treated with one NHT. At a prespecified interim analysis for the primary endpoint of overall survival (“OS”), a trend toward improvement of OS was observed, but the data was immature and did not meet the threshold for statistical significance.
Therefore, the trial will continue to the next analysis of OS, as planned.
Exelixis plans to discuss a potential regulatory submission when the results of the next OS analysis are available based on feedback from the FDA.
Detailed results from the late-stage CABINET study evaluating cabozantinib in advanced pancreatic and extra-pancreatic neuroendocrine tumors demonstrated a statistically significant and clinically meaningful improvement in PFS in those patients treated with cabozantinib. Earlier, The Alliance for Clinical Trials in Oncology’s independent Data and Safety Monitoring Board unanimously recommended unblinding and stopping the trial early due to a dramatic improvement in efficacy observed at an interim analysis.
In September, Exelixis received global rights to develop and commercialize XL309 from Insilico. The candidate is a potentially best-in-class small-molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize XL309 and other USP1-targeting compounds in exchange for an upfront payment of $80 million and potential future development and commercial milestone payments, as well as tiered royalties on net sales.
2023 Guidance Updated
Revenues are now projected between $1.825 billion and $1.850 billion compared with the previous estimate of $1.775-$1.875 billion.
Product revenues are estimated in the range of $1.625-$1.650 billion compared with the earlier guidance of $1.575-1.675 billion.
R&D expenses are now projected between $1.050 billion and $1.075 billion, up from the previous guidance of $1.0-$1.050 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review.
The consensus estimate has shifted 51.64% due to these changes.
VGM Scores
At this time, Exelixis has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Exelixis has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Exelixis belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 7.4% over the past month. More than a month has passed since the company reported results for the quarter ended September 2023.
Deciphera Pharmaceuticals, Inc. reported revenues of $43.31 million in the last reported quarter, representing a year-over-year change of +20.4%. EPS of -$0.58 for the same period compares with -$0.55 a year ago.
Deciphera Pharmaceuticals, Inc. is expected to post a loss of $0.59 per share for the current quarter, representing a year-over-year change of +1.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.8%.
Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 7.4% over the past month. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
|
Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 7.4% over the past month. Exelixis Q3 Earnings and Sales Miss, Annual View Updated Exelixis reported earnings of 10 cents per share in the third quarter of 2023, missing the Zacks Consensus Estimate of 17 cents and down from 31 cents in the year-ago quarter.
|
Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 7.4% over the past month. Exelixis Q3 Earnings and Sales Miss, Annual View Updated Exelixis reported earnings of 10 cents per share in the third quarter of 2023, missing the Zacks Consensus Estimate of 17 cents and down from 31 cents in the year-ago quarter.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 7.4% over the past month. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, research and development expenses were $332.6 million, up 67.2% year over year.
|
6dfbe609-fef7-4950-b954-407b3a83a4dd
|
715396.0
|
2023-11-30 00:00:00 UTC
|
Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?
|
DCPH
|
https://www.nasdaq.com/articles/amgen-amgn-up-2.2-since-last-earnings-report%3A-can-it-continue
|
nan
|
nan
|
A month has gone by since the last earnings report for Amgen (AMGN). Shares have added about 2.2% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Amgen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Beats on Q3 Earnings, Lags Sales, Ups View
Amgen reported third-quarter 2023 adjusted earnings of $4.96 per share, which beat the Zacks Consensus Estimate of $4.65. Earnings rose 6% year over year due to higher revenues, which were partially offset by higher operating costs.
Total revenues of $6.90 billion missed the Zacks Consensus Estimate of $6.96 billion. Total revenues rose 4% year over year, driven by higher product sales.
Total product revenues increased 5% from the year-ago quarter to $6.55 billion (U.S.: $4.69 billion; ex-U.S.: $1.86 billion). Higher volumes were partially offset by lower selling prices of several drugs. Volumes rose 11% in the quarter, partially offset by a 3% lower net selling price and 3% unfavorable changes to estimated sales deductions.
Other revenues were $355 million in the quarter, down 14.5% year over year due to lower revenues from its COVID-19 manufacturing collaboration.
The company witnessed robust volume growth across all its three therapeutic areas, general medicine, inflammation and hematology-oncology portfolios.
Performance of Key Drugs
General Medicine
Prolia revenues came in at $986 million, up 14% from the year-ago quarter, driven by volume growth and higher net selling prices. Prolia sales beat the Zacks Consensus Estimate of $983 million but missed our model estimate of $992 million. Prolia volumes are expected to continue to grow.
Evenity recorded sales of $307 million in the quarter, up 53% year over year, driven by volume growth in and outside the United States. Evenity sales beat the Zacks Consensus Estimate of $284 million as well as our model estimate of $289 million.
Repatha generated revenues of $406 million, up 31% year over year, as higher volume was partially offset by lower prices due to new formulary coverage by CVS in July for commercial patients. The volume growth was backed by a record number of new patients starting treatment. Repatha sales marginally missed the Zacks Consensus Estimate of $407 million but beat our model estimate of $400 million.
Aimovig recorded sales of $94 million in the quarter, down 12% year over year due to lower net selling price.
Hematology-Oncology
Xgeva delivered revenues of $519 million, up 5% year over year, driven by higher net selling prices. Xgeva sales missed the Zacks Consensus Estimate and our model estimate of $522 million and $527 million, respectively.
Kyprolis recorded sales of $349 million, up 10% year over year, driven by volume growth.
Vectibix revenues came in at $252 million, up 2% year over year, driven by volume growth and higher selling price, which were partially offset by unfavorable foreign exchange impact.
Nplate sales rose 45% to $419 million, driven by volume growth, driven by a $142 million order from the U.S. government. Amgen expects to fulfill another $62 million order from the U.S. government in the fourth quarter.
Blincyto sales increased 55% from the year-ago period to $220 million, also driven by volume growth as the drug benefited from broad prescribing for patients with B-cell precursor ALL and updated NCCN guidelines that were issued in May.
Lumakras/Lumykras recorded sales of $52 million in the quarter, down 31% from the year-ago period, due to unfavorable changes to estimated sales deductions related to ongoing reimbursement negotiations in France. Lumakras/Lumykras sales missed the Zacks Consensus Estimate of $87 million as well as our model estimate of $95 million.
In oncology biosimilars, sales of Kanjinti (Amgen’s biosimilar of Roche’s Herceptin) were $20 million, down 72% year over year due to lower pricing and volumes as a result of increased competition.
Sales of Mvasi (biosimilar of Roche’s Avastin) were $213 million in the quarter, up 2% year over year, driven by volume growth and favorable changes to estimated sales deductions, which were partially offset by lower pricing.
Inflammation
Sales of Otezla were $567 million in the quarter, down 10%, due to lower pricing, unfavorable changes to estimated sales deductions and lower inventory levels. Otezla sales in the United States continue to be hurt by free drug programs launched by new competitors. In the United States, Otezla sales price declined due to higher rebates to support expanded access for commercial and Medicare Part D patients. Otezla sales missed the Zacks Consensus Estimate of $635 as well as our estimate of $620 million.
On the conference call, Amgen said it is seeing a reduced impact of the free drug programs. Amgen is also making investments to educate physicians about the benefits of Otezla for appropriate patients and has increased the Otezla sales force by 20%. Amgen expects these initiatives to drive Otezla’s return to growth.
Enbrel revenues of $1.04 billion declined 6% year over year due to unfavorable changes to estimated sales deductions, which offset the impact of slightly improved volumes. Enbrel sales beat the Zacks Consensus Estimate and our estimate, both of which stood at $1.02 billion. Similar to the second quarter, improved payer coverage led to increase in new patients, which, in turn, led to some better volume growth in the third quarter. Amgen expects improved coverage to continue to lead to new patient growth and thus support volumes. However, prices are expected to continue to decline.
Newly approved asthma drug, Tezspire (tezepelumab) recorded sales of $161 million in the quarter, up 21% sequentially, driven by volume growth. Tezspire volumes benefited from the launch of a self-administered, pre-filled, single-use pen formulation of the drug in the first quarter, improving patient convenience and accessibility and also more flexibility in treatment options.
Amgevita sales were $152 million in the quarter, up 30% year over year, driven by 53% volume growth, partially offset by lower inventory levels and net selling price.
New drug Tavneos generated $37 million in sales in the third quarter compared with $30 million in the previous quarter. The drug’s 23% sequential growth was driven by new patient volume growth. Tavneos, approved for the treatment of patients with ANCA-associated vasculitis, a serious systemic autoimmune disease, was added to Amgen’s portfolio with the 2022 acquisition of ChemoCentryx.
Established Products
Total sales of established products, which include Epogen, Aranesp, Parsabiv and Neulasta, decreased 30% year over year in the third quarter.
Operating Margins Rise
Adjusted operating margin declined 0.5 percentage points to 52.0% in the quarter. Adjusted operating expenses increased 4% to $3.50 billion.
R&D expenses fell 2% year over year to $1.07 billion. SG&A spending rose 1% to $1.29 billion.
Adjusted tax rate was 16.1% for the quarter, a 3.2-point increase from the year-ago quarter.
2023 Guidance Raised
Following the completion of the Horizon acquisition, Amgen updated its previously issued revenue and earnings guidance for 2023.
Revenues are now expected in the range of $28.0 billion to $28.4 billion, up from the previous expectation of $26.6 billion to $27.4 billion.
Adjusted earnings are expected in the range of $18.20 to $18.80, up from the prior expectation of $17.80 to $18.80 per share. Adjusted EPS in the fourth quarter is expected to be lower than the third quarter due to increased investments in pipeline candidates like maridebart cafraglutide, olpasiran and AMG 193. In addition, the recognition of interest expense related to the Horizon financing will also hurt EPS in the fourth quarter.
Adjusted cost of sales as a percent of product sales is expected to be 16% to 17% in 2023 (maintained).
Adjusted R&D costs are expected to increase by about 10% year over year from the 2022 level versus the prior expectation of 5%. S&A spending is expected to decrease slightly year over year, driven by productivity improvements (maintained). Total operating expenses are expected to increase around 10% versus the prior expectation of 3% from 2022 level due to the closing of the Horizon acquisition. Amgen expects operating margin as a percentage of product sales to be roughly 50% in 2023.
The adjusted tax rate is expected to be in the range of 16.5% to 17.0% (previously 17.5%-18.5%), while capital expenditures are now expected to be approximately $950 million (previously $925 million). Amgen expects to buy back shares worth not more than $500 million (maintained) in 2023.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates.
VGM Scores
At this time, Amgen has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions has been net zero. Notably, Amgen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Amgen is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 4.6%. The company reported its results for the quarter ended September 2023 more than a month ago.
Deciphera Pharmaceuticals, Inc. reported revenues of $43.31 million in the last reported quarter, representing a year-over-year change of +20.4%. EPS of -$0.58 for the same period compares with -$0.55 a year ago.
Deciphera Pharmaceuticals, Inc. is expected to post a loss of $0.59 per share for the current quarter, representing a year-over-year change of +1.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.5%.
Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 4.6%. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Blincyto sales increased 55% from the year-ago period to $220 million, also driven by volume growth as the drug benefited from broad prescribing for patients with B-cell precursor ALL and updated NCCN guidelines that were issued in May.
|
Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 4.6%. Enbrel revenues of $1.04 billion declined 6% year over year due to unfavorable changes to estimated sales deductions, which offset the impact of slightly improved volumes.
|
Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 4.6%. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Evenity recorded sales of $307 million in the quarter, up 53% year over year, driven by volume growth in and outside the United States.
|
Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 4.6%. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Beats on Q3 Earnings, Lags Sales, Ups View Amgen reported third-quarter 2023 adjusted earnings of $4.96 per share, which beat the Zacks Consensus Estimate of $4.65.
|
0969158e-30a7-4a36-9f36-a698f14ff2a0
|
715397.0
|
2023-11-29 00:00:00 UTC
|
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?
|
DCPH
|
https://www.nasdaq.com/articles/why-is-deciphera-pharmaceuticals-inc.-dcph-up-1.7-since-last-earnings-report
|
nan
|
nan
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Shares have added about 1.7% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Deciphera Pharmaceuticals, Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Deciphera Q3 Earnings & Sales Beat Estimates
Deciphera Pharmaceuticals, Inc. reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had incurred a loss of 55 cents per share.
Net revenues were $43.3 million, which beat the Zacks Consensus Estimate of $40 million. The figure rose almost 20.4% year over year.
Quarter in Detail
Total revenues comprise net product revenues and collaboration revenues for Qinlock (ripretinib).
Deciphera’s sole marketed drug, Qinlock, was approved by the FDA in 2020 to treat adult patients with advanced GIST, who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock was approved in Europe in late 2021. Apart from Qinlock, there is no marketed drug in the company’s portfolio.
Net product revenues from Qinlock sales were $41.8 million, up 29% year over year. The drug generated sales of $32.7 million and $9.1 million in the United States and ex-U.S. markets, respectively.
Qinlock’s net product revenues beat the Zacks Consensus Estimate of $38.5 million and our model estimate of $37.8 million.
Collaboration revenues totaled $1.5 million, down 59% year-over-year which beat the Zacks Consensus Estimate of $1.33 million but missed our model estimate of $1.6 million.
Research and development expenses (including stock-based compensation) amounted to $62.5 million, up 31.6% year over year, owing to costs related to clinical studies on DCC-3116 and Qinlock.
Selling, general and administrative expenses (including stock-based compensation) totaled $33.3 million, up 11% year over year, owing to increased professional fees, personnel-related costs and consultant fees.
Deciphera had cash, cash equivalents and investments worth $376.9 million as of Sep 30, 2023, compared with $389.4 million as of Jun 30, 2023. The company expects its current cash balance, together with the anticipated product, royalty and supply revenues, excluding any potential future milestone payments under its collaboration or license agreements, to fund its operating and capital expenditures into 2026.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Deciphera Pharmaceuticals, Inc. has a nice Growth Score of B, a grade with the same score on the momentum front. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Deciphera Pharmaceuticals, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Blueprint Medicines (BPMC), has gained 16.2% over the past month. More than a month has passed since the company reported results for the quarter ended September 2023.
Blueprint Medicines reported revenues of $56.57 million in the last reported quarter, representing a year-over-year change of -14.3%. EPS of -$2.20 for the same period compares with -$2.23 a year ago.
For the current quarter, Blueprint Medicines is expected to post a loss of $2.02 per share, indicating a change of +23.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.3% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Blueprint Medicines. Also, the stock has a VGM Score of F.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 55 cents per share. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here. A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 55 cents per share.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 55 cents per share. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 55 cents per share. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
37c2147a-ecea-4cd1-8d7f-dc5be82f9bdb
|
715398.0
|
2023-10-31 00:00:00 UTC
|
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-stock-gains-17-on-q3-earnings-sales-beat
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had incurred a loss of 55 cents per share.
Net revenues were $43.3 million, which beat the Zacks Consensus Estimate of $40 million. The figure rose almost 20.4% year over year.
Deciphera’s stock gained 17.5% on Oct 30 and 3.7% in the after-hours, as the company reported better-than-expected results. Year to date, shares of the company have lost 27.2% compared with the industry’s 25.4% fall.
Image Source: Zacks Investment Research
Quarter in Detail
Total revenues comprise net product revenues and collaboration revenues for Qinlock (ripretinib).
Deciphera’s sole marketed drug, Qinlock, was approved by the FDA in 2020 to treat adult patients with advanced gastrointestinal stromal tumors (GIST), who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock was approved in Europe in late 2021. Apart from Qinlock, there is no marketed drug in the company’s portfolio.
Net product revenues from Qinlock sales were $41.8 million, up 29% year over year. The drug generated sales of $32.7 million and $9.1 million in the United States and ex-U.S. markets, respectively.
Qinlock’s net product revenues beat the Zacks Consensus Estimate of $38.5 million and our model estimate of $37.8 million.
Collaboration revenues totaled $1.5 million, down 59% year-over-year which beat the Zacks Consensus Estimate of $1.33 million but missed our model estimate of $1.6 million.
Research and development expenses (including stock-based compensation) amounted to $62.5 million, up 31.6% year over year, owing to costs related to clinical studies on DCC-3116 and Qinlock.
Selling, general and administrative expenses (including stock-based compensation) totaled $33.3 million, up 11% year over year, owing to increased professional fees, personnel-related costs and consultant fees.
Deciphera had cash, cash equivalents and investments worth $376.9 million as of Sep 30, 2023, compared with $389.4 million as of Jun 30, 2023. The company expects its current cash balance, together with the anticipated product, royalty and supply revenues, excluding any potential future milestone payments under its collaboration or license agreements, to fund its operating and capital expenditures into 2026.
Other Updates
Deciphera is working to expand the label of Qinlock for the larger commercial opportunity in GIST.
During the third quarter, the company reported initiating its phase III INSIGHT study evaluating Qinlock versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18.
Along with the third-quarter earnings release, Deciphera reported positive top-line results from its pivotal phase III MOTION study of vimseltinib for the potential treatment of tenosynovial giant cell tumor (TGCT). Vimseltinib is the company’s investigational, orally-administered CSF1R inhibitor.
Per the data readout, the MOTION study met its primary endpoint of statistically significant and clinically meaningful improvements in objective response rate (ORR) at week 25 compared with placebo in the intent-to-treat (ITT) population. In the ITT population, it was observed that the ORR at week 25 was 40% for patients treated with vimseltinib as compared with 0% in the placebo arm.
Deciphera also reported achieving all key secondary endpoints in the MOTION study with statistical significance and clinically meaningful improvement compared with placebo. The drug was overall well-tolerated in patients with TGCT, with a safety profile consistent with previously disclosed data. Furthermore, treatment with vimseltinib showed no evidence of cholestatic hepatotoxicity.
The company expects to submit regulatory applications for vimseltinib in the TGCT indication in the United States and EU in the second quarter of 2024 and the third quarter of 2024, respectively.
DCPH, in collaboration with Pfizer, Inc. PFE, is evaluating DCC-3116 in combination with Qinlock in patients with GIST and in combination with encorafenib and cetuximab in patients with colorectal cancer. Per the terms of the agreement with Pfizer, Deciphera will bear the cost of the study while Pfizer will supply encorafenib free of cost. Additionally, the company is also currently evaluating DCC-3116, in an early-mid-stage study, in combination with trametinib, binimetinib and sotorasib in patients with advanced solid tumors.
Enrollment is currently ongoing in all these combination escalation cohorts evaluating DCC-3116 in combination with binimetinib, trametinib, sotorasib, encorafenib/cetuximab and Qinlock to recommend phase II combination dose for potential expansion cohorts.
Deciphera Pharmaceuticals, Inc. Price and Consensus
Deciphera Pharmaceuticals, Inc. price-consensus-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Deciphera currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the same industry are Anixa Biosciences ANIX and Adicet Bio, Inc. ACET, each carrying a Zacks Rank #2 (Buy) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, the Zacks Consensus Estimate for Anixa Biosciences’ 2023 loss per share has remained constant at 32 cents. The estimate for Anixa Biosciences’ 2024 loss per share has remained constant at 37 cents. Year to date, shares of ANIX have lost 24.9%.
ANIX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 26.29%.
In the past 30 days, the estimate for Adicet Bio’s 2023 loss per share has remained constant at $2.93. The estimate for Adicet’s 2024 loss per share has remained constant at $2.40. Year to date, shares of ACET have fallen 85.3%.
ACET’s earnings beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 7.70%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Adicet Bio, Inc. (ACET) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had incurred a loss of 55 cents per share. DCPH, in collaboration with Pfizer, Inc. PFE, is evaluating DCC-3116 in combination with Qinlock in patients with GIST and in combination with encorafenib and cetuximab in patients with colorectal cancer.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had incurred a loss of 55 cents per share.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had incurred a loss of 55 cents per share.
|
Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had incurred a loss of 55 cents per share. DCPH, in collaboration with Pfizer, Inc. PFE, is evaluating DCC-3116 in combination with Qinlock in patients with GIST and in combination with encorafenib and cetuximab in patients with colorectal cancer.
|
c8d8e212-be4b-45cc-abfc-934a4231b347
|
715399.0
|
2023-10-31 00:00:00 UTC
|
Piper Sandler Upgrades Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/piper-sandler-upgrades-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Fintel reports that on October 30, 2023, Piper Sandler upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight .
Analyst Price Forecast Suggests 92.37% Upside
As of October 4, 2023, the average one-year price target for Deciphera Pharmaceuticals is 22.95. The forecasts range from a low of 9.09 to a high of $31.50. The average price target represents an increase of 92.37% from its latest reported closing price of 11.93.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Deciphera Pharmaceuticals is 157MM, an increase of 3.59%. The projected annual non-GAAP EPS is -2.26.
What is the Fund Sentiment?
There are 359 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is a decrease of 3 owner(s) or 0.83% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.12%, a decrease of 2.68%. Total shares owned by institutions decreased in the last three months by 2.64% to 59,688K shares.
The put/call ratio of DCPH is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
Deerfield Management Company, L.p. holds 6,707K shares representing 8.51% ownership of the company. In it's prior filing, the firm reported owning 5,219K shares, representing an increase of 22.19%. The firm increased its portfolio allocation in DCPH by 12.16% over the last quarter.
Redmile Group holds 4,879K shares representing 6.19% ownership of the company. In it's prior filing, the firm reported owning 5,582K shares, representing a decrease of 14.42%. The firm decreased its portfolio allocation in DCPH by 29.55% over the last quarter.
Armistice Capital holds 4,560K shares representing 5.79% ownership of the company. In it's prior filing, the firm reported owning 4,100K shares, representing an increase of 10.09%. The firm increased its portfolio allocation in DCPH by 1.85% over the last quarter.
Braidwell holds 3,646K shares representing 4.63% ownership of the company. In it's prior filing, the firm reported owning 3,241K shares, representing an increase of 11.11%. The firm increased its portfolio allocation in DCPH by 1.57% over the last quarter.
Goldman Sachs Group holds 2,124K shares representing 2.69% ownership of the company. In it's prior filing, the firm reported owning 3,058K shares, representing a decrease of 43.97%. The firm increased its portfolio allocation in DCPH by 105.76% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on October 30, 2023, Piper Sandler upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight . Average portfolio weight of all funds dedicated to DCPH is 0.12%, a decrease of 2.68%. The put/call ratio of DCPH is 0.01, indicating a bullish outlook.
|
Fintel reports that on October 30, 2023, Piper Sandler upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight . Average portfolio weight of all funds dedicated to DCPH is 0.12%, a decrease of 2.68%. The put/call ratio of DCPH is 0.01, indicating a bullish outlook.
|
Fintel reports that on October 30, 2023, Piper Sandler upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight . Average portfolio weight of all funds dedicated to DCPH is 0.12%, a decrease of 2.68%. The put/call ratio of DCPH is 0.01, indicating a bullish outlook.
|
Fintel reports that on October 30, 2023, Piper Sandler upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Overweight . Average portfolio weight of all funds dedicated to DCPH is 0.12%, a decrease of 2.68%. The put/call ratio of DCPH is 0.01, indicating a bullish outlook.
|
852a521a-5051-4712-a904-106c89a5be0f
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.